,descriptor,terms
0,characteristic_level,"nmbr - nmbr mg / dl ""-no-former never diabetes-yes-nmbr mg / dl-< nmbr yr-current-> nmbr mg / dl-white-< nmbr . nmbr mg / dl-nonwhite-nmbr mg / dl ldl cholesterol | |-nmbr - nmbr mg / dl-no beta - blocker use-nmbr yr-nmbr . nmbr mg / dl triglycerides^-< nmbr mg / dl"
2,measures,"% ""-%-no . event / total . { % )"
3,characteristic_level,"diabetic patients-non - diabetic patients ""-non - diabetic patients"
4,outcomes,"death-death ""-death , large mi-large mi-total-tvr"
6,characteristic_name,"weight ( kg )-cerebrovascular accident-coronary - artery bypass grafting-l eft anterior descending coronary artery-bypass graft-myocardial infarction-smoker ( % )-age ( yr )-left circumflex artery-restenotic vessel-diabetes ( % )-left circumflex artery ""-hypertension ( % )-r ight coronar artery-percutaneous coronary revascularization-male sex ( % )"
7,arms,"abciximab ( n = nmbr )-abciximab ( n = nmbr ) ""-tirofiban ( n = nmbr )"
8,characteristic_name,"location treatment center-indication stent ""-diabetes-age-clopidogrel given procedure-indication stent-sex"
10,characteristic_level,"weekly-current-monthly-past-history high cholesterol ( ) nmbr-infarction age nmbr ( )-daily-rarely-never ""-never"
11,characteristic_name,"age , years-use hormone replacement therapy ( ) ""-body mass index ( kg / mnmbr ) * '-use hormone replacement therapy ( )-post - menopausal ( )-history diabetes ( )-history hypertension ( ) c-randomized active yitamin e-alcohol intake ( )-exercise least weekly ( )-smoking ( )"
12,characteristic_level,"post - menopausal hormone replacement ""-post - menopausal hormone replacement-therapy ( asa nmbr / placebo nmbr )-hormonal status-pre - menopausal without hormone replacement-therapy ( asa nmbr , nmbr / placebo nmbr )-pre - menopausal hormone replacement-post - menopausal without hormone replacement-all randomized women"
13,measures,"number ( % ) reporting migraine nmbr - month questionnaire-number ( % ) reporting migraine nmbr - month questionnaire """
14,characteristic_name,"age , years-previous balloon angioplasty , n ( % )-platelet count , x nmbr mmnmbr-systemic arterial hypertension , n ( % )-previous myocardial infarction , n ( % )-women , n ( % )-hypercholesterolemia , n ( % )-diabetes , n ( % ) ""-diabetes , n ( % )-previous bypass surgery , n ( % )-unstable angina , n ( % )-smoking habit , n ( % )"
16,arms,"placebo ( n = nmbr )-simvastatin ( n = nmbr ) ""-simvastatin ( n = nmbr )"
17,characteristic_level,"alathosterol ( % )-anmbrs - hydroxy --aabnmbr ( % )-cholesterol ( % )-aldl cholesterol ""-aldl cholesterol-a ( nmbr ( % )-acholesterol ( % )"
18,characteristic_name,"csf-serum ""-serum-> < nmbr . nmbr , < nmbr . nmbr , r < mmse = mini - mental ;"
19,characteristic_level,"mmse nmbr - nmbr ""-mmse nmbr - nmbr"
20,arms,"placebo-simvastatin-simvastatin """
21,other,"( n = nmbr )-( n = nmbr ) """
22,characteristic_name,"blood pressure , mean ( sd ) , mm hg-lipids , mean ( sd ) , mg / dlt-lipids , mean ( sd ) , mg / dlt "" ; na-medication use"
23,characteristic_level,"congestive heart failure-digoxin-aspirin-ace inhibitor-total cholesterol-smoking , % current-anyantianginal agent-waist circumference , mean ( sd ) , in-p - blocker-ptca / cabg-race , % nonwhite-calcium channel blocker-prior stroke-prior myocardial infarction-triglycerides-fpg , mean ( sd ) , mg / dlt-age , mean ( sd ) , y-hdl - c-diastolic-systolic-alcohol , % > nmbr drink / d-ptca-fpi , mean ( sd ) , pu / mlt-ptca ""-ldl - c-bmi , mean ( sd )-cabg-hypertension"
24,characteristic_level,"p value-impaired fasting glucose level ( n = nmbr )-undiagnosed diabetes ( n = nmbr )-diagnosed diabetes ( n = nmbr ) ""-normal fasting glucose level ( n = nmbr )-diagnosed diabetes ( n = nmbr )"
25,characteristic_name,"female sex ( % )-> nmbr previous venous thromboembolisms ( % )-family history venous thromboembolism ( % )-duration full - dose warfarin therapy enrollment ( mo )-factor v leiden ( % )-body - mass index * ""-history diabetes ( % )-race ethnic group ( % )-age ( yr )-prothrombin mutation ( % )-time cessation full - dose warfarin therapy enrollment ( mo )-body - mass index *"
26,characteristic_level,"median-median ""-other-hispanic-non - hispanic white-interquartile range-non - hispanic black"
28,characteristic_name,". previous venous thromboembolic events ""-no . previous venous thromboembolic events-age-time since cessation full - dose warfarin therapy-time since randomization-factor v leiden prothrombin mutation-sex"
29,characteristic_level,"male-nmbr-absent-< nmbr yr-> nmbr mo-> nmbr yr-> nmbr-> nmbr ""-< nmbr mo-female-nmbr - nmbr yr-present"
31,measures,". events-no . events ""-no . / nmbr person - yr"
32,characteristic_name,"race ( % ) "" ; na-race ( % )"
33,arms,"placebo-rsg nmbr mg / day-placebo """
34,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
35,outcomes,"fpg ( mg / dl )-fpg ( mg / dl ) ""-hbanmbrc ( % )"
36,measures,"comparison placebo-patients ( n )-( mean change , nmbr % ci )-comparison baseline-week nmbr ( mean , sd )-( mean difference , nmbr % ci )-week nmbr ( mean , sd ) ""-baseline ( mean , sd )"
37,arms,"placebo-rsg nmbr mg / day-placebo """
38,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
39,measures,"comparison placebo-( mean % difference , nmbr % ci )-patients ( n )-( mean % change , nmbr % ci )-comparison baseline-week nmbr ( mean , sd )-patients ( n ) ""-baseline ( mean , sd )"
40,arms,"placebo-rsg nmbr mg / day ""-rsg nmbr mg / day"
41,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
42,measures,"patients ( n )-comparison placebo ( mean-% difference , nmbr % ci )-comparison baseline ( mean-baseline ( geometric mean , cv )-% change , nmbr % ci )-week nmbr ( geometric mean , cv )-patients ( n ) """
43,arms,"placebo-rsg nmbr mg / day ""-rsg nmbr mg / day"
44,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
45,measures,"comparison placebo-( mean % difference , nmbr % ci )-patients ( n )-( mean % change , nmbr % ci )-comparison baseline-week nmbr ( mean , sd )-patients ( n ) ""-baseline ( mean , sd )"
46,arms,"placebo-rsg nmbr mg / day ""-rsg nmbr mg / day"
47,characteristic_level,"< nmbr %-< nmbr % ""-> nmbr %"
48,characteristic_level,"sex , female-hypercholesterolemia-cabg surgery-aspirin-chf history-moderate dysfunction-severe dysfunction-anterior-peripheral vascular disease-previous cabg surgery-indeterminate unknown-systolic blood pressure , mean ( sd ) , mm hg-renal insufficiency-education , high school higher-p - blockers-ptca < nmbr h-previous ml-q wave-cerebrovascular disease-killip class lll - iv-smoking history-age , mean ( sd ) , y-mild dysfunction normal-thrombolytic therapy-anticoagulants-non - q wave-inferior-lipid - lowering drugs-depressed only-cardiac catheterization-ace inhibitors-ace inhibitors ""-diabetes-marital status , married-comorbidity score , mean ( sd ) t-previous ptca-low perceived social support only-depressed low perceived social support-body mass index , mean ( sd ) t-hypertension-race , nonwhite"
49,characteristic_name,"characteristics index ml-treatment index ml-current prescribed medications-current prescribed medications ""-medical characteristics-psychosocial risk factors-ejection fraction category"
50,arms,"usual care ( n = nmbr )-intervention ( n = nmbr ) ""-intervention ( n = nmbr )"
51,characteristic_name,". coronary vessels > nmbr % diameter stenosis-no . coronary vessels > nmbr % diameter stenosis "" ; na-entry criteria"
52,characteristic_level,"nmbr-active smoker-serum cholesterol , median ( iqr ) , mg / dl-cardiac troponin level > nmbr . nmbr pg / l-age , median ( iqr ) , y-previous cabg surgery-women-left ventricular ejection fraction , median ( iqr ) , %-diabetes mellitus-previous myocardial infarction-none-arterial hypertension-insulin - dependent ""-insulin - dependent-previous balloon angioplasty-st - segment depression-cardiac troponin level , median ( iqr ) , pg / l"
53,measures,". ( % )-no . ( % ) """
54,arms,"nmbr prolonged antithrombotic pretreatment ( n = nmbr )-nmbr early intervention ( n = nmbr )-nmbr early intervention ( n = nmbr ) """
55,characteristic_name,"cabg > nmbr month ago-bmi , mean ( sd ) , kg / mnmbr ""-left ventricular hypertrophy-pci > nmbr month ago-peripheral vascular disease-heart failure ( class l - lll )-angina pectoris-abnormal angiogram-stroke-other nsaids-aspirin antiplatelet agent-race / ethnicity white-potassium supplement-any lipid - lowering agent-bmi , mean ( sd ) , kg / mnmbr-age , mean ( sd ) , y-antidiabetic medication | |-hormone replacement ! !-arrhythmia-hypercholesterolemiat-renal impairmentt-prior ml abnormal angiogram-myocardial infarction-diabetesf-unstable angina > nmbr mo ago-cabg pci"
56,arms,"calcium antagonist strategy ( n = nmbr nmbr )-non - calcium antagonist strategy ( n = nmbr nmbr ) ""-non - calcium antagonist strategy ( n = nmbr nmbr )"
57,characteristic_name,"us resident-congestive heart failure-hypercholesterolemia-left ventricular hypertrophy-myocardial infarction-age , y-revascularization-diabetes-sex ""-race / ethnicity-sex"
58,characteristic_level,"male-no-yes-other-> nmbr-white-hispanic-female-female ""-black-< nmbr"
60,arms,"placebo ( n = nmbr )-abciximab ( n = nmbr )-placebo ( n = nmbr ) """
61,characteristic_level,"male-no-yes-< nmbr yr-> nmbr yr-female-female """
62,characteristic_name,"diabetes-age-intervention complex lesions-angina class iii iv prior-sex ""-sex"
63,arms,"abciximab . / total ( % )-placebo . / total ( % )-placebo . / total ( % ) """
64,outcomes,"primary outcome !-cardiovascular hospitalization ""-nonfatal ml-nonfatal stroke-cardiovascular hospitalization-death ( cause )-cardiovascular death !"
65,measures,"strategy-hr-nmbr % cl-strategy """
66,arms,"atenolol n = nmbr-verapamil sr n = nmbr ""-verapamil sr n = nmbr"
67,measures,". ( % )-rate *-rate * """
68,other,"placebo treatment ""-or placebo treatment"
69,characteristic_level,"ii-iv-iv ""-iii"
71,characteristic_name,"medical history-mean age , yrs-health habits ""-health habits"
72,arms,"placebo ( n = nmbr , nmbr )-beta - carotene ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) """
73,characteristic_level,"nmbr - nmbr ""-nmbr - nmbr-nmbr +-total"
75,characteristic_level,"nmbr - nmbr ""-nmbr - nmbr-nmbr +-total"
77,outcomes,"total cataract-total cataract extraction ""-total cataract extraction"
78,characteristic_level,"current non - smoker ""-current smoker-current non - smoker"
80,characteristic_name,"sex , . ( % )-baseline lipid / lipoprotem values-baseline lipid / lipoprotem values ""-pace , . ( nmbr )"
81,characteristic_level,"tc , mean ( sd ) , rrig / dl-male-tg , median ( sdy rng / cjl-apo - nmbr , mean ( sd ) , mg / dl-other-b lack-non - hdl - c , mean ( sd ) , rng / dl-white-hispanic-tchdl - c , mean ( sd )-apo b , mean ( sd ) , mg / dl-crp median ( se ) , rng / l-female-ldl - c , mean ( sd ) , mg / dl-ldl - cihdl - c , mean ( sd )-hdl - c , mean ( sd ) , mg / dl-plp - c , mean ( sd ) , mg / dl-tchdl - c , mean ( sd ) """
82,arms,"eze-pooled eze / simva ""-placebo-pooled simva-pooled eze / simva"
83,measures,"( n = nmbr )-( ri = nmbr )-( n = nmbr ) ""-( n = ms )"
84,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-amiodarone ( n = nmbr )-icd therapy ( n ="
85,characteristic_level,"age > nmbr yr-nmbr - nmbr ft-age < nmbr yr-< nmbr ft-qrs < nmbr msec-diabetes-no beta - blocker-female sex-male sex-lvef < nmbr %-beta - blocker-no beta - blocker ""-nonwhite race-lvef > nmbr %-no diabetes-white race-qrs > nmbr msec nmbr - min walk test-> nmbr ft"
86,measures,"icd therapy vs . placebo . hazard ratio ( nmbr . nmbr % cl )-amiodarone vs . placebo . hazard ratio ( nmbr . nmbr % cl )-icd therapy vs . placebo . hazard ratio ( nmbr . nmbr % cl ) """
87,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-aspirin ( n = nmbr , nmbr )-total ( n = nmbr , nmbr )"
88,characteristic_level,"no-yes-< nmbr / < nmbr mm hg-current-uncertain-> nmbr yr-postmenopausal , current hrt-postmenopausal , hrt-nmbr - nmbr / nmbr - nmbr mm hg-past never-nmbr - nmbr / nmbr - nmbr mm hg ""-> nmbr / > nmbr mm hg-< nmbr . nmbr-premenopausal-> nmbr . nmbr-nmbr - nmbr yr-nmbr . nmbr nmbr . nmbr"
89,characteristic_name,"body - mass indexf-smoking status-menopause hrt-age-blood pressure ""-hypertension !-blood pressure"
90,outcomes,"major cv event-myocardial infarction-total .-ischemic stroke-stroke-major cv event """
92,arms,"clopidogrel ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) """
93,characteristic_name,"predominant type heparin-types fibrinolytic agent ""-age-types fibrinolytic agent-infarct location-sex"
94,characteristic_level,"fibrin - specific-male-fibrin - specific ""-characteristic-< nmbr yr-overall-unfractionated-> nmbr yr-low - molecular - weight-nonanterior-none-female-anterior-non - fibrin - specific"
96,characteristic_name,"weight ( kg )-bmi ( kg / mnmbr )-apo b ( g / l )-men ( % )-tc ( mmol / l )-ldl - c ( mmol / l )-hdl - c ( mmol / l )-age ( years )-non - hdl - c ( mmol / l )-hscrp ( mg / l ) c-apo - l ( g / l )-diabetes ( % )-hscrp ( mg / l ) c ""-fibrinogen ( pmol / l ) c-tg ( mmol / l ) c-metabolic syndrome ( % ) b"
97,arms,"placebo ( n = nmbr )-feno nmbr mg / eze nmbr mg ( n = nmbr )-feno nmbr mg ( n = nmbr )-feno nmbr mg / eze nmbr mg ( n = nmbr ) ""-eze nmbr mg ( n = nmbr )"
98,characteristic_level,"tg > nmbr . nmbr ""-tg > nmbr . nmbr-tg < = nmbr . nmbr"
99,arms,"feno + eze-feno-eze-placebo-feno + eze """
100,arms,"placebo ( n = nmbr )-ezetimibe nmbr mg ( n = nmbr )-ezetimibe nmbr mg ( n = nmbr ) """
101,characteristic_name,"body mass index :-baseline ldl - c :-age : ""-age :-diabetes mellitus :-treatment stratum^ :"
102,measures,"mean baseline ldl - c ( mmol / l ) ""-mean baseline ldl - c ( mmol / l )"
104,characteristic_name,"menopausal status use ht-family history cancerf-smoking status-randomized receive beta carotene-randomized receive vitamin e-alcohol use , drinks / wk-age , y-bmi-bmi ""-physical activity , kcal / wk"
105,characteristic_level,"mean ( sd )-no-yes-current-past-uncertain-postmenopausal current ht-> nmbr-nmbr < nmbr-< nmbr ""-premenopausal-nmbr - nmbr-< nmbr-postmenopausal ht-never"
109,outcomes,"itherchdt-other vasculars-ml c-noneh-itherchdt """
110,characteristic_name,"age ( years ) :-ldl cholesterol ( mmol / l ) :-diastolic blood pressure ( mm hg ) :-sex :-previous disease : ""-triglycerides ( mmol / l ) :-treated hypertension :-hdl cholesterol ( mmol / l ) :-previous disease :-total cholesterol ( mmol / l ) :-history diabetes :"
112,characteristic_name,"age ( years ) :-ldl cholesterol ( mmol / l ) :-diastolic blood pressure ( mm hg ) :-sex :-previous disease : ""-triglycerides ( mmol / l ) :-treated hypertension :-hdl cholesterol ( mmol / l ) :-previous disease :-total cholesterol ( mmol / l ) :-history diabetes :"
114,arms,"eze / simva nmbr / nmbr mg ( n = nmbr )-atvnmbr mg ( n = nmbr ) ""-atvnmbr mg ( n = nmbr )"
115,arms,"placebo ( n = nmbr )-glucosamine + chondroitin sulfate ( n = nmbr )-chondroitin sulfate ( n = nmbr )-glucosamine ( n = nmbr )-celecoxib ( n = nmbr )-celecoxib ( n = nmbr ) """
116,characteristic_name,"bare - metal stent-nitrates-calcium antagonists-hypercholesterolemia *-complex lesions^-current smoking *-prior aortocoronary bypass surgery-elevated troponin ( > nmbr . nmbr pg / l )-women-p - blockers-multivessel disease-prior myocardial infarction-left ventricular ejection fraction , mean ( sd ) , %-age , mean ( sd ) , y-vessel size , mean ( sd ) , mm-insulin - treated diabetes-hours clopidogrel loading , mean ( sd )-arterial hypertension *-lesion length , mean ( sd ) , mm-ace inhibitors-left circumflex artery-statins-left circumflex artery ""-diabetes *-body mass index , mean ( sd ) t-elevated creatine kinase mb ( > nmbr u / l )-diameter stenosis , mean ( sd ) , %"
117,characteristic_level,"nmbr . nmbr ( nmbr . nmbr )-nmbr ( nmbr . nmbr ) ""-nmbr ( nmbr . nmbr )"
118,measures,"p value-p value """
119,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) """
120,characteristic_name,"diabetes-troponin level ""-troponin level-clopidogrel pretreatment duration"
121,characteristic_level,"< nmbr . nmbr l - g / l-no-yes-> nmbr . nmbr - g / l-> nmbr . nmbr - g / l ""-< nmbr h-all participants-> nmbr h"
122,measures,"primary end point , . events / total . ( % )-primary end point , . events / total . ( % ) """
123,arms,"placebo-placebo ""-abciximab"
124,characteristic_level,"male-yes ""-yes-female"
125,characteristic_name,"proteinurianmbr ( g / day )-weight ( kg )-serum creatinine ( mg / dl )-bmi ( kg / mnmbr )-albuminuria ( g / g )-cholesterol ( mg / dl )-hbanmbrc ( % )-weight ( kg ) "" ; na-age ( years )-sbp ( mmhg )-gender-dbp ( mmhg )-smoking-hemoglobin ( gm / dl )"
126,measures,"range ""-n ( % )-range-( gm )-mean ( . . )-w-n"
128,characteristic_level,"asian-black ""-white-hispanic-black"
130,measures,"n event ( rate )-w event ( rate )-w event ( rate ) """
131,characteristic_level,"baseline ldl - c-entire cohort-chd status-age-race ""-gender-race"
132,characteristic_name,"bmi ( kg / mnmbr )-diagnoses / risk factors , n ( % )-hs - crp ( mg / l )-lipid lipoprotein values ( mg / dl )-age , years , mean ( range )-race , n ( % )-diagnoses / risk factors , n ( % ) ""-gender , n ( % )"
133,characteristic_name,"age-race-age "" ; na"
134,characteristic_level,"male ""-male-< nmbr years-caucasian-> nmbr years baseline ldl - c-non - caucasian-chd-< nmbr mg / dl-female-entire cohort gender-no chd-> nmbrmg / dl chd status"
135,arms,"simva-eze / simva-eze / simva """
136,arms,"nmbr / nmbr mg-nmbr mg-nmbr / nmbr mg """
137,characteristic_name,"entire cohort-chd status-age-entire cohort ""-race"
138,characteristic_level,"eze / simva gender ""-> nmbr years eze / simva baseline ldl - c-chd eze / simva-non - caucasian eze / simva-< nmbr years eze / simva-> nmbr mg / dl simva-chd simva-< nmbr years simva-< nmbr mg / dl simva-no chd eze / simva-caucasian eze / simva-caucasian simva-male simva-female eze / simva-female simva-simva-< nmbr mg / dl eze / simva-> nmbr mg / dl eze / simva-no chd simva-male eze / simva-non - caucasian simva-eze / simva gender-> nmbr years simva"
139,other,"select lipids lipoproteins-select lipids lipoproteins """
140,outcomes,"tg +-tc-tg + ""-hdl - c-non - hdl - c-apo b-apo -"
141,outcomes,"laboratory ae , n ( % }-laboratory ae , n ( % } ""-clinical ae , n ( % }"
142,outcomes,"myopathyt-alt / ast > nmbr times uln consecutive #-serious ae-cpk > nmbr times uln ""-drug - related ae *-deaths-discontinuations due ae-cpk > nmbr times uln-any clinical ae"
143,characteristic_name,"demographics-additional investigations-history-rankin grade-time longest event randomisation-type vessel involved-dose aspirin-blood pressure ( mm hg )-antithrombotic drug use time event-qualifying event-history ""-randomisation scheme"
144,characteristic_level,"nmbr - nmbr months-intermittent claudication-other-aspirin-nmbr = help needed ; still independent-< nmbr week-current cigarette smoking ""-current cigarette smoking-transient ischaemic attack-two arm-ultrasound carotid arteries-any relevant infarct-minor ischaemic stroke-three arm-diastolic ( mean , sd )-male-nmbr mg-angina pectoris-vascular intervention-nmbr = symptoms-diabetes mellitus-transient monocular blindness-stroke-hyperlipidaemia-ct mr scan brain *-nmbr = restrictions ; help needed-none-nmbr = minor symptoms ; limitations-nmbr week nmbr month-small vessel-age ( years ) ( mean , sd )-large vessel-myocardial infarction-systolic ( mean , sd )-stenosis > nmbr %-oral anticoagulants-unspecified-any infarct-hypertension"
145,arms,"aspirin alone ( n = nmbr )-aspirin alone ( n = nmbr ) ""-aspirin + dipyridamole ( n = nmbr )"
146,characteristic_name,"female ( % )-previous myocardial infarction ( % )-cabg ( % )-previous stroke ortransient ischaemic attack ( % )-lipid - lowering agents ( % )-systolic blood pressure ( mm hg )-diastolic blood pressure ( mm hg ) medications-p blockers ( % )-peripheral - artery disease ( % )-calcium - channel blockers ( % )-antiplatelet agents ( % )-serum cholesterol ( mg / l ) *-hypertension ( % )-current smokers ( % ) ""-age ( years )-diabetes ( % )-current smokers ( % )-pci ( % )-diuretics ( % )"
147,other,"hope ( n = nmbr )-peace ( n = nmbr )-hope patients coronary - artery disease ( n = nmbr )-europa ( n = nmbrlnmbr )-peace ( n = nmbr ) """
148,characteristic_level,"revascularisation + antiplatelets + lipid - lowering agents + p blockers-with antiplatelets-without p blockers-all above-two above-with revascularisation-without antiplatelets-one above-without lipid - lowering agents-with p blockers-revascularisation antiplatelets , lipid - lowering agents , p blockers-with revascularisation ""-with lipid - lowering agents-without revascularsation-none"
150,characteristic_name,"aspirin-hypertension *-medications antihypertensive drugs ""-women-systolic blood pressure ( mm hg )-lipoprotein ( ) ( mmol / l )-current / past smoker-body - mass index ( kg / mnmbr )-diuretics-demographics age ( years )-hdl cholesterol ( mmol / l )-triglyceride ( mmol / l ) t-ldl cholesterol ( mmol / l )-p blockers-lipid concentrations total cholesterol ( mmol / l )-calcium - channel blockers-medications antihypertensive drugs-diastolic blood pressure ( mm hg )-diabetes *-ace inhibitors / arb-men"
151,arms,"diet group ( n = nmbr )-diet plus pravastatin group ( n = nmbr ) ""-diet plus pravastatin group ( n = nmbr )"
152,characteristic_name,"ldl cholesterol-body - mass index-current / past-triglycerides-hdlcholesterol-diabetes-smoker-age-total cholesterol-body - mass index ""-hypertension-sex"
153,characteristic_level,"< nmbr kg / mnmbr-male-no-nmbr - nmbr mmol / l-yes-nmbr kg / mnmbr-< nmbr kg / mnmbr ""-< nmbr years-nmbr years-< nmbr - nmbr mmol / l-female"
155,characteristic_name,"race , n ( % ) ""-race , n ( % )-metabolic syndrome characteristics , n ( % )"
156,characteristic_level,"blood pressure ; pbo patients diabe teristics ( ncep atp i-nmbr ( nmbr . nmbr )-nmbr . nmbr + nmbr . nmbr-n = nmbr-nmbr ( nmbr . nmbr ) """
157,characteristic_level,"metabolic syndrome * n = nmbr ""-metabolic syndrome * n = nmbr-neither n = nmbr , nmbr"
158,arms,"eze + statin n = nmbr ""-eze + statin n = nmbr-pbo + statin n = nmbr"
159,measures,"treatment difference-treatment difference "" ; na"
160,measures,"% change-at six weeks-baseline-( % , nmbr % cl )-baseline """
161,outcomes,"ldl - c ( mmol / l , mean )-apo b / apo - l ratio ( mean )-non - hdl - c ( mmol / l , mean )-hs - crp ( mg / l , median )-hdl - c ( mmol / l , mean )-total c ( mmol / l , mean )-key : tc = triglyceride ; hs - crp = ldl - c = low - density lipoprotein fc = fasting glucose ; ncep atp * category include ar > _ nmbr indicated char least - square means , except tc note : treatment subgroup-ldl - c ( mmol / l , mean ) ""-tg ( mmol / l , median )"
163,arms,"pbo + statin-ze + statin-pbo + statin nmbr-eze + statin ""-eze + statin"
164,characteristic_level,"statins "" ; na-aspirin-ace inhibitors-statins-, nmbr - blockers"
165,characteristic_name,"prior myocardial infarction-hypercholesterolemia ( > nmbr mg / dl )-elevated troponin ( > nmbr . nmbr / xg / l )-women-body mass index , kg / mnmbr-elevated creatine kinase - mb ( > nmbr u / l )-age , y-diabetes-prior pci-arterial hypertension-current smoking-elevated creatine kinase - mb ( > nmbr u / l ) ""-therapy discharge-serum creatinine , mg / dl-interval clopidogrel loading , h-prior coronary artery bypass surgery"
166,characteristic_level,"age ' nmbr ( n nmbr ) ""-age ' nmbr ( n nmbr )-age > nmbr ( n = nmbr )"
168,outcomes,"profound thrombocytopenia ( < nmbrxnmbr / l )-hemorrhagic stroke-blood transfusion-death-myocardial infarction-major bleeding-minor bleeding-major bleeding ""-mace-target - vessel revascularization-moderate thrombocytopenia ( < nmbrxnmbr / l )-mild thrombocytopenia ( < nmbrx nmbr / l )-death myocardial infarction"
169,characteristic_level,"age ' nmbr ( n nmbr ) ""-age ' nmbr ( n nmbr )-age > nmbr ( n = nmbr )"
171,characteristic_name,"baseline pasi score-prior use $ nmbr systemic therapies-prior use biologic agents-prior use biologic agents ""-baseline % bsa involvement-dissatisfied / stopped $ nmbr prior systemic therapy side effects-dissatisfied / stopped $ nmbr prior systemic therapies side effects"
172,characteristic_level,"no-yes-\nmbr-$ nmbr-$ nmbr %-no ""-\nmbr %"
173,characteristic_name,"disease ""-low - dose aspirin use baseline-diabetes-age-etoricoxib dose-established ascvd-established ascvd > nmbr cv risk factors-disease-sex"
174,characteristic_level,"nmbr - nmbr ""-nmbr-nmbr - nmbr"
176,measures,"n / pyr-rate *-rate * """
177,arms,"metformin ( n = nmbr )-glyburide ( n = nmbr )-metformin ( n = nmbr ) ""-rosiglitazone ( n = nmbr )"
178,characteristic_name,"randomization-to randomization ""-baseline characteristic-time symptoms treatment-medical treatment"
179,characteristic_level,"median-interval onset symptoms-double - vessel disease , n ( % )-infarct related artery location-interval randomization angiography-heart rates ( beats / minutes )-ace - inhibitors , n ( % )-beta - blockers , n ( % )-previous angina , n ( % )-aspirin , n ( % )-calcium antagonists , n ( % )-current smoking , n ( % )-number vessels disease-systolic blood pressure ( mm hg )-age ( year )-previous angioplasty , n ( % )-diabetes , n ( % )-angiographic features-family history , n ( % )-degree stenosis , % diameter-triple - vessel disease , n ( % )-median ""-previous myocardial infarction , n ( % )-interquartile range-evidence thombus , n ( % )-left anterior descending , n ( % )-single - vessel disease , n ( % )-non - stenotic vessels , n ( % )-hypertension , n ( % )-cholesterol , ( . nmbr . nmbr mmol / l ) , n ( % )-rca , n ( % )-left circumflex , n ( % )-male sex , n ( % )"
181,arms,"etoricoxib group ( n = nmbr nmbr )-diclofenac group ( n = nmbr nmbr )-diclofenac group ( n = nmbr nmbr ) """
182,characteristic_name,"patients clinical event-patients uncomplicated events ""-patients complicated events-patients uncomplicated events"
183,characteristic_level,"aspirin use ( p = nmbr - nmbrt )-ppi use ( p = nmbr - nmbrt ) ""-ppi use ( p = nmbr - nmbrt )"
184,characteristic_level,"no-yes-no """
186,measures,"rate *-n / n ( % )-n / n ( % ) """
187,characteristic_name,"demographics-medications , n ( % )-extent disease , n ( % )-extent disease , n ( % ) ""-health - related quality life-disease characteristics"
188,arms,"infliximab-infliximab """
189,arms,"combined ( n = nmbr )-nmbr mg / kg ( n = nmbr )-nmbr mg / kg ( n = nmbr ) """
190,characteristic_name,"hmgcoa rl-risk factors-medication use-risk factors """
191,characteristic_level,"hypertension serum lipid values-other statin-hypertension serum lipid values ""-cabgorptca-bmi ( kg / mnmbr ) cardiovascular history-diastolic ( mm hg )-systolic ( mm hg )-simvastatin-male-hdl - cholesterol ( mmol / l )-other antihypertensive agents-pravastatin-ldl - cholesterol ( mmol / l )-hypoglycaemic agents-age ( years )-total cholesterol ( mmol / l )-angina-myocardial infarction-diabetes-p blocker-triglyceride ( mmol / l ) * blood pressure-calcium antagonist-smoking-antiplatelet agent-nitrate"
192,arms,"epa treatment ( n = nmbr ) ""-epa treatment ( n = nmbr )-controls ( n = nmbr )"
193,characteristic_name,"total cholesterol ( mmol / l ) ""-diabetes-sex-hdl - cholesterol-age ( years )-triglyceride ( mm-total cholesterol ( mmol / l )-bmi-ldl - cholesterol (-smoking-previous cad"
194,characteristic_level,"male-< nmbr - nmbr-absent-> nmbr - nmbr-> nmbr-smoker-> nmbr ""-female-hypertension absent-non - smoker-present-< nmbr"
197,arms,"ranolazine ( n = nmbr )-ranolazine ( n = nmbr ) ""-placebo ( n = nmbr )"
198,characteristic_name,"demographic characteristics-comorbid diseasesa diabetesb-race , . ( % )-recurrent infections ( > nmbr per year )-race , . ( % ) ""-cardiovascular risk factors , . ( % )"
199,characteristic_level,"insulin dependentc-oral hypoglycaemics only-other-hispanic-sinusitis-age , mean ( min - max ) ( yrs )-duration ra , mean ( min - max ) ( yrs )-urinary tract infection-at least two cardiovascular risk factors-congestive heart failure ( definite )-white-native american-bronchitis-arrhythmia-comorbidities diabetes-black-female , ( % )-pneumonia past year-asian-coronary artery disease-myocardial infarction-hispanic ""-chronic pulmonary disease-hypertension"
200,arms,"placebo ( n = nmbr )-etanercept ( n = nmbr ) ""-etanercept ( n = nmbr )"
201,characteristic_name,"intestinal area involved , n ( % ) $ ""-intestinal area involved , n ( % ) $-concomitant medication , n ( % )-antibodies infliximab , n ( % ) * *"
202,arms,"placebo group ( n = nmbr )-adalimumab group ( n = nmbr ) ""-adalimumab group ( n = nmbr )"
203,other,"atorvastatin factorial study-pooled simvastatin factorial studies-pooled simvastatin factorial studies """
204,arms,"ezetimibe + simvastatin ( n = nmbr , nmbr * )-ezetimibe + simvastatin ( n = nmbr * )-placebo ( n = nmbr * )-simvastatin monotherapy ( n = nmbr , nmbr * )-atorvastatin monotherapy ( n = nmbr * )-ezetimibe nmbr mg ( n = nmbr * )-ezetimibe nmbr mg ( n = nmbr * ) """
206,characteristic_name,"major risk factors-blood pressure control-blood pressure control ""-previous vascular disease"
207,characteristic_level,"serum total cholesterol ( mmol / l ) , mean ( sd )-systolic blood pressure ( mm hg ) , mean ( sd )-serum hdl cholesterol ( mmol / l ) , mean ( sd )-urinary albumin : creatinine ratio ( pg / mg ) , median ( iqr )-history stroke , n ( % )-history major macrovascular disease , n ( % )-serum creatinine ( pmol / l ) , mean ( sd )-current smokers , n ( % )-history macroalbuminuriat , n ( % )-diastolic blood pressure ( mm hg ) , mean ( sd ) ""-history major microvascular disease , n ( % )-diastolic blood pressure ( mm hg ) , mean ( sd )-microalbuminuria , n ( % )-history myocardial infarction , n ( % )-history currently treated hypertension , n ( % )-body - mass index ( kg / mnmbr ) , mean ( sd )-serum haemoglobin anmbrc concentration ( % ) , mean ( sd )-history microvascular eye disease < u + nmbrc > , n ( % )"
208,other,"randomised treatment-randomised treatment """
209,arms,"placebo ( n = nmbr )-active ( n = nmbr )-placebo ( n = nmbr ) """
210,characteristic_name,"treatment bp lowering drugs-sbp ( mm hg )-treatment anti - platelet drugs-age ( years )-history hypertension *-treatment open - label perindopril ""-history macrovascular disease-treatment statins-hbanmbrc ( % )-treatment open - label perindopril-history microvascular disease-sex"
211,characteristic_level,"no-^nmbr - nmbr-yes ""-yes-> nmbr - nmbr-women-> nmbr-combined macro + micro-men-< nmbr"
212,measures,"relative risk reduction ( nmbr % cl )-number ( % ) patients event ""-number ( % ) patients event"
213,arms,"placebo ( n = nmbr )-pctindopnl - indapamide ( n = nmbr )-placebo ( n = nmbr ) """
214,arms,"placebo-rosuvastatin-rosuvastatin """
215,measures,"( n = nmbr )-( n = nmbr ) """
216,characteristic_name,"systolic blood pressure-previous myocardial infarction-age-previous hypertension-bmi-cardiac rhythm ""-anticoagulants-cardiac rhythm"
217,characteristic_level,"< nmbr . nmbr bpm-all patients-> nmbr-> nmbr mm hg-iii iv ejection fraction-< nmbr . nmbr mmol / liter estimated gfr-< nmbr ml / min / nmbr . nmbr mnmbr nt - pro - bnp-< nmbr mm hg heart rate-> nmbr . nmbr-> nmbr . nmbr mmol / liter-yes previous revascularization-atrial fibrillation ldl cholesterol level-< nmbr . nmbr pmol / liter-yes-> nmbr . nmbr pmol / liter hscrp level-< nmbr yr-sinus rhythm-> nmbr yr sex-< nmbr . nmbr mg / liter-no diabetes-no-> nmbr . nmbr hdl cholesterol level-< nmbr . nmbr-female-> nmbr . nmbr mg / liter antiplatelet agents-< nmbr . nmbr mmol / liter apob : apoa - l ratio-< nmbr . nmbr mmol / liter triglyceride level-male nyha class-> nmbr . nmbr mm hg-> nmbr ml / min / nmbr . nmbr mnmbr-> nmbr . nmbr bpm current smoker-< nmbr . nmbr mm hg diastolic blood pressure-ii-< nmbr-> nmbr . nmbr mmol / liter """
218,arms,"rosuvastatin patients ( rate ) ""-placebo . events / .-rosuvastatin patients ( rate )"
219,characteristic_name,"race ethnicity , n ( % ) ""-race ethnicity , n ( % )"
220,characteristic_level,"age , years-uacr , mgg nmbr ( gm )-male , n ( % )-other-hemoglobin , g nmbr nmbr-hispanic-white-serum creatinine , limo nmbr nmbr-serum albumin , g nmbr nmbr-phosphorus , mmol nmbr nmbr-other ""-black-diastolic bp , mm hg-asian-egfr , ml min nmbr nmbr . nmbr nmbr-systolic bp , mm hg-triglycerides , mmoltnmbr ( gm * )-calcium , mmol nmbr nmbr-female , n ( % )"
221,characteristic_level,"baseline hb nmbrg nmbr n = nmbr-combined n = nmbr-baseline hb < nmbr g nmbr nmbr n = nmbr-baseline hb < nmbr g nmbr nmbr n = nmbr """
222,arms,"nmbr placebo n = nmbr ""-losartan n = nmbr-nmbr placebo n = nmbr-placebo n = nmbr"
223,outcomes,"esrd-esrd ""-esrd death"
224,characteristic_level,"cox bsl onlyc-cox bsl + yr nmbr hbd ""-cox bsl + yr nmbr hbd"
226,measures,"k ( rate )-n ""-n"
227,characteristic_name,"age-age """
228,characteristic_level,"tg , median ( interquartile range )-mean ( sd ) , y-tc , mean ( sd )-< nmbr , n ( % )-bmi , mean ( sd ) , kg / mnmbr-smoker , ! n ( % )-ldl - c , mean ( sd )-dbp , mean ( sd ) , mm hg-bmi indicates body mass index ; sbp , systolic blood pressure ; dbp , lipoprotein ( ) . ldl - c calculated friedewald formula . ' hypertension diabetes based physician diagnosis . ! smoker includes current past smokers .-> nmbr , n ( % )-diabetes , * n ( % )-hypertension , * n ( % )-lp ( ) , mean ( sd )-drinking , n ( % ) lipid values , mmol / l-hdl - c , mean ( sd )-sbp , mean ( sd ) , mm hg-ldl - c , mean ( sd ) """
229,characteristic_level,"women-men , total ( n = nmbr )-men , total ( n = nmbr ) """
230,arms,"diet ( n = nmbr )-total ( n = nmbr )-total ( n = nmbr ) ""-diet - - pravastatin ( n = nmbr )"
231,outcomes,"total mortality ""-total mortality-chd + cerebrovascular disease men nmbr / nmbr ( nmbr . nmbr )-stroke"
232,characteristic_level,"nmbr / nmbr ( nmbr . nmbr ) ""-nmbr / nmbr ( nmbr . nmbr )"
234,outcomes,"chd + cerebral infarction-total mortality-stroke ""-stroke"
235,characteristic_level,"""-> nmbr years-all-> nmbr years nmbr / nmbr ( nmbr . nmbr )"
236,measures,"incidence rate . ( / nmbrperson - years )-incidence rate . ( / nmbrperson - years ) ""-hazard ratiof ( nmbr % ci )-p value f"
237,arms,"diet ""-diet + pravastatin-diet"
238,characteristic_name,"laboratory variables-race ethnic group , . ( % ) ""-sex , . ( % )-serum cholesterol , mg / dld-known duration diabetes , yr-medical history , . ( % )-race ethnic group , . ( % )-blood pressure , mmhg"
239,characteristic_level,"age , yr-other-body mass indexnmbr-hispanic-use antihypertensive drugs-glomerular filtration rate , nmbr ml / min / nmbr . nmbr mnmbr-serum albumin , g / dl-urinary albumin / creatinine ratio , median mg / g ( range )-glycosylated hemoglobin , %-male-amputation-coronary revascularization procedure-angina pectoris-< nmbr yr-white-hemoglobin , g / dlf-total-serum creatinine , mg / dlb-stroke-retinopathy-hdl-serum triglycerides , mg / dle-> nmbr yr-ldl-diastolic-lipid disorder-female-not available-systolic-black-asian-neuropathy-myocardial infarction-hispanic ""-current smoking"
241,arms,"ii ( n = nmbr )-dd ( n = nmbr )-id ( n = nmbr )-id ( n = nmbr ) """
242,outcomes,"doubling serum creatinine-death-death ""-esrd death-esrd"
243,characteristic_level,"id ""-id-dd-ii-composite endpoint doubling serum creatinine , esrd ,"
245,characteristic_name,"time since diagnosis diabetes ""-time since diagnosis diabetes"
246,characteristic_level,"thiazide diuretics-waist - - hip ratio-anmbrc ( % )-loop diuretics-postmenopausal-> nmbr years-< nmbr year-glucocorticoids *-nmbr - nmbr years-estrogen - containing hormones-bmi ( kg / mnmbr )-fasting plasma glucose ( mg / dl ) ""-systolic blood pressure ( mmhg )-age ( years )-diastolic blood pressure ( mmhg )-waist circumference ( cm )-n-fasting plasma glucose ( mg / dl )-bisphosphonates-calcium supplements-fasting insulin ( pmol / l )"
247,characteristic_level,"women ""-women-men"
248,arms,"metformin-metformin ""-glyburide-rosiglitazone"
249,outcomes,"skull , facial bone fractures-radius fracture-fractures ( site specified )-others ""-tibia fracture-humerus fracture-femur fracture-wrist fracture-spinal fractures-upper limb fracture-others-ankle fracture-thoracic cage fractures-lower limb fractures-lower limb fracture-hip fracture-clavicle fracture-upper limb fractures-number patients fractures-foot fracture-fibula fracture-hand fracture-patella fracture"
250,arms,"metformin-metformin ""-glyburide-rosiglitazone"
251,measures,"( n = nmbr , ""-( n = nmbr ,"
252,measures,"py = nmbr . nmbr )-py = nmbr . nmbr ) """
253,measures,"%-py *-n ""-n"
254,outcomes,"skull , facial bone fractures-radius fracture-forearm fracture-fractures ( site specified )-tibia fracture-humerus fracture-femur fracture-wrist fracture-spinal fractures-upper limb fracture-wrist fracture ""-others-ankle fracture-pelvic fractures-thoracic cage fractures-lower limb fractures-lower limb fracture-hip fracture-clavicle fracture-upper limb fractures-number patients fractures-foot fracture-fibula fracture-hand fracture-patella fracture"
255,arms,"metformin-metformin ""-glyburide-rosiglitazone"
256,measures,"( n = nmbr , ""-( n = nmbr ,"
257,measures,"py = nmbr . nmbr )-py = nmbr ) ""-py = nmbr )"
258,measures,"% ""-%-py *-n"
259,characteristic_name,"prior treatment-diabetic status-severity hypertensionb-age category-prior treatment ""-race-sex"
260,characteristic_level,"other-arb-p - blocker-male-age , ya-< nmbr y-white-less severe-ccb-diuretic-mssbp , mm hga-more severe-nondiabetic-female-acei-black-diuretic ""-sitting pulse , bpma-diabetic-msdbp , mm hga-> nmbr"
262,characteristic_name,"alcohol consumption ( % )-exercise ( % ) ""-postmenopausal hormone use-exercise ( % )-smoking status ( % )"
263,characteristic_level,"nmbr - nmbr / week-current-postmenopausal-past-> nmbr / week-bmi > nmbr kg / mnmbr ( % )-history hypertension ( % )-history diabetes ( % )-, nmbr / week-mean ( sd ) age ( years )-, nmbr / week ""-current ( , nmbr cigs / day )-nmbr - nmbr / month-> nmbr / day-current ( nmbr + cigs / day )-rarely-mean ( sd ) bmi ( kg / mnmbr )-never"
265,characteristic_level,"exercise-bmi ( kg / mnmbr )-smoking status-exercise ""-vitamin e-age ( years )-postmenopausal hormone use"
266,characteristic_name,"stratified analyses-stratified analyses """
268,characteristic_level,"prior mi ""-no prior mi-prior mi"
269,measures,"non - fatal mi ""-death-non - fatal mi-non - fatal stroke-adverse outcome-n"
272,characteristic_name,"total body ( without head )-lumbar spine-one - third radius "" ; na-trochanter-one - third radius-total hip-femoral neck"
273,characteristic_level,"< nmbr yr since menopause-> nmbr yr since menopause "" ; na-> nmbr yr since menopause-overall"
274,arms,"placebo-denosumab ""-denosumab"
275,measures,"difference baselinea ""-difference baselinea-difference placeboa"
276,measures,"( ci ) b-ls mean-( ci ) b ""-p value c"
277,characteristic_name,"cardiac "" ; na-carotid-aspirin use ( > nmbr mg )-diabetes therapy-cardiac-cholesterol ( mg / dl )"
278,characteristic_level,"body mass index ( bmi ) , kg / mnmbr-lifestyle-lv mass index ( g / mnmbr - nmbr )-lv ejection fraction "" ; na-insulin plus oral-egfr-plaque ( n , % )-lv mass-yes-systolic blood pressure ( mm hg )-imt ( mm )-insulin-waist ( cm )-total-arterial area ( mmnmbr )-non - hdl-lv ejection fraction-hdl-ale-current-ldl-oral hypoglycemics-former-age ( years )-triglycerides ( mg / dl ) * *-plaque score ( nmbr - nmbr )-crp ( mg / dl ) * *-gender , women n , % )-diastolic blood pressure ( mm hg )-smoking-never"
280,measures,"aggressive ( nmbr )-p - val . ( nmbr )-standard ( nmbr )-imt ( nmbr )-group dif . ( nmbr ) ""-group dif . ( nmbr )-lvmi ( nmbr"
281,measures,"mean ( sd )-inter .-mean ( sd ) ""-n"
282,characteristic_level,"cerebral thrombosis-unknown "" ; na-cerebral hemorrhage-unknown-cerebral embolism-subarachnoid hemorrhage-tia"
283,characteristic_name,"antiplatelet agents-sbp indicates systolic blood pressure ; dbp , diastolic blood pressure ; aa , arachidonic acid ; epa , eicosapentaenoic acid . values age , bmi , total cholesterol , ldl cholesterol , hdl cholesterol , sbp , dbp , aa , epa , epa / aa ratio represent mean values represent median ( interquartile range ) . p values differences epa epa groups .-male-smoker-epa , mol %-stroke-dbp , mm hg-hdl cholesterol , mmol / l-aa , mol %-sbp , mm hg-total cholesterol , mmol / l-antihypertensive agents-coronary artery disease-bmi , kg / mnmbr-ldl cholesterol , mmol / l-age , y-diabetes-stroke ""-epa / aa ratio-triglyceride , mmol / l-hypertension"
284,characteristic_level,"secondary prevention subgroup-secondary prevention subgroup ""-primary prevention subgroup"
286,characteristic_name,"secondary prevention subgroup-secondary prevention subgroup ""-primary prevention subgroup"
288,characteristic_name,"surgery-anaesthesia / analgesia ""-pre - operative cardiac medications *-anaesthesia / analgesia-other cardiovascular risk factors"
289,characteristic_level,"lumbar epidural ""-intraperitoneal-other-aspirin-statin-orthopaedic-history hypertension-sex ( female )-any history congestive heart failure-age > nmbr years-regional anaesthesia-vascular-general andthoracic epidural-preoperative serum creatinine > nmbr pmol / l-calcium channel blocker-lumbar epidural-stroke thought due atherothrombotic disease-spinal-preoperative heart rate ( beats per minute )-general-hospitalisation chf within nmbr years randomisation-general lumbar epidural-history transient ischaemic attack-intrathoracic intraperitoneal surgery-emergent / urgent surgery-current smoker-diuretic-age ( years )-peripheral arterial disease-low - molecular weight heparin intravenous unfractionated heparin-coronary artery disease-preoperative blood pressure ( mm hg ) patients fulfilling eligibility criteria-ace inhibitor arb-three seven risk factors-undergoing major vascular surgery-diabetes currently oral hypoglycaemic agent orinsulin"
291,characteristic_name,"other-aspirin-> nmbr-hispanic-hormone therapy-oral contraceptives-male-overweight ( nmbr < nmbr kg / mnmbr )-past-white-obese ( > nmbr kg / mnmbr )-current-diastolic-female-systolic-systolic ""-black-lean ( < nmbr kg / mnmbr )-statins-< nmbr-never"
292,measures,"hctz = hydrochlorothiazide . * based wilcoxon nmbr - sample rank - sum tests age body mass index , tests systolic diastolic blood ' / nmbr tests categorical variables . data missing patients .-sex , . ( % )-body mass index category , . ( % ) l-race , . ( % )-weight , median ( interquartile range ) , kg-blood pressure , mean ( sd ) , mm hg-smoking status , . ( % )-age , median ( interquartile range ) , y-age group , . ( % ) , y-blood pressure , mean ( sd ) , mm hg ""-concomitant therapy , . ( % )-diabetes , . ( % )"
294,characteristic_level,"current nonsmokers-overweight ( nmbr < nmbr kg / mnmbr )-women-> nmbr-white-hispanic-lean ( < nmbr kg / mnmbr )-obese ( > nmbr kg / mnmbr ) ""-obese ( > nmbr kg / mnmbr )-current smokers-men-black-< nmbr"
295,characteristic_name,"race-smoking status-body mass index + ""-age , y-body mass index +-sex"
297,characteristic_level,"current smoker ""-overweight ( nmbr < nmbr kg / mnmbr )-current nonsmoker-diabetic-women-current smoker-> nmbr-white-hispanic-nondiabetic-lean ( < nmbr kg / mnmbr )-obese ( > nmbr kg / mnmbr )-men-black-< nmbr"
298,characteristic_name,"smoking status-body mass index *-diabetes status-age , y-race-smoking status ""-sex"
301,characteristic_name,"lowering drugs ""-body - mass index-lowering drugs-systolic blood pressure-glycated hemoglobin-age-history macrovascular disease-blood glucose-treatment statins-treatment antiplatelet drugs-history microvascular disease-sex"
302,characteristic_level,"male-no-yes ""-yes-< nmbr yr-overall-> nmbr yr-< nmbr . nmbr mmol / liter-< nmbr . nmbr %-> nmbr mm hg-> nmbr-female-< nmbr-> nmbr . nmbr mmol / liter-< nmbr mm hg-> nmbr . nmbr %"
304,characteristic_name,"other-> nmbr years-male-mssbp , mmhg ( sd )-mean weight , kg ( sd )-white-diabetes mellitus-native american-mean age , years ( sd )-< nmbr years-pacific islander-female-black-asian-no . patients-serum creatinine , mean ( sd ) , pmol / l-mean bmi , kg / mnmbr ( sd )-msdbp , mmhg ( sd )-pacific islander """
305,arms,"v alsartan / hctz , n ( % )-valsartan , n ( % ) ""-valsartan , n ( % )"
306,characteristic_name,"age-age ""-race-severity"
307,characteristic_name,"demographic-medications , . ( % )-medical history , . ( % )-medical history , . ( % ) ""-race / ethnicity , . ( % )-blood pressure"
308,arms,"atenolol strategy ( n = nmbr , nmbr )-verapamil sr strategy ( n = nmbr , nmbr ) ""-verapamil sr strategy ( n = nmbr , nmbr )"
309,outcomes,"- cause mortality "" ; na-all - cause mortality-nonfatal ml-primary outcome-nonfatal stroke"
310,characteristic_level,"nmbr-nmbr """
311,arms,"verapamil sr-atenolol *-verapamil sr """
312,measures,"hazard ratio ( nmbr % confidence interval ) *-p-incidence *-incidence * """
313,arms,"p-atenolol strategy ( n = nmbr )-v total ( n = nmbr ) ""-rerapamil - sr strategy ( n = nmbr )-v total ( n = nmbr )"
314,outcomes,"cv death-fatal nonfatal stroke-death-fatal nonfatal ml-nonfatal stroke-primary outcome-nontatal ml-nonfatal stroke """
316,characteristic_name,"tobacco use ( % )-exercise category ( % )-toast classification qualifying stroke ( % )-score modified rankin scale ( ' % / ' ""-time qualifying stroke randomization-alcohol use ( % )-ethnic group ( % )-baseline nihss score ( % ) #-region ( % )-score modified rankin scale ( ' % / '"
317,arms,"clopidogrel ( n = nmbr , nmbr ) ""-clopidogrel ( n = nmbr , nmbr )-aspirin - erdp ( n = nmbr , nmbr )"
318,characteristic_name,"medical history-toast classification qualifying stroke-obesity ""-randomization placebo telmisartan-prespecified analysis-ace - inhibitor use-diabetes mellitus-age-stroke risk score-obesity-time onset qualifying stroke randomization-alcohol use-statin use-medical history hypertension-baseline systolic blood pressure-ethnic group-sex"
319,characteristic_level,"large - artery atherosclerosis-nmbr drinks / wk-slo days-> nmbr mm hg-placebo-no ""-nmbr - nmbr drinks / wk-< nmbr mm hg-> nmbr drinks / wk-male-yes-< nmbr yr-> nmbr - nmbr ( moderate risk )-nmbr - nmbr ( low risk )-> nmbr < nmbr yr-> nmbr days-previous stroke tia-no-small - artery occlusion-any recurrent stroke-telmisartan-> nmbr yr-african-female-south asian-other atherosclerotic event-> nmbr ( high risk )-undetermined , , cardioembolism-native latin-> nmbr < nmbr mm hg-other asian-chinese-neither-white / european"
321,arms,"telmisartan ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) """
322,characteristic_name,"medical history-patients ' characteristics-heart disease risk factors ""-ecg findings-nyha class-heart disease risk factors-physical examinations-medical treatment-heart failure cause"
323,characteristic_level,"mitral insufficiency-atrial fibrillation-nitrates-other antiplatelet agents-neoplasia-copd-history atrial fibrillation-left ventricular hypertrophy-ace inhibitors / arbs-aspirin-spironolactone-current smoking ""-history hypertension-hypertensive-peripheral vascular disease-amiodarone-age > nmbr years-aortic stenosis-women-non - detectable / unknown-oral anticoagulant drugs-arbs-previous ami-lvef ( % )-bmi ( kg / mnmbr )-sbp ( mm hg )-icd-pulmonary rales-age ( years )-heart rate ( beats per min )-iii-lvef > nmbr %-dilatative-pathological q waves-p blockers-ischaemic-iv-dbp ( mm hg )-pci-admission hf previous year-qrs > nmbr ms *-third heart sound-calcium - channel blockers-ace inhibitors-diabetes-other cause-current smoking-pacemaker-diuretic drugs-ii-digitalis-cabg-previous stroke"
324,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-rosuvastatin ( n = nmbr )"
325,characteristic_level,"total cholesterol < nmbr nmbr mmol / lt-non - ischaemic cause-total cholesterol < nmbr nmbr mmol / lt ""-nyha ii-age > nmbr years ( median )-total cholesterol > nmbr ' nmbr mmol / lt-diabetes-lvef < nmbr %-nyha iii iv-lvef > nmbr %-no diabetes-age < nmbr years ( median )-ischaemic cause"
327,characteristic_name,"medical history-cause heart failure-patients ' characteristics-ecg findings-patients ' characteristics ""-nyha class-heart disease risk factors-medical treatment-physical examination"
328,characteristic_level,"mitral insufficiency-atrial fibrillation-nitrates-other antiplatelet agents-neoplasia-other-copd-history atrial fibrillation-left ventricular hypertrophy-ace inhibitors / arbs-aspirin-women ""-statin ( open )-spironolactone-history hypertension-hypertensive-peripheral vascular disease-amiodarone-age > nmbr years-aortic stenosis-women-non - detectable / unknown-diabetes mellitus-oral anticoagulant drugs-arbs-previous ami-lvef ( % )-dbp ( mmhg )-sbp ( mm hg )-icd-pulmonary rales-age ( years )-heart rate ( beats per min )-iii-lvef > nmbr %-dilatative-pathological q waves-p blockers-ischaemic-iv-pci-bmi ( kg / rrr )-admission hf previous year-qrs > nmbr ms *-third heart sound-calcium - channel blockers-ace inhibitors-current smoking-pacemaker-diuretic drugs-ii-digitalis-cabg-previous stroke"
329,arms,"placebo ( n = nmbrl ) ""-placebo ( n = nmbrl )-n - nmbr pufa ( n = nmbr )"
330,characteristic_level,"non - ischaemic cause-nyhaii-total cholesterol < nmbr - nmbr mmol / lt ""-age > nmbr years ( median )-diabetes-total cholesterol > nmbr - nmbr mmol / lt-nyhaiiioriv-lvef < nmbr %-lvef > nmbr %-no diabetes-age < nmbr years ( median )-ischaemic cause-total cholesterol < nmbr - nmbr mmol / lt"
332,characteristic_level,"prior upper gi clinical event-prior lower gi clinical event-cox - nmbr selective nsaid use-> nmbr-established atherosclerotic cardiovascular disease-> nmbr < nmbr-> nmbr < nmbr ""-systemic corticosteroid use-< nmbr"
333,characteristic_name,"mean ( sd )-proton pump inhibitor use-other dmard use-women-mean ( sd ) ""-rheumatoid arthritis-smoker-diabetes-low - dose aspirin use-traditional nsaid use-methotrexate use-osteoarthritis"
334,arms,"etoricoxib ( n = nmbr , nmbr )-diclofenac ( n = nmbr , nmbr ) ""-diclofenac ( n = nmbr , nmbr )"
335,characteristic_level,"prior lgi event-> nmbr - nmbr-aspirin-> nmbr-osteoarthritis-male-no prior lgi event-nonsmoker-cigarette smoker ""-rheumatoid arthritis-no aspirin-no ascvd-ascvd-no prior ugi event-no corticosteroid-cigarette smoker-prior ugi event-femaleb-corticosteroid-< nmbr"
336,measures,"hazard ratio ( nmbr % ci )-rates per nmbr patient - years-rates per nmbr patient - years """
337,arms,"etoricoxib-diclofenac-diclofenac """
338,characteristic_name,"bmi category ( % ) ""-age category ( % )-ethnicity ( % )-bmi category ( % )"
339,characteristic_level,"< nmbr . nmbr kg / mnmbr-anmbrc ( % )-exercise > weekly-hispanic-postmenopausal ( % )-> nmbr . nmbr kg / mnmbr-asian pacific islander-total cholesterol - - hdl cholesterol ratio-> nmbr years-available baseline blood specimen n-current smoker ( % )-nmbr . nmbr - nmbr . nmbr kg / mnmbr-american indian alaskan native-unknown ( none )-family history diabetes ( % ) *-african american-nmbr - nmbr years-white hispanic origin-hdl cholesterol ( mmol / l )-ldl cholesterol ( mmol / l )-total population n-history hyperlipidemia ( % )-history hypertension ( % )-baseline use hormone therapy ( % )-non - hdl cholesterol ( mmol / l )-alcohol consumption > weekly-> nmbr . nmbr kg / mnmbr ""-hscrp ( mg / l )-total cholesterol ( mmol / l )"
340,arms,"aspirin-placebo-placebo """
341,characteristic_name,"ldl choleslerol-family history ol diabetes ?-tolal choleslerol - lo - hdl choleslerol ralio-ldl choleslerol ""-hdl choleslerol-exercise > weekly ?-non - hdl choleslerol-anmbrc-age-bmi-menopause ht-hscrp-hyperlipidemia-hyperlension-tolal choleslerol"
342,characteristic_level,"< nmbr . nmbr kg / mnmbr-> nmbr . nmbr mmol / l-nmbr . nmbr - nmbr . nmbr mg / l-poslmenopausal , ht-< nmbr . nmbr %-> nmbr years-> nmbr . nmbr-< nmbr . nmbr mmol / l-> nmbr kg / mnmbr-yes-< nmbr . nmbrmg / l-> nmbr . nmbr mg / l-nmbr - nmbr . nmbr kg / mnmbr-nmbr . nmbr - nmbr . nmbr mmol / l ""-nmbr - nmbr years-no-poslmenopausal , ht-< nmbr . nmbr-nmbr . nmbr - nmbr . nmbr mmol / l-nmbr . nmbr - nmbr . nmbr-premenopausal-uncerlain-> nmbr . nmbr %"
344,measures,"evenls per nmbr , nmbr palienl - years-no . evenls-evenls per nmbr , nmbr palienl - years """
345,arms,"placebo ( n = nmbr )-tiotropium ( n = nmbr )-placebo ( n = nmbr ) """
346,characteristic_name,"gold stage-smoking status-reversibility * ""-region-age ( years )-bmi-gender-reversibility *-race"
347,characteristic_level,"latin america-full cohort-usa-> nmbr-laba-anticholinergic-laba + ics-male-yes-white-no-current-former-female-> nmbr , < nmbr-iii-black-iv-asian-yes ""-i / ii-e . europe-ics-w . europe-< nmbr-asia"
348,arms,"placebo ( n = nmbr )-irbesartan ( n = nmbr ) ""-irbesartan ( n = nmbr )"
349,characteristic_name,"ejection fraction ""-hospitalization heart failure within nmbr mo-use beta - blocker-use ace inhibitor-diabetes-age-ejection fraction-geographic region-sex"
350,characteristic_level,"male-no-> nmbr % ""-yes-< nmbr yr-other-north america-> nmbr yr-all patients-europe-> nmbr %-female-< nmbr %-nmbr - nmbr yr"
352,characteristic_name,"visit nmbr ldl cholesterol strata-race ""-ncep atp iii risk factors-mean body mass index ( kg / mnmbr ) *-race"
353,arms,"atorvastatin nmbr mg ( n = nmbr )-atorvastatin nmbr mg ( n = nmbr ) ""-atorvastatin nmbr mg + ezetimibe nmbr mg ( n = nmbr )"
354,characteristic_name,"duration type nmbr diabetes mellitus ( years )-naive antihyperglycemic agent therapy-duration type nmbr diabetes mellitus ( years ) ""-nationality-hbanmbrc ( % )"
355,characteristic_level,"sex , female-korean-body mass index ( range ) ( kg / mnmbr )-all randomized patients-chinese ""-all randomized patients ( range )-chinese-weight ( range ) ( kg )-age ( range ) ( years )-indian-fpg ( range ) ( mmol / l )"
356,measures,"number patients ( % ) mean < u + nmbreb > sd ""-number patients ( % ) mean < u + nmbreb > sd"
357,arms,"placebo ( n = nmbr )-sitagliptin ( n = nmbr )-sitagliptin ( n = nmbr ) """
359,arms,"nmbr-nmbr """
360,measures,"baseline mean < u + nmbreb > sd-ls - mean change baseline ( nmbr % ci )-week nmbr mean < u + nmbreb > sd-ls - mean change baseline ( nmbr % ci ) ""-ls - mean - group difference ( nmbr % ci )"
361,characteristic_name,"age group , n ( % )-baseline hbanmbrc , n ( % )-body mass index , kg / mnmbr-glyburide dose duringthe study ( mg )-race , n ( % ) ""-age ( years )-race , n ( % )-pacific islander-alaska native-diabetes duration ( years )-sex , n ( % )"
362,characteristic_level,"native hawaiian / other-male-asian-median-other-patients > nmbr %-< nmbr years-black / african american-white-range-female-patients < nmbr %-mean ( . . )-native hawaiian / ""-> nmbr years-american indian /-median ( range )"
363,other,"glyburide ""-glyburide"
364,arms,"alogliptin nmbr . nmbr mg ( n nmbr nmbr ) ""-with alogliptin nmbr mg ( n nmbr nmbr )-with placebo ( n nmbr nmbr )-with alogliptin nmbr . nmbr mg ( n nmbr nmbr )"
366,measures,"baseline mssbp / msdbp , mm hg-mssbp-change bp , mm hg-msdbp-change bp , mm hg """
367,arms,"aliskiren-hydrochlorothiazide-aliskiren """
368,characteristic_level,"< nmbr ( n = nmbr )-> nmbr ( n = nmbr )-> nmbr ( n = nmbr ) """
369,arms,"ezetimibe nmbr mg + statin ( n = nmbr , nmbr )-placebo + statin ( n = nmbr , nmbr )-ezetimibe nmbr mg + statin ( n = nmbr , nmbr ) """
370,characteristic_name,"severity n ( % )-mean blood pressure , mmhg ( . . j-race / ethnicity n ( % )-severity n ( % ) ""-sex , n ( % )-populations :"
371,arms,"amlodipine ( n = nmbr )-amlodipine ( n = nmbr ) ""-amlodipine / vaisartan ( n = nmbr )"
372,characteristic_name,"mean ( sd )-baseline cdai score , mean ( sd ) ""-crp concentration > nmbr . nmbr mg / dl ( nmbr mg / l ) , n ( % )-any glucocorticoid *-budesonide-any immunosuppressive agent-current smoker , ( % )-baseline cdai score , mean ( sd )-methotrexate-nmbr - aminosalicylates {-previous tnf antagonist exposure , n ( % )-azathioprine-male , ( % )-prednisone-nmbr - mercaptopurine-age years , mean ( sd )-median ( range )"
373,other,"patients fistulas baseline-patients fistulas baseline """
374,arms,"adalimumab ( n = nmbr ) ""-placebo ( n = nmbr )-all patients fistulas ( n = nmbr )-adalimumab ( n = nmbr )"
375,characteristic_name,"arterial blood pressure , mm hg-patient characteristics-infarct characteristics-patient characteristics """
376,characteristic_level,"heart rate , bpm-current smoker , n ( % )-hypercholesterolemia , n ( % )-anterior-infarct localization , n ( % )-diabetes mellitus , n ( % )-diabetes mellitus , n ( % ) ""-peak creatine kinase - mb , u / l-body mass index , kg / mnmbr-diastolic-arterial hypertension , n ( % )-women , n ( % )-history cabg surgery , n ( % )-iii-killip class , n ( % ) i-systolic-lateral-iv-history mi , n ( % )-inferior-age , y-ii-insulin - requiring"
378,characteristic_name,"interval clopidogrel pci ""-interval pain onset admission-history mi-interval study drug pci-diabetes-sex-age-interval clopidogrel pci-infarct localization"
379,characteristic_level,"> nmbr . nmbr yrs-male-no-all-> nmbr min-> nmbr min ""-non - anterior"
381,arms,"placebo-placebo """
382,characteristic_level,"diabetes mellitus-diabetes mellitus ""-no diabetes mellitus"
384,arms,"placebo ( n = nmbr )-valsartan ( n = nmbr )-placebo ( n = nmbr ) """
385,characteristic_name,"use beta - blockers ""-hf , lvd , both-use ace inhibitor-af alone-age-use beta - blockers-use antiarrhythmic agent"
386,characteristic_level,"no-yes-< nmbr yr-other-> nmbr yr-all patients-none-no ""-amiodarone"
388,characteristic_name,"risk factors atherosclerosis-cardiac medications index hospital stay / discharge-cardiac history-ccsc nmbr month enrollment ""-ccsc nmbr month enrollment"
389,characteristic_level,"nmbr / nmbr , nmbr ( nmbr . nmbr ) ""-nmbr / nmbr , nmbr ( nmbr . nmbr )-nmbr ( nmbr , nmbr )-nmbr / nmbr ( nmbr . nmbr )-nmbr , nmbr / nmbr , nmbr ( nmbr . nmbr )"
390,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) """
391,characteristic_name,"smoking status-smoking status "" ; na-sex"
392,characteristic_level,"male-total pack - yrs-reversibility %-current-former-patients n ""-patients n-baseline fevnmbr #-female-age yrs"
394,characteristic_name,"blood pressure-lipid profile-fatty acid profile-glucose metabolism-lipid profile ""-clinical history"
395,characteristic_level,"fpg ( mg / dl )-coronary artery disease ( % )-hdl - cholesterol ( mg / dl )-bmi > nmbr ( % )-average age ( year )-smoker ( % )-drinker ( % )-epa ( mol % )-ldl - cholesterol ( mg / dl )-male ( % )-systolic ( mmhg )-hdl - cholesterol ( mg / dl ) ""-hba , c ( % )-total cholesterol ( mg / dl )-diastolic ( mmhg )-hypertension ( % )-triglyceride ( median ; mg / dl ) - nmbr [nmbr - nmbr percentile |"
396,characteristic_level,"lgm ( n = nmbr ) ""-lgm ( n = nmbr )-ng ( n = nmbr , nmbr )"
397,arms,"epa ( n = nmbr ) ""-epa ( n = nmbr )-non - epa ( n = nmbr )"
398,outcomes,"lipid profile-fatty acid profile-blood pressure ""-glucose metabolism-blood pressure"
400,characteristic_level,"igm ( n = nmbr )-ng ( n = nmbr , nmbr )-igm ( n = nmbr ) """
401,arms,"epa ( n = nmbr ) ""-epa ( n = nmbr )-non - epa ( n = nmbr )"
402,characteristic_level,"igm ""-igm-ng"
404,characteristic_name,"atrial fibrillation onset-chadsnmbr score * ""-characteristics-chadsnmbr score *-atrial fibrillation pattern-race / ethnicity"
405,characteristic_level,"nmbr-congestive heart failure-other-persistent-history hypertension-nmbr year more-fraction ( % )-male-hawaiian / pacific islander-white-age nmbr years more-permanent-black / african - american-paroxysmal-hispanic / latin american-previous transient ischaemic attack / ischaemic stroke previous warfarin use-age ( years )-less nmbr year ""-left ventricular ejection-asian-no estimate-unknown-diabetes-less nmbr year"
406,arms,"control group ( n = nmbr ) ""-intervention group ( n = nmbr )-control group ( n = nmbr )"
407,characteristic_name,"serum creatinine , ^mol / l-age completion highest education , years ( sd )-macroalbuminuria , n ( % )-current smoker , n ( % )-history major microvascular disease , n ( % )-hbanmbrc , % ( sd )-history hypertension , n ( % )-current alcohol use , n ( % )-diastolic bp , mmhg ( sd )-uacr , mg / mmol ( interquartile range ) b-history major cardiovascular disease , n ( % )-myocardial infarction , n ( % )-past smoker , n ( % )-bmi ( kg / mnmbr )-duration diabetes ( years )-estimated gfr , < nmbr ml min - nmbr nmbr . nmbr - nmbr , n ( % ) a-age ( years )-systolic bp , mmhg ( sd )-major diabetic eye disease , n ( % )-serum creatinine , ^mol / l ""-estimated gfr , ml min - nmbr nmbr . nmbr - nmbr ( sd ) a-stroke , n ( % )-female , n ( % )-serum total cholesterol , mmol / l ( sd )"
409,characteristic_level,"< nmbr ( n = nmbr ) ""-nmbr - nmbr ( n = nmbr , nmbr )-< nmbr ( n = nmbr )"
410,outcomes,"- cause death-cardiovascular death-cardiovascular death ""-major cardiovascular events"
412,arms,"placebo-placebo ""-perindopril"
413,characteristic_name,"fevnmbr ( l )-fevnmbr ( l ) ""-smoking status-fevnmbr ( % predicted )"
414,characteristic_level,"male-smoking history ( pack - years )-duration copd ( years )-postbronchodilator-current smoker-age ( years )-prebronchodilator ""-prebronchodilator-sgrq total score * ( units )-body - mass index ( kg / mnmbr )"
415,characteristic_level,"gold stage iii-gold stage iv-gold stage ii ""-gold stage ii"
416,arms,"control ( n = nmbr )-tiotropium ( n = nmbr )-control ( n = nmbr ) """
417,outcomes,"mean number exacerbations ( per patient - year [nmbr % ci] )-one copd exacerbations ( n / n [ % ] )-median time first exacerbation ( months [nmbr % ci] )-mean number exacerbations ( per patient - year [nmbr % ci] ) """
418,characteristic_level,"gold stage iii ""-gold stage iii-gold stage iv-gold stage ii"
419,characteristic_name,"medical history-heart failure cause-ecg findings-lipid profile-laboratory examination-medical treatment "" ; na-medical treatment-physical examinations"
420,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-rosuvastatin ( n = nmbr )"
422,arms,"fluvastatin ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
423,characteristic_name,"baseline ldl cholesterol ""-cardiac risk-temporary discontinuation study drug-baseline ldl cholesterol-baseline high - sensitivity crp-baseline total cholesterol-type surgery"
424,characteristic_level,"no-all-high-yes-< nmbr yr-< nmbr . nmbr mmol / liter-> nmbr yr-low-> nmbr . nmbr mg / liter-open-< nmbr . nmbr mg / liter-< nmbr . nmbr mmol / liter ""-> nmbr . nmbr mmol / liter-endovascular-intermediate"
426,measures,". events / . patients-no . events / . patients """
427,arms,"amlodipine nmbrmg / v = nmbr-amlodipine / valsartan nmbr / nmbr mg / v = nmbr-amlodipine nmbrmg / v = nmbr """
428,characteristic_level,"age > = nmbr years-age < nmbr years ""-age < nmbr years"
429,characteristic_name,"ethnicity , . ( % )-tnmbr lesion volume , mmnmbr-prior ms treatment ifn - beta or-total gadolinium - enhancing lesion count , . ( % ) ""-edss score-total gadolinium - enhancing lesion count , . ( % )-disease duration , mean yr ( sd )-edss stratification , . ( % )-gender , . ( % )-brain volume , cmnmbr"
430,characteristic_level,"mean ( sd )-male-median-= nmbr ""-msfc timed nmbr - foot walk test , median seconds-other-= nmbr-ended > nmbr days trial entry-age , mean yr ( sd )-minimum - maximum-> nmbr-white-median ( min , max )-since diagnosis-since onset-no prior ms therapies-female-> nmbr . nmbr"
431,arms,"total , n = nmbr-total , n = nmbr ""-placebo , n = nmbr-rituximab , n = nmbr"
432,characteristic_name,"location infarction-location infarction "" ; na-cigarette smoker"
434,characteristic_name,"geographic location-time symptom onset randomization ( hrs )-time symptom onset balloon inflation ( hrs )-age ( yrs )-high risk-pci delay due low risk-enrollment lmwh-previous ml ""-baseline killip class-history diabetes mellitus-gender-time qualifying ecg balloon inflation ( hrs )-sites-previous ml-infarct location"
435,characteristic_level,"male-no-no / unknown-yes-= nmbr-hub-all subjects-north america-> nmbr-rest world-tertile nmbr-female-spoke-anterior-tertile nmbr index pci performed-no / unknown ""-< nmbr-not anterior"
436,measures,"% nmbr-i % nmbr ""-n .-n"
437,characteristic_name,"geographic location-time symptom onset randomization ( hrs )-time symptom onset balloon inflation ( hrs )-age ( yrs )-high risk-pci delay due low risk-index pci performed-enrollment lmwh-previous ml ""-history diabetes mellitus-gender-time qualifying ecg balloon inflation ( hrs )-sites-previous ml-infarct location"
438,characteristic_level,"male-no-no / unknown-yes-= nmbr-hub-all subjects-north america-> nmbr-rest world-< nmbr baseline killip class-female-spoke-anterior-tertile nmbr-no / unknown ""-< nmbr-not anterior"
439,measures,"nmbr % nmbr ""-n_-ni-nmbr % nmbr"
440,characteristic_name,"smoking status * ""-time treatment ( min ) t-smoking status *"
441,characteristic_level,"ex - smoker-weight ( kg )-hypertension-systolic blood pressure ( mm hg )-median ( iqr )-current smoker-time treatment initiation ( min ;-diabetes-never smoked ""-age ( years )-history stroke-atrial flutter / fibrillation-diastolic blood pressure ( mm hg )-men-previous use antiplatelet drugs-nmbr - nmbr-baseline nihss-never smoked"
442,arms,"alteplase ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) """
443,characteristic_name,"time treatment initiation ( min )-arial flutter fibrillation-previous diabetes-previous diabetes ""-smoking history-nihss baseline-age ( years )-history stroke-previous chronic use antiplatelet drugs-hypertension-sex"
444,characteristic_level,"ex - smoker-male-no-yes-current smoker-> nmbr-female-no ""-non - smoker-itt population-nmbr - nmbr-< nmbr"
445,characteristic_level,"intention - - treat st - segment - elevation myocardial infarction ""-intention - - treat-intention - - treat st - segment - elevation myocardial infarction-intention - - treat without st - segment - elevation myocardial infarction"
446,arms,"clopidogrel ( n = nmbr )-clopidogrel ( n = nmbr ) ""-cangrelor ( n = nmbr )"
447,outcomes,"coronary eventsnmbr-all - cause mortality ""-primary endpointnmbr-all - cause mortality"
448,characteristic_level,"hs - crp jnmbr . nmbr mg / l ""-hs - crp mg / l-hs - crp jnmbr . nmbr mg / l-all cause mortality hosp . worsening hf hs - crp < nmbr . nmbr mg / l-hs - crp < nmbr . nmbr mg / l-all randomized-hs - crp < nmbr . nmbr nlg l-hs - crp jnmbr . nmbrmg / l-hs - crp _ = nmbr . nmbr mg / l"
450,characteristic_level,"hs - crp < nmbr . nmbr g / l ""-hs - crp < nmbr . nmbr mg / l-hs - crp > nmbr . nmbr mg / l-hs - crp < nmbr . nmbr g / l"
451,measures,"hospitalizations , n ""-hospitalizations , n-patients , n"
452,outcomes,"worsening heart failure-all - cause-noncardiovascular-noncardiovascular ""-cardiovascular"
454,characteristic_level,"hs - crp < nmbr . nmbr mg / l-hs - crp < nmbr . nmbr mg / l ""-hs - crp > nmbr . nmbr mg / l"
455,outcomes,"hdl cholesterol , mmol / l *-hs - crp , mg / l-triglycerides , mmol / lf ""-triglycerides , mmol / lf-ldl cholesterol , mmol / l *"
456,arms,"placebo-rosuvastatin-rosuvastatin """
457,measures,"p , net difference-baseline median ( iq range )-baseline median ( iq range ) ""-difference , % median-nmbr - month follow - median ( iq range )"
458,characteristic_level,"tnmbrdm-neither tnmbrdm mets-metabolic syndrome w / tnmbrdm-neither tnmbrdm mets """
459,arms,"anmbr ""-anmbr + eznmbr-anmbr"
460,characteristic_name,"non - hdl - c / hdl - c ""-triglycerides-apo b / apo - l-hs - crp-non - hdl - c / hdl - c-hdl - c-non - hdl - c-ldl - c-total cholesterol-ldl - c / hdl - c-apolipoprotein b^-apolipoprotein - *-total cholesterol / hdl - c"
461,characteristic_level,"treatment difference ( nmbr % ci )-treatment difference ( nmbr % cl )-treatment difference ( nmbr % ci ) """
462,characteristic_level,"mets w / tnmbrdm-tnmbrdm-neither tnmbrdm mets-mets w / tnmbrdm """
463,arms,"anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr )-anmbr + ezio anmbr ( n = nmbr ) ( n = nmbr )-anmbr + eznmbr anmbr ( n = nmbr ) ( n = nmbr ) """
464,arms,"anmbr / nmbr ( n = nmbr ) ""-anmbr / nmbr ( n = nmbr )-anmbr + enmbr ( n = nmbr )"
465,characteristic_name,"antidiabetes drug usage [ % ( n ) ]-antidiabetes drug usage [ % ( n ) ] "" ; na"
466,characteristic_level,"age ( years ) [median ( nmbrth nmbrth percentile ) ]-a - glucosidase inhibitor-female sex ( % )-no antidiabetic drug-current smoker ( % )-meglitinide-weight ( kg / mnmbr ) [median ( nmbrth nmbrth percentile ) ]-insulin-thiazolidinedione-monotherapy-bmi ( kg / mnmbr ) [median ( nmbrth nmbrth percentile ) ] ""-sulfonylurea-hyperlipidemia ( % )-n-bmi ( kg / mnmbr ) [median ( nmbrth nmbrth percentile ) ]-dual therapy-biguanide ( metformin )-hypertension ( % )-three drugs"
467,arms,"placebo-ranolazine-ranolazine """
468,characteristic_level,"women-men-men """
469,outcomes,"cardiovascular death-myocardial infarction-primary endpoint-recurrent ischemia-myocardial infarction """
470,measures,"p nmbr interaction women vs men-hr ( nmbr % cl )-hr ( nmbr % cl ) """
472,characteristic_name,"fevnmbr ( % predicted )-fevnmbr ( l )-smoking status-fvc ( % predicted ) ""-fvc ( l )-( b ) concomitant respiratory medications [n ( % ) ]-fvc ( % predicted )-( ) demographics-gold stage [n ( % ) ]"
473,characteristic_level,"women ""-women-men"
474,arms,"tiotropium ( nznmbr )-control ( nznmbr )-control ( nznmbr ) """
475,outcomes,"fevnmbr post - bronchodilator-fvc post - bronchodilator-fevnmbr pre - bronchodilator-fvc pre - bronchodilator-fevnmbr post - bronchodilator """
476,characteristic_level,"women ""-women-men"
479,measures,"% pred-ml-n ""-n"
480,characteristic_name,"pm pef ( sd ) , l / min-albuterol use ( sd ) , puffs / day-fevnmbr percent predicted ( sd )-female ( % )-number subjects-albuterol use ( sd ) , puffs / day ""-symptom score ( sd )-asthma duration ( sd ) , years-mean age ( sd ) , years-am pef ( sd ) , l / min"
481,characteristic_name,"bmi category-bmi category """
482,characteristic_level,"nmbr-> nmbr-nmbr - nmbr . nmbr-nmbr - nmbr . nmbr """
483,characteristic_name,"age , yr , mean ( sd )-ics users , n ( % )-fevnmbr / fvc , % , mean ( sd ) nmbr-reversibility ( anticholinergic ) , % , mean ( sd ) $-age , yr , mean ( sd ) ""-reversibility ( bnmbr - agonist ) , % , mean ( sd ) nmbr-fevi , % predicted , mean ( sd ) nmbr-bmi , mean ( sd )-smoking history , pack - years , mean ( sd )-fevi , l , mean ( sd ) nmbr-male sex , n ( % )-n"
484,arms,"placebo-tiotropium-indacaterol nmbr mg-placebo """
485,characteristic_level,"male-female-female """
486,arms,"ami nmbr mg-aml / val nmbr / nmbr mg ""-aml / val nmbr / nmbr mg"
487,characteristic_level,"pad baseline-no pad baseline ""-no pad baseline"
488,arms,"control-epa-epa "" ; na"
490,characteristic_name,"cardiovascular disease ""-fasting lipid levels , mmol / l-diabetes-cardiovascular disease-race , n ( % )"
491,characteristic_level,"mean nmbr - year cvd risk * ""-asian-male , n ( % )-age , years-type nmbr , n ( % )-other-current cvd / diabetes , n ( % )-> nmbr years , n ( % )-caucasian-current smoker , n ( % )-hdl - c-ldl - c-mean nmbr - year cvd risk *-total cholesterol-high - risk cvd , n ( % )-black-triglycerides , median ( range )"
492,arms,"atorvastatin nmbr mg ( n = nmbr )-atorvastatin nmbr mg ( n = nmbr ) ""-ezetimibe / simvastatin nmbr / nmbr mg ( n = nmbr )-rosuvastatin nmbr - nmbr mg ( n = nmbr )"
493,characteristic_level,"nice primary prevention onlyb-nice secondary prevention onlyb-ldl - c < nmbr . nmbr mmol / l-nice primary prevention onlyb ""-jbs - nmbr primary prevention onlynmbr-baseline ldl - c nmbr . nmbr < nmbr . nmbr mmol / lc-baseline ldl - c > nmbr . nmbr < nmbr . nmbr mmol / lc-jbs - nmbr secondary prevention onlynmbr"
494,measures,"percentage patients reaching target ""-percentage patients reaching target"
495,arms,"exetimibe / simvastatin-rosuvastatin-atorvastatin ""-atorvastatin"
496,characteristic_name,"location crohn ' disease , %-medications baseline , n ( % )-medications baseline , n ( % ) """
497,characteristic_level,"mean cdai score-mean duration disease , years-ileocolon-resection performed , %-corticosteroids-corticosteroids immunosuppressants-male , %-no corticosteroids immunosuppressants-geometric mean crp concentration ( mg / l )-colon-mean ( . . ) age , years-penetrating disease , %-terminal ileum-upper gastrointestinal-no corticosteroids immunosuppressants ""-immunosuppressants"
498,arms,"infliximab - naive ( n = nmbr )-infliximab - experienced ( n = nmbr ) ""-infliximab - experienced ( n = nmbr )"
499,characteristic_level,"> nmbr . nmbr yrs-male-no-> nmbr min-yes-> nmbr . nmbr min-yes ""-female-nmbr . nmbr yrs-anterior-< nmbr min-nmbr - nmbr min-non - anterior-nmbr . nmbr min-nmbr min"
500,characteristic_name,"interval pain onset admission-history mi-diabetes ""-interval study drug pci-diabetes-sex-age-interval clopidogrel pci-infarct localization"
502,characteristic_name,"waist circumference-fasting blood glucose-elevated blood pressure-blood pressure-elevated tg-increased waist circumference-diastolic-elevated fasting glucose-changes ( ) metabolic syndrome parameters hdl cholesterol-low hdl cholesterol ""-low hdl cholesterol-systolic-prevalence metabolic syndrome criterion"
503,arms,"fenofibric acid-fenofibric acid + moderate - dose statin-moderate - dose statin-high - dose statin-fenofibric acid + low - dose statin-low - dose statin ""-low - dose statin"
504,characteristic_name,"screening visit ""-randomisation visit ( baseline )-screening visit"
505,characteristic_level,"short - acting bnmbr - agonists-fevnmbr ( l )-smoking history ( pack - years )-post - bronchodilator fevnmbr ( % predicted normal ) a-post - bronchodilator fevnmbr / fvc ( % ) a-fvc ( l ) proportion taking pulmonary medications ( % ) b-time since copd diagnosis ( yrs )-fevnmbr ( % predicted normal )-pre - bronchodilator fevnmbr ( l )-oral corticosteroids-current smoker : ex - smoker ( % )-pre - bronchodilator fvc ( l )-mucolytics-reversibility fevnmbr ( % )-pre - bronchodilator fevnmbr ( % predicted normal )-post - bronchodilator fevnmbr ( l ) a-long - acting bnmbr - agonists-supplementary oxygen-age ( years )-inhaled corticosteroids-any medication-xanthines-men : women ( % )-pre - bronchodilator fvc ( l ) ""-post - bronchodilator fvc ( l ) a-short - acting anticholinergics-pre - bronchodilator fevnmbr / fvc ( % )"
506,characteristic_name,"short - acting bnmbr - agonists-fevnmbr ( l )-smoking history ( pack - years )-fvc ( l )-post - bronchodilator fevnmbr ( % predicted normal ) a-post - bronchodilator fevnmbr / fvc ( % ) a-time since copd diagnosis ( yrs )-fevnmbr ( % predicted normal )-short - acting anticholinergics ""-pre - bronchodilator fevnmbr ( l )-oral corticosteroids-current smoker : ex - smoker ( % )-pre - bronchodilator fvc ( l )-mucolytics-reversibility fevnmbr ( % )-pre - bronchodilator fevnmbr ( % predicted normal )-post - bronchodilator fevnmbr ( l ) a-long - acting bnmbr - agonists-supplementary oxygen-age ( years )-inhaled corticosteroids-any medication-xanthines-men : women ( % )-tiotropiumc-post - bronchodilator fvc ( l ) a-short - acting anticholinergics-pre - bronchodilator fevnmbr / fvc ( % )"
507,characteristic_level,"laba non - users-laba non - users ""-laba users"
508,characteristic_name,"risk factors immobility level , n ( % )-race ethnicity , n ( % )-region enrollment , n ( % ) +-previous medications , n ( % )-race ethnicity , n ( % ) ""-primary enrollment diagnoses , n ( % )"
509,measures,"preamendment-postamendment-total population-preamendment """
510,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-extended - duration enoxaparin ( n = nmbr )"
511,outcomes,"vte day nmbr +-major bleeding events *-vte day nmbr + """
512,characteristic_name,"age > nmbr y-age < nmbr ""-age < nmbr"
513,characteristic_level,"women-men-level nmbr-level nmbr """
515,characteristic_name,"previous copd treatment , n ( % ) *-previous copd treatment , n ( % ) * ""-geographical region , n ( % )"
516,characteristic_level,"nmbr-usa-other-postbronchodilator fevnmbr , % predicted-asia pacific-current smoker , n ( % )-nmbre < nmbr % , n ( % )-ics + laba-$ nmbr % , n ( % )-< nmbr % , n ( % )-eastern europe-age enrolment , years-male gender , n ( % )-body mass index , kg / mnmbr-laba alone-$ nmbr-baseline cv treatment , n ( % ) y-neither ics laba-nmbr ""-western europe-ics alone-baseline short - acting anticholinergics , n ( % )-previous mi , n ( % )-pack - years smoked"
517,arms,"placebo ( n[nmbr )-salmeterol ( n [nmbr )-sfc ( n [nmbr )-sfc ( n [nmbr ) ""-fp ( n [nmbr )"
518,characteristic_name,"smoking status-baseline short - acting anticholinergics-baseline fevnmbr-prior mi-age-baseline cv treatment-sex ""-sex"
519,characteristic_level,"male-no-yes-current-$ nmbr-$ nmbr %-nmbre < nmbr %-former-nmbrenmbr-female-< nmbr %-female ""-< nmbr"
521,characteristic_name,"nyha class-demographic characteristics-demographic characteristics ""-medical history duration heart failure ( years ) primary cause heart failure"
522,characteristic_level,"sex ( male ) ethnic origin-other-diuretic drugs ( excluding antialdosterone )-heart rate ( bpm )-class iv-ace inhibitor-arb-non - ischaemic-egfr ( ml / min per nmbr - nmbr mnmbr ) ""-class ii-white-cardiac glycosides-class iii-lvef ( % )-dbp ( mmhg )-sbp ( mm hg )-icd-egfr ( ml / min per nmbr - nmbr mnmbr )-age ( years )-antialdosterone agents-ischaemic-history atrial fibrillation flutter treatment randomisation-asian-bmi ( kg / mnmbr ) cardiac parameters-myocardial infarction-devices-diabetes-crt-p blocker-current smoking-previous stroke-hypertension"
523,arms,"ivabradine group ( n = nmbr )-placebo group ( n = nmbr ) ""-placebo group ( n = nmbr )"
524,characteristic_name,"cause heart failure-baseline heart rate-diabetes-age-nyha class-cause heart failure ""-p blockers-hypertension-sex"
525,characteristic_level,"history diabetes ( n = nmbr )-no history diabetes ( n = nmbr )-non - ischaemic ( n = nmbronmbr ) ""-age < nmbr years ( n = nmbr )-ischaemic ( n = nmbrlnmbr )-= nmbr bpm ( n = nmbr )-female ( n = nmbr )-nyha class ii ( n = nmbrlnmbr )-> = nmbr years ( n = nmbr )-no p - blocker intake randomisation ( n = nmbr )-nyha class iii iv ( n = nmbr )-history hypertension ( n = nmbr )-< nmbr bpm ( n = nmbr )-p - blocker intake randomisation ( n = nmbro )-no history hypertension ( n = nmbr )-non - ischaemic ( n = nmbronmbr )-male ( n - nmbr )"
527,characteristic_name,"demographics-laboratory measurements-medical history , n ( % )-medication , n ( % ) ""-medication , n ( % )"
530,characteristic_name,"medical history ( % )-demographic characteristics-measurements-medications day nmbr-treatment admission-blood pressure ( mm hg )-medical history ( % ) ""-medications discharge day nmbr , earlier ( % )-treatment admission ( % )"
532,characteristic_name,"medical history , n ( % )-age , y-ethnicity , n ( % )-race , n ( % )-medical history , n ( % ) """
533,arms,"fenofibric acid nmbr = nmbr-fenofibric acid nmbr = nmbr ""-rosuvastatin n = nmbr-rosuvastain + fenofibric acid nmbr = nmbr"
534,outcomes,"tg-ldl - c-hdl - c "" ; na-hdl - c"
535,measures,"% ( se )-final mean , mg / dl ""-final mean , mg / dl-mean change ,-baseline mean , mg / dl"
536,arms,"treatment group ""-treatment group"
537,arms,"acid-fenofibric acid ""-fenofibric acid"
538,characteristic_level,"non - diabetic ""-diabeticb-non - diabetic"
539,other,"study end concentration ""-study end concentration"
540,characteristic_name,"hdlnmbr - c-hdlnmbr - c ""-ldu - c-ldl , - c-non - hdl - c *-apo b *-total ldl - c *-triglyceride-ldlnmbr - c"
541,characteristic_level,"baseline triglycerides < nmbr mg / dl-overall population ""-baseline trig > nmbr millycerides g / dl-overall population"
542,arms,"anmbr n = nmbr-anmbr n = nmbr ""-anmbr + ez n = nmbr-anmbr + ez n = nmbr anmbr n = nmbr"
543,other,"continued treatment study ""-continued treatment study-acute dvt study"
544,arms,"rivaroxaban ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) ""-standard therapyy ( n = nmbr )"
545,characteristic_name,"miami k antagonist received-wegu ""-modmy al randcnxzaton-cardiac disease-redon-wegu-kheeatne index dvt-age-rarertd antocagibtcn andorrtzafon-pre ' rtous eptscde ( } dvt / pe-locafon index dvt-mafcaiancy randorrtzaton-known ' rc - iitoji cccndilon-renal fmclicn : creatntoe clearance-intended durat - sm antccagubficn-sex"
546,arms,"riva roxa ban n / n { % ) nmbr ( nmbr . nmbr ) ""-enoxaparin / vka n / n ( % ) nmbr / nmbr ( nmbr . nmbr )-riva roxa ban n / n { % ) nmbr ( nmbr . nmbr )"
547,characteristic_name,"parenteral anticoagulalion randomization-malignancy randomization-renal function : creatinine clearance-intended duration anticoagulation-race ""-age-weight-race"
548,arms,"enoxaparin / vka-enoxaparin / vka ""-rivaroxaban"
549,measures,"n / n nmbr / nmbr-( % ) ( nmbr . nmbr )-( % ) ( nmbr - nmbr ) ""-( % ) ( nmbr - nmbr )"
550,characteristic_name,"race , n ( % ) ""-body weight ( kg ) , n ( % )-age ( years )-race , n ( % )-mean lipid values , mg / dl-dm medication , n ( % ) c-sex , n ( % )-comorbidities , n ( % )"
551,arms,"fa nmbr mg-r nmbr mg + fa-r nmbr mg-r nmbr mg + fa """
552,characteristic_name,"concomitant medication , n ( % ) "" ; na-disease location ( % ) *-concomitant medication , n ( % )"
553,characteristic_level,"corticosteroid ( without imm )-crp , mg / l : median ( range )-mayo score , mean ( sd )-extensive colitisy-stool frequency subscore-male ( % )-male ( % ) ""-otherx-no corticosteroid , imm-corticosteroid + imm-imm ( without corticosteroid )-rectal bleeding subscore {-weight , kg : mean ( sd )-endoscopy subscore-aminosalicylates * *-pga subscore-left - sided colitisz-age , years : median ( range )-disease duration , years : median ( range )"
554,arms,"placebo ( n[nmbr )-ada nmbr / nmbr ( n[nmbr )-ada nmbr / nmbr ( n[nmbr ) """
556,arms,"placebo n[nmbr-ada nmbr / nmbr n[nmbr ""-ada nmbr / nmbr n[nmbr"
557,characteristic_name,"age , years-asian-fevnmbr , % predicteda-male / female , %-other-body mass index , kg / mnmbr-age > nmbr , %-ex - smoker / smoker , %-fevnmbr , la-caucasian-history current cardiac disorders , %-ics use yes / , %-treatment duration , days-patients treated > nmbr weeks ( % )-ex - smoker / smoker , % ""-black-n"
558,arms,"tiotropium nmbr gg qd-indacaterol nmbr gg qd-formoterol nmbr gg bid ""-placebo-formoterol nmbr gg bid-salmeterol nmbr gg bid"
559,characteristic_name,"hbanmbrc category , n ( % )-age category ( years ) , n ( % )-hbanmbrc category , n ( % ) ""-duration tnmbrdm ( years )-race , n ( % )-gender , n ( % )-renal impairment , n ( % )"
560,characteristic_level,"body mass index ( kg / mnmbr ) ,-oral blood glucose - lowering drug nmbr ( nmbr . nmbr )-< nmbr . nmbr %-> nmbr-a - glucosidase inhibitor-hbanmbrc ( % )-sulphonylurea-diabetes therapy , n ( % ) ""-> nmbr . nmbrto < nmbr . nmbr %-women-age ( years ) , mean ( . . )-white-moderate-insulin-thiazolidinedione-glinide-weight ( kg ) , mean ( . . )-diabetes therapy , n ( % )-mean ( . . )-oral blood glucose - lowering-> nmbr , n ( % )-fpg ( mmol / l )-esrd-< nmbr-severe-men-> nmbr . nmbr %-crcb - ( ml / min ) , mean ( . e . )"
561,arms,"pbo ( n = nmbr ) ""-pbo ( n = nmbr )-saxa nmbr . nmbr mg ( n = nmbr )"
562,characteristic_level,"moderate renal impairment-difference vs . pbof mean ( . e . ) t-adjusted change baseline mean ( . e . ) ""-esrd-adjusted change baseline mean ( . e . )-severe renal impairment-week nmbr hbanmbrc , mean ( . e . )-baseline hbanmbrc , mean ( . e . )"
563,arms,"pbo-saxa nmbr . nmbr mg ""-saxa nmbr . nmbr mg"
564,measures,"n = nmbr ""-n = nmbr"
565,characteristic_level,"moderate renal impairment-pbo ( n = nmbr )-severe renal impairment-esrd saxa nmbr . nmbr mg ( n = nmbr )-severe renal impairment """
566,arms,"pbo ( n = nmbr )-saxa nmbr . nmbr mg ( n = nmbr )-saxa nmbr . nmbr mg ( n = nmbr ) """
567,characteristic_name,"treated vessel-antithrombotic therapy ""-clinical presentation-medical therapy-antithrombotic therapy"
568,characteristic_level,"right coronary-left anterior descending-multivessel pci-saphenous vein graft-unfractionated heparin-/ nmbr - blockers-bivalirudin-ace inhibitors / sartans-glycoprotein llb / llla inhibitors-enoxaparin ""-chronic stable angina-left main-left circumflex-lesions bnmbr / c-acs-multivessel disease-enoxaparin"
569,arms,"high - dose statin pretreatment ( n = nmbr )-controls ( n = nmbr ) ""-controls ( n = nmbr )"
570,arms,"bosentan ( n = nmbr )-placebo ( n - nmbr ) ""-placebo ( n - nmbr )"
571,characteristic_name,"age , years-smoking history-baseline fvc , l-baseline fvc , l ""-location"
573,characteristic_name,"baseline low - density lipoprotein cholesterol ( mg / dl )-race-baseline low - density lipoprotein cholesterol ( mg / dl ) ""-risk group"
574,characteristic_level,"black african american-asian-nmbr - nmbr-nmbr - < nmbr-women-> nmbr-white-high risk atherosclerotic vascular disease *-age ( years )-american indian alaska-body mass index ( kg / nr )-> nmbr ""-men-moderately high risk without atherosclerotic vascular disease *-high risk without atherosclerotic vascular disease +-multiracial-< nmbr"
575,other,"stratum ii-stratum i-stratum ii """
576,arms,"rnmbr + ezio ( n = nmbr )-rnmbr ( n = nmbr ) ""-rnmbr ( n = nmbr )"
577,characteristic_name,"geographical region ( % )-geographical region ( % ) "" ; na"
578,characteristic_level,"post - bronchodilator fevnmbr ( l ) *-post - bronchodilator fevnmbr ( % predicted * )-bmi ( kg / mnmbr )-asia - pacific-usa-western europe-other-current smoker ( % )-pre - bronchodilator fevnmbr / fvc ratio *-reversibility ( % predicted fevnmbr ) *-baseline sgrq total score-age enrollment ( years )-male gender ( % ) ""-male gender ( % )-eastern europe-pack - years smoked"
580,characteristic_name,"concomitant medication , n ( % )-diagnosis ( ) , mean ( sd )-hrqol-location disease , n ( % )-hrqol "" ; na"
581,characteristic_level,"nmbr-inflammatory-ileocolon-immunosuppressant ( without corticosteroid )-ibdq score , mean ( sd )-> nmbr-corticosteroid immunosuppressant-colon-stricturing-ibdq score , mean ( sd ) "" ; na-mean body mass index ( kg / mnmbr )-corticosteroid immunosuppressant-terminal ileum-neither corticosteroid immunosuppressant-geometric mean baseline-corticosteroid ( without immunosuppressants )"
582,arms,"certolizumab pegol ( n = nmbr )-certolizumab pegol ( n = nmbr ) ""-placebo ( n = nmbr )"
583,characteristic_name,"nmbr-inflammatory-cdai score < nmbr-nmbr - nmbr yrs-nmbrbaseline mean-disease duration : < baseline mean-> nmbr-stricturing-previous current im use : no-penetrating-male-nmbr yrs-yes-nonsmoker-< nmbr yr-prior surgery : no-previous current use im cs : no-smoker-im use : no-bmi ( kg / mnmbr ) < nmbr-cs use : no-noncaucasian-crp ( mg / l ) : < nmbr-caucasian-nonsmoker ""-colon-previous current use im cs : no-female-previous current cs use : no-im cs use : no-disease location / type : terminal ileum-age ( yrs ) nmbr - nmbr-im cs use : no-lleocolon-< nmbr"
584,characteristic_name,"country ""-country"
585,characteristic_level,"new zealand-north america-united states-israel-australia-belgium-europe ( zone nmbr )-estonia-ukraine-canada-czech republic-hungary-new zealand ""-russia-italy-romania-latvia-rest world-poland-germany-austria-brazil"
586,characteristic_name,"crohn ' disease - related medication baseline , n ( % ) "" ; na-c - reactive protein ( mg / dl_ )-involved intestinal area , n ( % )-crohn ' disease - related medication baseline , n ( % )"
587,characteristic_level,"other-body weight ( kg ) , mean ( . . )-baseline cdai score , mean ( . . )-previous tnf - antagonist use , n ( % )-aminosalicylates-age ( years ) , mean ( . . )-gastroduodenum-colon-current smoker , n ( % )-male patients , n ( % )-ileum-mean ( . . )-immunosuppressants-draining cutaneous fistula baseline , n ( % )-age ( years ) , mean ( . . ) ""-median ( range )"
588,characteristic_name,"baseline corticosteroids * ""-baseline corticosteroids *-no baseline corticosteroids"
589,arms,"nmbr mg ew n = nmbr-nmbr mg eow n = nmbr-nmbr mg eow n = nmbr ""-placebo n = nmbr"
590,characteristic_name,"smoking , %-body mass index , %-body mass index , % """
591,characteristic_level,"< nmbr kg / mnmbr-current-past-nmbr - nmbr . nmbr kg / mnmbr-nmbr - nmbr . nmbr kg / mnmbr ""-> nmbr kg / mnmbr-never"
592,characteristic_level,"migraine without aura-migraine aura-prior migraine *-migraine aura """
593,arms,"placebo nmbr ""-placebo nmbr-aspirin nmbr"
594,outcomes,"coronary revascularization-hemorrhagic stroke-myocardial infarction-major cvd /-coronary revascularization ""-ischemic stroke-no .-cvd death-stroke-tia"
595,characteristic_level,"migraine without aura-migraine aura-p *-no history migraine ""-no history migraine-prior migraine"
597,characteristic_name,"tobacco use-history bone disease ( predefined ) , n ( % )-tobacco use ""-history medical conditions , n ( % )-fracture history ( predefined ) , n ( % )-race , n ( % )-alcohol consumption-gender , n ( % )-risk factor ( predefined ) falling screening , n ( % )-paternal history , n ( % )-maternal history , n ( % )"
598,characteristic_level,"priorother ( predefined ) medical conditions-other-former , n ( % )-age ( years ) , mean ( sd )-bmi ( kg / mnmbr ) , mean ( sd )-african america-duration diabetes-years , mean ( sd ) ""-priorother ( predefined ) medical conditions-current bone disease-male-current ( predefined ) medical conditions-past-fpg ( mmol / l ) , mean ( sd ) < u + nmbr >-priorbone disease-currentother ( notpredefined ) medical conditions-units per week , mean ( sd )-hbalc ( % ) , mean ( sd ) ^-current-caucasian-current , n ( % )-female-osteoporosis-asian-yes , n ( % )-years , mean ( sd )-hip fracture-weight ( kg ) , mean ( sd )-any condition"
599,arms,"met ( n = nmbr )-avm ( n = nmbr )-avm ( n = nmbr ) """
600,other,"lumbar spine-total body-distal one - third radius-total hip-femoral neck-lumbar spine """
601,measures,"met % < u + nmbrbnmbr > ( se )-treatment difference ""-avm % < u + nmbrbnmbr > ( se )-treatment difference"
602,characteristic_level,"male-overall-postmenopausal-overall ""-female-premenopausal"
603,arms,"apixaban ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) """
604,characteristic_name,"heart failure-acs treatment-diabetes mellitus-level renal impairment-age-apixaban dose ( matching placebo )-bmi-history stroke-geographic region-acs type-history stroke ""-race-sex"
605,outcomes,"cv death , ml , ischemic stroke ""-cv death , ml , ischemic stroke"
606,measures,"n / n ""-interaction p value-n / n-hr ( nmbr % cl )"
607,characteristic_name,"weight , kg ""-age , y-weight , kg"
610,characteristic_name,"severity copd , ( gold nmbr ) , %-severity copd , ( gold nmbr ) , % ""-race , %"
611,characteristic_level,"other-ex - smoker / smoker , %-fevnmbr % predicted , post - albuterol , %-fevnmbr , post - albuterol , l-sex , male / female , %-baseline sgrq score-white-moderate-days without albuterol use , * %-fevnmbr / fvc , post - albuterol , %-ex - smoker / smoker , % ""-duration copd , y-ics use , yes / , %-severe severe-fevnmbr reversibility , pre - / post - albuterol , %-smoking history , pack - years-use rescue albuterol , puffs / day *-black-asian-fevnmbr , pre - albuterol , l-age ,"
612,other,"study nmbr ""-study nmbr"
613,arms,"placebo group ( n = nmbr )-indacaterol group ( n = nmbr )-placebo group ( n = nmbr ) ""-all patients ( n = nmbr )"
614,characteristic_name,"copd severity ( gold nmbr )-use ics-copd severity ( gold nmbr ) ""-bmi , kg / mnmbr-smoking history-age , y-waist - hip ratio-albuterol reversibility , %-sex"
615,characteristic_level,"nmbr / nmbr-nmbr / nmbr """
616,other,"study nmbr ""-study nmbr"
617,measures,"treatment difference , ml-no . patients ( indacaterol / placebo )-treatment difference , ml """
618,characteristic_name,"race , % patients-cv risk factors , % patients-diabetes duration ( known ) , % patients ""-cv medication , % patients-previous oral glucose - lowering agents , % patients-framingham nmbr - year cv risk score-gender , % patients-egfr using cg / mdrd formulae , % patients-diabetes duration ( known ) , % patients"
619,characteristic_level,"age , years-nmbr-antihypertensive-score > nmbr % , % patients-ex - / current smoker-> nmbr-peripheral artery disease-lipid - lowering therapy-fpg , mmol / l-> nmbr years-acetyl - salicylic acid-hbanmbrc , mmol / mol-metabolic syndrome *-white-score , %-> nmbr years ""-moderately impaired-nmbr - nmbr years-cerebrovascular disease-normal-< nmbr years-none-severely impaired-black-asian-coronary artery disease-any above-hbanmbrc , %-mildly impaired-bmi , kg / mnmbr-male / female-hypertension"
620,arms,"total comparators ( n = nmbr ) ""-total comparators ( n = nmbr )-linagliptin ( n = nmbr )"
621,characteristic_name,"framingham nmbr - year cv risk score-gender ""-investigator - reported hypoglycaemia *-gender-use rescue medication-age ( years ) *-race"
622,characteristic_level,"male-asian-no-yes-> nmbr-white-> nmbr %-female-< nmbr %-female ""-black-< nmbr"
624,characteristic_name,"bmi ( kg / mnmbr )-duration tnmbrdm-age category >-fpg ( mmol / l )-nmbr - h ppg ( mmol / l ) * ""-body weight-age ( years )-female , n ( % )-nmbr - h ppg ( mmol / l ) *-hbanmbrc ( % )"
625,arms,"placebo n = nmbr-vildagliptin nmbr mg qd n = nmbr ""-vildagliptin nmbr mg bid n = nmbr-vildagliptin nmbr mg qd n = nmbr"
626,characteristic_name,"duration metformin therapy ( months )-bmi baseline ( kg / mnmbr )-hbanmbrc baseline , % ""-age ( years )-gender-duration diabetes ( months )-hbanmbrc baseline , %"
627,characteristic_level,"male-> nmbr-> nmbr ""-female-< nmbr"
628,arms,"placebo-vildagliptin nmbr mg bid-vildagliptin nmbr mg qd-vildagliptin nmbr mg qd """
629,measures,"ama < u + nmbreb > . e .-am < u + nmbrbnmbr > < u + nmbreb > . e .-baseline-baseline ""-n"
630,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-vorapaxar ( n = nmbr , nmbr )"
631,characteristic_name,"thienopyridine enrollment-current smoker-diabetes-region ""-body weight-qualifying atherosclerosis-age-history stroke-aspirin enrollment-region-egfr ( mumin / nmbr . nmbr mnmbr )-sex"
632,characteristic_level,"no-europe i-latin america-yes-asia-< nmbrkg-pad-women-north america-europe ii-australia / nz-mi-> = nmbrkg-stroke-< nmbr-men-> = nmbr-north america """
634,other,"nmbr . nmbr-nmbr . nmbr """
635,characteristic_name,"thienopyridine enrollment-diabetes ""-current smoker-diabetes-body weight-qualifying atherosclerosis-age-history stroke-aspirin enrollment-region-estimated glomerular filtration-sex"
636,characteristic_level,"no-yes-< nmbrkg-women-no ""-overall nmbr-stroke-< nmbr-> = nmbr"
638,measures,"hazard ratio ( nmbr % cl )-hazard ratio ( nmbr % cl ) """
639,characteristic_name,"inadequate response / intolerance prior therapy , %-extent disease , %-inadequate response / intolerance prior therapy , % """
640,characteristic_level,"anti - tnf agent ( )-mean hscrp , mg / l ( sd )-mean mayo score ( sd )-mean weight , kg ( sd )-mean cdai score ( sd )-mean age , ( sd )-corticosteroidsa-mean disease duration , ( sd )-oral aminosalicylates-prednisone use , %-immunosuppressant use , % ""-immunosuppressants-immunosuppressant use , %-left - sided disease only-extensive disease other-sex , % female"
641,characteristic_level,"ulcerative colitis ""-ulcerative colitis-crohn ' disease"
642,characteristic_name,"severity copd , n ( % ) * ""-severity copd , n ( % ) *-race , %"
643,characteristic_level,"other-fevnmbr reversibilityz ( pre / post ipratropium ) , %-ex - smoker / smoker , %-fevnmbr , litres ( pre ipratropium ) , mean ( sd )-age ( years ) , mean ( sd )-fevnmbr / fvc ( post salbutamol )-fevnmbr % predicted ( post salbutamol )-ics use , yes / %-fevnmbr , litres ( post ipratropium ) , mean ( sd )-pack - years , mean ( sd )-duration copd ( years ) , mean ( sd )-native american-fevnmbr , litres ( post - salbutamol ) , mean ( sd )-severe severe-caucasian-black-moderatey-asian-sex , men / women , %-fevnmbr , litres ( pre salbutamol ) , mean ( sd )-fevnmbr reversibilityz ( pre / post salbutamol ) , %-moderatey """
644,other,"study nmbr ""-study nmbr"
645,arms,"tiotropium + placebo ( n[nmbr )-tiotropium + placeb ( n[nmbr )-indacaterol + tiotropium ( n[nmbr )-tiotropium + placeb ( n[nmbr ) """
646,characteristic_name,"age , years-tc , mmol / l ( mg / dl )-age > nmbr years , %-obesity ( bmi > nmbr kg / mnmbr ) , %-bmi , mean ( sd ) , kg / mnmbr-ldl - c , mmol / l ( mg / dl )-women , %-fpg , mmol / l ( mg / dl )-hdl - c , mmol / l ( mg / dl ) ""-current smoker , %-diabetes , n ( % )-hypertension , n ( % )-hdl - c , mmol / l ( mg / dl )-tg , mmol / l [mg / dl]-dbp , mm hg-sbp , mm hg"
649,outcomes,"total cholesterol , mg / dl-apo - , mg / dl-ldl cholesterol , mg / dl-total cholesterohhdl cholesterol ratio-triglycerides , mg / dl-hdl cholesterol , mg / dl-ldl cholesterohhdl cholesterol ratio-apo b , mg / dl-apo b : apo - ratio-total cholesterohhdl cholesterol ratio """
650,characteristic_level,"patients without ra , , psa ( n = nmbr , nmbr )-patients ra , , psa ( n = nmbr )-patients without ra , , psa ( n = nmbr , nmbr ) """
652,arms,"standard care-standard care ""-insulin glargine"
653,characteristic_name,"anmbr = nmbr . nmbr % ( median )-no metformin-anmbrc < nmbr . nmbr % ( median )-age < nmbr yrs-placebo allocation-male-new dm-no prior cv event-overall-bmi > nmbr-prior dm-no statin use-metformin-age > = nmbr yrs-no ace - / arb-female-ace - / arb-bmi < = nmbr-omega nmbr allocation-prior cv event-placebo allocation ""-ifg / igt-statin use"
655,characteristic_name,"smoking status , n ( % )-mean *-baseline crp ( mg / dl ) ""-baseline crp ( mg / dl )"
656,characteristic_level,"fistula baseline , n ( % )-age ( yrs ) , mean *-> nmbr . nmbr , n ( % )-mean-current-> nmbr . nmbr , n ( % ) ""-baseline cdai ,-baseline ibdq total score , mean-white , n ( % )-prior-women , n ( % ) *-never"
657,outcomes,"disease duration nmbr bnmbr years ( n = nmbr ) ""-disease duration > nmbr years ( n = nmbr )-disease duration b nmbr years ( n = nmbr )-disease duration nmbr bnmbr years ( n = nmbr )"
658,characteristic_name,"age group , . ( % )-ethnicity , . ( % )-demographics-regular alcohol consumption per week , . ( % )-exercise-toast classification qualifying stroke , . ( % ) ""-antihypertensive medication , open - label , . ( % )-smoker-toast classification qualifying stroke , . ( % )-clinical history , . ( % )-clinical details"
659,characteristic_level,"large - artery atherosclerosis-atrial fibrillation-> nmbr drinks-sex , male , . ( % )-beta receptor antagonist-other-body mass index , kg / mnmbr , mean ( sd )-ace inhibitor-age , , mean ( sd )-alpha receptor antagonist-hyperlipidemia-diastolic blood pressure , mm hg , mean ( sd )-< nmbr y-cardioembolism-hypertension , treated-sedentary-white-diabetes mellitus-calcium channel blocker-some-undetermined etiology-small - artery occlusion-current-diuretic-former-baseline nihss score , median ( range )-nmbr - nmbr drinks-intense-tia-black-systolic blood pressure , mm hg , mean ( sd )-asian-other determined etiology-other determined etiology ""-nmbr drinks-> nmbr y-hypertension-never"
660,arms,"telmisartan ( n = nmbr )-placebo ( n = nmbr ) ""-mri substudy ( n = nmbr )-placebo ( n = nmbr )"
661,characteristic_name,"wml load follow - mri-wml load baseline mri-subcortical wml load diameter , mm , mean ( sd ) ""-subcortical wml load diameter , mm , mean ( sd )-total periventricular wml score , mean ( sd )"
662,characteristic_level,"subcortical wml load diameter , mm , , mean ( sd )-mild moderate-subcortical wml load diameter , mm , mean ( sd )-none-none ""-total periventricular wml score , mean ( sd )-severe"
663,arms,"placebo group ( n = nmbr )-placebo group ( n = nmbr ) ""-telmisartan group ( n = nmbr )"
664,measures,"percent patients-percent patients """
665,characteristic_name,"baseline serum k + , meq / l-diabetes status , . ( % )-eos serum k + , meq / l-diabetes status , . ( % ) """
667,other,"serum k + level drug treatment-serum k + level drug treatment """
668,characteristic_level,"baseline : > nmbr . nmbr meq / l eos : < nmbr . nmbr meq / l-baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l-baseline : < nmbr . nmbr meq / l eos : > nmbr . nmbr < nmbr . nmbr meq / l-baseline : > nmbr . nmbr meq / l eos : > nmbr . nmbr meq / l """
669,arms,"aml / hctz ( n = nmbr ) ""-aml / hctz ( n = nmbr )-val / hctz ( n = nmbr )"
670,outcomes,"sesbp-sedbp ""-sedbp"
671,arms,"aml nmbr mg / hctz nmbr mg-om nmbr mg / aml nmbr mg-om nmbr mg / aml nmbr mg / hctz nmbr mg-om nmbr mg / hctz nmbr mg-om nmbr mg / aml nmbr mg / hctz nmbr mg """
672,characteristic_level,"non - black-black-non - black """
673,measures,"n = nmbr ""-n = nmbr"
674,arms,"placebo ( n = nmbr )-tofacitinib , nmbr mg ( n = nmbr )-tofacitinib , nmbr mg ( n = nmbr ) """
676,outcomes,"total cholesterol , %-nmbr - year framingham chd risk , %-systolic blood pressure , mm hg-low - density lipoprotein cholesterol , % ""-low - density lipoprotein cholesterol , %-diastolic blood pressure , mm hg"
677,characteristic_level,"without diabetes-with diabetes-with diabetes """
678,measures,"difference ls meannmbr ( nmbr % cl )-difference ls meannmbr ( nmbr % cl ) """
679,characteristic_name,"concomitant drugs-time qualifying myocardial infarction "" ; na-time qualifying myocardial infarction"
680,characteristic_level,"nmbr - nmbr months-aspirin-weight < nmbr kg ""-thienopyridine-< nmbr months-> nmbr months-age > nmbr years-weight < nmbr kg-women-white ethnic origin-diabetes mellitus-previous cerebrovascular event-hyperlipidaemia-previous coronary revascularisation-any peripheral arterial disease-hypertension-median age ( iqr ; years )-current smoker-p blockers-lipid - lowering drug-angiotensin - converting enzyme inhibitor angiotensin receptor blocker"
681,arms,"placebo group ( n = nmbr )-placebo group ( n = nmbr ) ""-vorapaxar group ( n = nmbr )"
682,characteristic_name,"egfr ( ml / min / nmbr . nmbrmnmbr )-planned thienopyridine enrollment-diabetes-qualifying myocardial infarction-region-age-weight-prior stroke tia-prior stent-age ""-sex"
683,characteristic_level,"latin america-> = nmbr kg-north america-europe nmbr-> = nmbr yr-male-stemi-yes-< nmbr yr-overall-< nmbr-< nmbr yr ""-no-< nmbr kg-female-asia-unknown-nstemi-australia / nz-> = nmbr"
686,other,"study nmbr ""-study nmbr"
687,arms,"indacaterol n = nmbr-placebo n = nmbr ""-placebo n = nmbr"
689,other,"study nmbr ""-study nmbr"
690,characteristic_level,"gold iii - iv-gold ii-gold iii - iv """
691,arms,"placebo-indacaterol nmbr pg-placebo """
693,characteristic_level,"severe copdc [n z nmbr]-moderate copdb [n z nmbr] ""-moderate copdb [n z nmbr]"
694,arms,"placebo [n z nmbr]-indacaterol nmbr mg[n z nmbr] ""-indacaterol nmbr mg[n z nmbr]"
695,measures,"absolute change-percent change-percent change "" ; na"
696,outcomes,"apob-total c-apob ""-triglyceride a-ldl - c-non - hdl - c-tc / hdl - c"
697,other,"baseline sitosterol-baseline sitosterol """
698,outcomes,"muscle spasms-bronchitis-headache-hvookalemia-all teaes *-drug - related teaes *-headache "" ; na-edema , peripheral-discontinuations teaes-teaes ( > nmbr % treatment group ) *"
699,characteristic_name,"chronic cvd-ckd ""-ckd-diabetes"
700,arms,"om nmbr / ""-om nmbr / aml nmbr /-aml nmbr /-om nmbr /"
701,arms,"hctz-aml-hctz """
702,arms,"nmbr mg-nmbr mg """
703,arms,"monitoring ( n = nmbr ) ""-conventional treatment ( n = nmbr )-monitoring ( n = nmbr )"
704,characteristic_name,"acs-full po pulatio n-age > nmbr ""-bmi > nmbr-women-diabetes-age < nmbr-n diabetes-number stent = nmbr-no smo king-age > nmbr-number ste "" "" > nmbr-acs-men-smoking-bm < nmbr"
706,characteristic_name,"acs-full po pulatio n-bmi > nmbr-women-diabetes-age < nmbr-n diabetes-number stent = nmbr-no smo king-age > nmbr-bmi > nmbr ""-number ste "" "" > nmbr-acs-men-smoking-bm < nmbr"
708,other,"% ""-%-n"
709,characteristic_level,"warfarin-atrial fibrillation-other cardiac surgery , n ( % )-ticlopidine-iii ""-other-aspirin-valve surgery , n ( % )-ventricular tachycardia fibrillation-coronary bypass , n ( % )-others-clopidogrel-heparin-other supraventricular tachycardia-iii-not available-ii-iv"
710,characteristic_level,"> nmbr years ( n = nmbr )-> nmbr servings / wk ( n = nmbr )-usa ( n = nmbr )-> nmbr % ( n = nmbr )-yes ( n = nmbr )-female ( n = nmbr )-> nmbr mm ( n = nmbr )-> l : nmbrhrs : min ( n = nmbr )-> nmbr . nmbrmmol / l ( n = nmbr )-nmbr ( n = nmbr )-> nmbr : nmbr hrs : min ( n = nmbr )-italy ( n = nmbr )-yes ( n = nmbr ) """
712,measures,"events ( % ) ""-events ( % )-odds ratio-pfor"
714,characteristic_name,"geographic site , % "" ; na-geographic site , %-blood pressure , mm"
715,characteristic_level,"metformin dose , mg-homa - ir-female , % ""-europe-duration diabetes mellitus , y-insulin , pmol / l-glucose , mmol / l-female , %-hdl - c , mmol / l-fibrinogen , g / l-il - nmbr , ng / l-body mass index , kg / mnmbr-diastolic-current smoker , %-systolic-ldl - c , mmol / l-previous metformin use , %-hbanmbrc , %-americas-age , y-hscrp , mg / l-triglyceride , mmol / l-asia-non - hdl - c , mmol / l"
716,arms,"placebo ( n = nmbr )-total group ( n = nmbr )-canakinumab dose ( per mo ) ""-canakinumab dose ( per mo )"
717,arms,"nmbr mg ( n = nmbr ) ""-nmbrmg ( n = nmbr )-nmbr mg ( n = nmbr )"
718,outcomes,"crp ""-fibrinogen-crp-il - nmbr"
720,arms,"placebo-nmbrmg-canakinumab dose ( per month )-placebo """
721,arms,"nmbrmg-nmbrmg """
722,arms,"placebo ( n = nmbr )-apixaban , nmbr mg ( n = nmbr )-apixaban , nmbr mg ( n = nmbr ) ""-apixaban , nmbr . nmbr mg ( n = nmbr )"
723,characteristic_level,"male-severe moderate-normal renal function-< nmbr yr-dvt only-mild-> nmbr yr-< nmbr kg ""-< nmbr kg-> nmbr kg-nmbr < nmbr yr-female-pe ( without dvt )"
724,arms,"placebo-apixaban , nmbr . nmbr mg-apixaban , nmbr . nmbr mg ""-apixaban , nmbr mg"
725,characteristic_name,"overall-index event-level renal impairment-age-weight ""-weight-sex"
726,arms,"placebo-apixaban ""-apixaban"
727,measures,". patients ""-no . events-no . patients"
728,characteristic_name,"pah origin / cause-pah origin / cause ""-race"
729,characteristic_level,"functional class ii / iii-nmbrmwd , m-years since pah diagnosis-asian *-ipah / hpah-repaired chd-age , y-cvd-white-hiv-native american-female-cvd ""-black-not provided"
730,other,"itt population-mitt population ""-mitt population"
731,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-oral treprostinil ( n = nmbr )"
732,characteristic_level,"male-> nmbr mg / g-other-white-missing-< nmbr mg / g-female-black-missing ""-nmbr - nmbr mg / g"
733,characteristic_name,"bmi , kg / mnmbr uac , . ( % )-msdbp , mm hg-nmbr - hour madbp , mm hg-race , . ( % )-nmbr - hour masbp , mm hg-msdbp , mm hg ""-mssbp , mm hg-age , sex , . ( % )"
734,arms,"valsartan ( n = nmbr ) ""-valsartan ( n = nmbr )-aliskiren / valsartan ( n = nmbr )"
735,characteristic_name,"serum potassium , meq / l ""-bun , mg / dl-egfr , ml / min / nmbr . nmbr mnmbr-serum creatinine , mg / dl-serum potassium , meq / l"
737,characteristic_name,"nmbr mg / g-overall-uac nmbr - nmbr mg / g-uac =-uac > nmbr mg / g-uac > nmbr mg / g """
738,arms,"/ v ( n = nmbr )-a / v ( n = nmbr ) v ( n = nmbr ) ""-a / v ( n = nmbr ) v ( n = nmbr )-v ( n = nmbr )"
739,characteristic_name,"mean dlqi score ( nmbr % ci ) ""-mean sfnmbr score ( nmbr % ci )-mean dlqi score ( nmbr % ci )-characteristic"
740,characteristic_level,"male , n ( % )-mean bmi ( nmbr % ci )-work school-physical functioning-bodily pain-social functioning-personal relationships-physical role-vitality-treatment satisfaction-total score-work school ""-physical component summary-general health-mean involved bsa , % ( nmbr % ci )-emotional role-caucasian , n ( % )-mean eq - nmbrd response ( nmbr % ci )-mean ham - score ( nmbr % ci )-symptoms feelings-mean age , years ( nmbr % ci )-mean pasi score ( nmbr % ci )-mental health-mental component summary-leisure-daily activities"
741,arms,"psa ( n = nmbr ) ""-no psa ( n = nmbr )-psa ( n = nmbr )"
742,characteristic_name,"concomitant asthma medications , n ( % )-race , n ( % )-sex , n ( % )-race , n ( % ) """
743,characteristic_level,"hospitalized asthma , n ( % ) *-mean ( sd ) total asthma symptom scores-mean ( sd ) feno , ppb-mnmbr subgroup-mean prebronchodilator fevnmbr ( sd ) , % predicted-mean ( sd ) aqlq-mean ( sd ) periostin , ng / ml-white-mean prebronchodilator fevnmbr ( sd ) , % predicted ""-mean total serum ige ( sd ) , iu / ml-mean ( sd ) age , yr-female-mean ( sd ) number exacerbations *-mean eosinophil count , per ml-mean body weight ( sd ) , kg-mean ( sd ) number albuterol per day , puff"
744,characteristic_name,"high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr ) ""-low eosinophil subgroup ( , nmbr / ml ) ( n = nmbr )-low periostin subgroup ( , nmbr ng / ml ) ( n = nmbr )-high periostin subgroup ( > nmbr ng / ml ) ( n = nmbr )-high eosinophil subgroup ( > nmbr / ml ) ( n = nmbr )-high feno subgroup ( > nmbr . nmbr ppb ) ( n = nmbr )-low feno subgroup ( , nmbr . nmbr ppb ) ( n = nmbr )"
745,outcomes,"albuterol use-change baseline % predicted fevnmbr-change baseline % predicted fevnmbr ""-aqlq score-total asthma symptom score"
746,characteristic_name,"high subgroup-low subgroup-high subgroup """
747,arms,"clopidogrel ( n = nmbr )-clopidogrel ( n = nmbr ) ""-cangrelor ( n = nmbr )"
749,characteristic_name,"hypertension-time randomization-systolic blood pressure-time randomization-diabetes-age-weight-place randomization-killip class-timi risk score-sex ""-infarct location-sex"
750,characteristic_level,"other-> nmbr mm hg-ii - iv-> nmbr kg-> nmbr-after amendment-anterior-< nmbr mm hg-overall event rate-male-yes-< nmbr yr-ambulance-nmbr < nmbr mm hg-male ""-no-before amendment-> nmbr yr-i-< nmbr kg-female-nmbr < nmbr kg-inferior-> nmbr hr-nmbr < nmbr hr-< nmbr-community hospital"
752,characteristic_name,"antianginal medications-antianginal medications """
753,characteristic_level,"beta - blockers-dyslipidemia-antiplatelet agents-ace - l / arbs-baseline diastolic blood pressure ( mm hg )-beta - blockers ""-white-insulin-prior bypass graft surgery-prior angioplasty-antidiabetic medication-age , yrs-hbalc , %-prior myocardial infarction-on nmbr-long - acting nitrates-duration diabetes , yrs-baseline systolic blood pressure ( mm hg )-calcium - channel blockers-statins-current smoking-baseline heart rate ( beats / min )-men-hypertension"
754,arms,"ranolazine ( n = nmbr ) placebo ( n = nmbr )-ranolazine ( n = nmbr ) placebo ( n = nmbr ) """
755,characteristic_name,"experience ""-islander-experience-mellitus-chads score"
756,characteristic_level,"nmbr-other-black / african american-history hypertension-male-yes-weight , lbs-> nmbr yr warfarin experience-age , yrs-hawaiian / pacific-history diabetes-no-history diabetes ""-caucasian-hispanic / latino-female-warfarin naive-history cad-race / ethnicity-height , inches-sex-chads score-asian-> nmbr days warfarin"
758,characteristic_level,"north america-india-europe-australia ""-australia-south america"
759,characteristic_name,"prior new diabetes-statin-women - . ( % )-average maximum common bifurcation cimt ( mm )-estimated glomerular filtration rate ( ml / min / nmbr . nmbrmnmbr )-hyperlipidemia-ankle / brachial index-impaired glucose tolerance impaired fasting glucose-urinary albumin : creatinine ratio *-calcium channel blocker-beta - blocker-other oral hypoglycemic drug ( )-hdl - cholesterol ( mmol / l )-average maximum common carotid cimt ( mm )-geographic distribution - . ( % ) ""-metformin-heart rate ( beats per minute )-prior cardiovascular event "" "" ' "" ""-systolic blood pressure ( mmhg )-average maximum far wall cimt ( mm )-geographic distribution - . ( % )-sulfonylurea-microalbuminuria macroalbuminuria-anticoagulant-diastolic blood pressure-mean age ( years )-ldl - cholesterol ( mmol / )-serum creatinine ( gmol / )-glycated hemoglobin ( % )-dietary epa - dha intake ( mg / day ) *-triglycerides ( mmol / l )-asa antiplatelet agent-ace inhibitor arb-thiazide diuretic-current smoking-body mass index ( kg / mnmbr )-fasting plasma glucose ( mmol / l )-average maximum cimt ( mm )-hypertension-total cholesterol ( mmol / l )"
760,arms,"placebo ( n = nmbr )-insulin glargine ( n = nmbr )-placebo ( n = nmbr ) ""-n - nmbr fatty acids ( n = nmbr )-standard care ( n = nmbr )"
761,characteristic_name,"hbalca median-tngtycendes median-male-stalin-overall-age < nmbr-previous cv event-no diabetes-ageadj-tnglycendes < median-fascng plasma glucose medan-hbalc < medan-no ace - / arb-female-maximum cimt < median-ace - / arb-no statin-no previous cv event-diabetes ""-diabetes-maximum cimt med an-fastng plasma glucose < median"
762,characteristic_name,"hbalc < median-no ststm-tngtycerides median-llv wlalil nmbr statin-fasting plasma glucose nmbr medan-hbalca median-age nmbr-male-overall-age < nmbr-previous cv event-fasting plasma glucose < median-no diabetes-dabetes ""-no ace - / arb-female-maximum cimt < median-ace - / arb-dabetes-tngtycerides < median-no previous cv event-maximum cimt med"
763,characteristic_name,"anmbrc ( % )-> nmbr years education-statin-hdl ( mmol / l )-randomized-total cholesterol-p - blocker-bmnmbr ( kg / mnmbr )-urine acr ( mg / g )-thiazide-omega - nmbr fa-tg ( mmol / l )-waist - - hip , male-sbp ( mmhg )-fpg ( mmol / l ) ""-females-dbp ( mmhg )-depression-ldl ( mmol / l )-> nmbr drinks / week-current smoker-abi < nmbr . nmbr-age ( years )-waist - - hip , female-ace - / arb-weight ( kg )-prior cv event-egfr ( ml / min )-anmbrc ( mmol / mol )-fpg ( mmol / l )-grip strength ( kg )-alt ( units / l )-nmbr - h pg ( mmol / l )-hypertension"
764,arms,"glargine-standard therapy-standard therapy ""-overall"
766,characteristic_name,"frailty status-race-frailty status ""-gfr ( mdrd ) ( ml / min / nmbr - nmbr mnmbr )"
767,characteristic_level,"no-yes-mild ( > nmbr < nmbr )-other-moderate ( > nmbr < nmbr )-systolic blood pressure ( mm hg )-range-white-missing-age ( years )-duration type nmbr diabetes ( years )-normal ( > nmbr )-diastolic blood pressure ( mm hg )-fasting plasma glucose ( mmol / l )-body - mass index ( kg / mnmbr )-men-hbanmbrc ( % )-missing """
768,arms,"vildagliptin ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) """
769,characteristic_name,"hbanmbrc levels-age ( years )-frailty status-hbanmbrc levels """
770,characteristic_level,"non - frail-> nmbr % ""-> nmbr-> nmbr %-< nmbr-frail-snmbr %"
771,arms,"vildagliptin ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) """
772,characteristic_name,"smoking status-post - bronchodilator-concomitant medications , % ""-gold stage , %-pre - bronchodilator-concomitant medications , %"
773,characteristic_level,"fvc , l-male , %-ocs-fevnmbr , % predicted-sgrq total score , units-fevnmbr , l-saaca-theophylline compound-labaa-sabaa-iii-labaa ""-iv-laaca-copd duration , y-current smokers , %-bmi , kg / mnmbr-icsa-age , y-history , pack - years-ii-fevnmbr / fvc"
774,arms,"tiotropium ( n z nmbr )-control ( n z nmbr ) ""-control ( n z nmbr )"
775,characteristic_level,"tiotropium ( n z nmbr )-western europe ( n = nmbr )-female ( n z nmbr )-nmbr < nmbr ( n = nmbr )-iv ( n z nmbr )-usa ( n = nmbr )-asia ( n = nmbr )-current smoker ( n z nmbr )-ex - smoker ( n z nmbr )-male ( n z nmbr )-nmbr < nmbr ( n z nmbr )-control ( n z nmbr )-iii ( n z nmbr )-< nmbr ( n = nmbr )-eastern europe ( n = nmbr )-< nmbr ( n z nmbr )-iorii ( n z nmbr )-latin america ( n = nmbr )-< nmbr ( n z nmbr ) ""-> nmbr ( n = nmbr )"
776,characteristic_name,"smoking status-bronchodilator response , ml-age , y-age , ""-copd severity ( gold stage )-region-treatment arm-sex"
777,outcomes,"mean - sd change pre - bronchodilator fevnmbr , l ""-mean - sd change pre - bronchodilator fevnmbr , l"
778,characteristic_name,"smokers , n ( % ) ""-smokers , n ( % )"
779,characteristic_level,"uae ( p , g / min )-triglycerides ( mg / dl )-sbp ( mmhg ) ""-map ( mmhg )-sex ( male ) , n ( % )-glucose ( mg / dl )-hdl cholesterol ( mg / dl )-mmol / mol-ldl cholesterol ( mg / dl )-sbp ( mmhg )-total cholesterol ( mg / dl )-serum creatinine ( mg / dl )-dbp ( mmhg )-bmi ( kg / mnmbr )-current-former-age ( years )-n-hbalc ( % )-diabetes duration ( years )-never"
780,characteristic_name,"pro / pro homozygotes ""-ala carriers-pro / pro homozygotes"
781,outcomes,"cvd events-renal events-cvd events ""-composite events"
782,arms,"acei vs . non - acei-acei vs . non - acei """
783,characteristic_name,"pro / pro homozygotes ""-ala carriers-pro / pro homozygotes"
784,measures,"p-p ""-hr ( nmbr % ci )"
785,characteristic_name,"anmbrc distribution ( % ) "" ; na-race-anmbrc distribution ( % )"
786,characteristic_level,"black african american-asian-received oral aha within nmbr weeks prior screening "" ; na-= nmbr . nmbr %-> nmbr . nmbr % = nmbr . nmbr %-native hawaiian pacific islander-white-american indian native alaskan-known duration type nmbr diabetes ( years )-> nmbr . nmbr %-received oral aha within nmbr weeks prior screening-multi - racial"
787,arms,"sita nmbr-sita nmbr + pio nmbr-pio nmbr-sita nmbr """
788,measures,"change baseline-baseline-change baseline "" ; na-n"
789,characteristic_level,"anmbrc baseline < nmbr . nmbr % ""-anmbrc baseline < nmbr . nmbr %-anmbrc baseline = nmbr . nmbr %"
790,arms,"sita nmbr-sita / pio nmbr / nmbr-pio nmbr-pio nmbr """
791,characteristic_name,"time since diagnosis type nmbr diabetes-race ""-race-sex"
792,characteristic_level,"egfr ( ml / min / nmbr . nmbr mnmbr [mdrdequation] )-american indian / alaska native ""-> nmbr - nmbr years-black / african american-number patients-> nmbr years-hbanmbrc ( % )-male-white-sbp ( mmhg )-body weight ( kg )-dbp ( mmhg )-bmi ( kg / mnmbr )-# nmbr year-age ( years )-american indian / alaska native-female-asian-fpg ( mmol / l )-mdg ( mmol / l )"
793,arms,"pen - label empagliflozin nmbr mg ( baseline hbanmbrc > nmbr % )-placebo-o total randomized-placebo ""-empagliflozin nmbr mg"
794,arms,"placebo-empagliflozin nmbr mg ""-empagliflozin nmbr mg"
795,arms,"total ( n = nmbr )-total ( n = nmbr ) ""-vedolizumab"
796,other,"cohort nmbr ( n = nmbr )-combined ( n = nmbr )-cohort nmbr ( n = nmbr ) f-combined ( n = nmbr ) """
797,characteristic_name,"extent disease-baseline composite mayo clinic score-prior treatment historynmbr-sex-stratification variables-age-baseline composite mayo clinic score ""-baseline fecal caicrctectin-duration ulcerative colitis"
798,characteristic_name,"chronic kidney disease stage : egfr ( ml / min per nmbr . nmbr mnmbr )-race ""-geographic region-pre - enrollment antihyperglycemic therapy-race"
799,characteristic_level,"fpg ( mg / dl )-latin america-sulfonylurea based-other-insulin based-europe-thiazolidinedione based-hbanmbrc ( % )-stage nmbr : > = nmbr-fpg ( mg / dl ) ""-women-northamerica-white-bmi , xnmbr kg / mnmbr-african american-duration diabetes ( years )-age ( years )-stage nmbrb : > = nmbr < nmbr-asia / pacific-stage nmbr : < nmbr-urinary protein : creatinine ratioa ( mg / mg )-patients diabetic nephropathy-n-asian-weight ( kg )-urinary albumin : creatinine ratioa ( mg / g )-stage nmbra : > = nmbr < nmbr-men"
800,arms,"placebo-dapagliflozin nmbrmg ""-dapagliflozin nmbrmg-dapagliflozin nmbr mg"
801,arms,"dapagliflozin nmbr mg ""-dapagliflozin nmbr mg"
802,characteristic_name,"stage nmbra : egfr > = nmbr < nmbr ml / min per nmbr . nmbr mnmbr-stage nmbrb : egfr > = nmbr < nmbr ml / min per nmbr . nmbr mnmbr-stage nmbrb : egfr > = nmbr < nmbr ml / min per nmbr . nmbr mnmbr """
803,outcomes,"fpg ( mg / dl )-hbanmbrc ( % ) ""-hbanmbrc ( % )-weight ( kg )"
804,measures,"difference placebo ""-difference placebo-n"
805,characteristic_name,"comorbidites , n ( % )-concomitant medication , n ( % )-disease location , %-disease location , % """
806,characteristic_level,"mayo score , mean ( sd ) ""-men , %-mayo score , mean ( sd )-corticosteroid azathioprine / nmbr - mercaptopurine-oral corticosteroid-weight , kg , median ( range )-stool frequency subscore-age , median ( range )-hyperlipidemia-crp , nmol / l , median ( range )-uc duration , , mean ( range )-anemia-pancolitis-aminosalicylates-corticosteroid - azathioprine / nmbr - mercaptopurine-azathioprine / nmbr - mercaptopurine-rectal bleeding subscore-asthma-endoscopy subscore-gastroesophageal reflux disease-prior therapy tnf antagonist , n ( % )-diabetes-pga subscore-partial mayo score , mean ( sd )-hypertension"
807,arms,"adalimumab ( n = nmbr ) ""-placebo ( n = nmbr )-adalimumab ( n = nmbr )"
808,characteristic_name,"risk factors-medications discharge-> nmbr mg / dl-time intervals , h-clinical presentation-angiographic data treatment :-> nmbr ( ml ) additional angiography-randomization-first procedure-blockers-distribution time-laboratory variables baseline-medications coronary angiography-> nmbr ml-blockers ""-pci data"
809,characteristic_level,"nitrates-unstable angina-multivessel pci-beta - blockers-> nmbr-ctn - l , ng / ml-previous pci cabg-total cholesterol-hdl cholesterol , mg / dl-nmbr - nmbr-score distribution : < nmbr-management distribution medical treatment-active smoking-calcium channel blockers-male-angiotensin receptor-contrast volume ( ml )-gp llb / llla inhibitors-diabetes mellitus-glycemia , mg / dl-triglycerides , mg / dl-age , yrs-after nmbr h-multivessel disease-age > nmbr yrs-ef < nmbr %-nste - mi-previous ml-randomization - --within nmbr h-diuretics-baseline lvef , %-hospital stay ( days )-egfr < nmbr , ml / min / mnmbr-contrast volume , ml-ldl cholesterol , mg / dl-contrast volume-within nmbr h after-ecrcl < nmbr ml / min-serum creatinine , mg / dl-contrast nephropathy risk score-pci-egfr , ml / min / mnmbr-haemoglobin , mg / dl-high - risk clinical features-ecrcl , ml / min-bmi , kg / mnmbr-ace inhibitors-calcium channel-ck - mb , ng / ml-nitrates ""-symptom onset - --cabg-hypertension"
811,characteristic_level,"male-no-> nmbr yrs-yes-< nmbr ml-yes ""-< nmbr yrs-> nmbr-> nmbr ml / min-> nmbr %-< nmbr ml / min-female-< nmbr %-> nmbr ml-< nmbr"
812,characteristic_name,"baseline lvef-diabetes mellitus ""-pci-contrast volume-diabetes mellitus-age-baseline ecrcl-high risk-ci - aki risk score-sex"
814,characteristic_name,"discharge medication , n ( % )-clinical indication index procedure , n ( % )-type drug - eluting stent , n ( % ) ""-type drug - eluting stent , n ( % )"
815,arms,"clopidogrel + aspirin ( n = nmbr ) ""-aspirin alone ( n = nmbr )-clopidogrel + aspirin ( n = nmbr )"
816,characteristic_name,"time randomization-multivessel stenting-diabetes-sex-type des-age-ejection fraction-left main disease-bifurcation-cohort-type des ""-acute coronary syndrome"
817,arms,"aspirin + clopidogrel ( n = nmbr ) nmbr . nmbr-nmbr . nmbr ( nmbr . nmbr . nmbr . nmbr )-nmbr . nmbr-nmbr . nmbr ""-aspirin alone ( n = nmbr ) nmbr . nmbr"
818,characteristic_name,"copd severity , n ( % ) ""-smoking status , n ( % )-race , n ( % )-lung function , mean-copd severity , n ( % )"
819,characteristic_level,"male , n ( % )-other-postbronchodilator fevnmbr , % predicted-age , mean-white-moderate-with laba , n ( % ) pretreatment-concomitant treatment-postbronchodilator fevnmbr , l-very severe-current-mild-moderate ""-former-prebronchodilator fevnmbr , % predicted-black-asian-prebronchodilator fevnmbr , l-severe"
820,characteristic_name,"copd severity-smoking status-pretreatment / concomitant treatment-age-geographic region-smoking status """
821,characteristic_level,"> nmbr years n z nmbr-< nmbr years n z nmbr-rest world n z nmbr-north america n z nmbr-very severe n z nmbr-europe n z nmbr-former n z nmbr-- ics / + laba n z nmbr-severe n z nmbr-former n z nmbr ""-+ ics / + laba nz nmbr-current n z nmbr-moderate n z nmbr"
822,characteristic_level,"ex - smoker-asian-very severe-current smoker ""-> nmbr exacerbations-nmbr exacerbations-other-current smoker-caucasian-moderate-severe-black"
823,characteristic_name,"mean ( sd ) duration copd , years-mean ( sd ) fevnmbr ( l ) post - bronchodilator ""-mean ( sd ) fevnmbr ( l ) post - bronchodilator-copd exacerbation history , n ( % )-ethnicity , n ( % )-mean ( sd ) duration smoking , pack years-mean ( sd ) age , years-mean ( sd ) post - bronchodilator fevnmbr percentage predicted-mean ( sd ) post - bronchodilator fevnmbr / fvc , %-gender , n ( % ) male-severity disease ( gold nmbr ) , n ( % )-mean ( sd ) body mass index , kg / mnmbr-mean ( sd ) post - bronchodilator fevnmbr reversibility , %-mean ( sd ) fevnmbr ( l ) pre - bronchodilator-smoking history , n ( % )-ics use baseline , n ( % )"
824,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-tiotropium nmbrmg ( n = nmbr-glycopyrronium nmbr mg ( n = nmbr )"
826,arms,"losartan plus lisinopril ( n = nmbr )-losartan plus lisinopril ( n = nmbr ) ""-losartan plus placebo ( n = nmbr )"
827,characteristic_level,"global ischemia ( % ) * *-other ""-prior myocardial infarction-other-smoking past yr-diabetes-hyperlipidemia-% stenosis , assessed core laboratory-magnetic resonance angiography-% stenosis , assessed investigator-bilateral disease ( % ) ' j ' ' j '-angiography-computed tomographic angiography-black-duplex ultrasonography-history heart failure"
828,arms,"medical therapy ( n = nmbr ) ""-medical therapy ( n = nmbr )-stenting plus medical therapy ( n = nmbr )"
829,characteristic_level,"nmbr-unstable angina ( biomarker negative )-hypercholesterolemia-cabg surgery-north america-aspirin-metabolic syndrome-p - blocker-otherb-stemi-white-stroke-eastern europe-triglycerides-hdl - c-peripheral arterial disease-western europe lebanon-australia new zealand-black-triglycerides ""-pci-present smokerc-asian-myocardial infarction-ace inhibitor arb-diabetes-nstemi-clopidogrel , ticlopidine , prasugrel-ldl - c-asia-hypertension"
830,characteristic_name,"index event randomization , median ( iqr ) , h-c - reactive protein , median ( iqr ) , mg / l-c - reactive protein , median ( iqr ) , mg / l ""-pci cabg surgery index event-medications randomization-age , mean ( sd ) , y-( sd ) , mg / dl-prior lipid - modifying therapy-cardiovascular risk factors-female sex-cardiovascular disease history-region enrollment-body mass index , mean ( sd ) d-concomitant atorvastatin dose , mg-race / ethnicity-index diagnosis"
831,arms,"placebo ( n = nmbr )-varespladib ( n = nmbr ) ""-varespladib ( n = nmbr )"
832,characteristic_name,"race , n ( % ) ""-race , n ( % )-country , n ( % )"
833,characteristic_level,"asian-romania-ukraine-germany-other-african american ""-united states-white-japan-australia-philippines-poland-russia-mexico-argentina-african american"
835,characteristic_level,"handihaler , n-diskus , n-mdi / hfa , n ""-mdi / hfa , n-handihaler diskus , n-dpi ( diskus ) , n"
836,characteristic_name,"age , years-current inhaler +-self - reported disease severity , nmbr - nmbr scale *-current inhaler + ""-duration disease , years"
837,characteristic_level,"copd population ( n = nmbr )-asthma population ( n = nmbr )-copd population ( n = nmbr ) """
838,characteristic_name,"age group , n ( % )-severity copd * , n ( % )-ethnicity , n ( % )-severity copd * , n ( % ) "" ; na-race , %"
839,characteristic_level,"age , years-indian ( indian subcontinent )-male / female , %-duration copd , years-other-> nmbr years-fevi , l *-smokers , %-fevnmbr / fvc , % *-moderate-ics use , %-reversibility salbutamol , %-age , years ""-< nmbr years-caucasian-smoking history , pack - years-asian-chinese-severe-fevi , % predicted *"
841,characteristic_level,"no-yes-smokers-moderate-> nmbr %-chinese-< nmbr %-smokers ""-severe-ex - smokers"
842,characteristic_name,"copd severity-theophylline use screening-smoking history-smoking history ""-saba reversibility-ethnicity-ics use"
843,arms,"n ( indacaterol nmbr ug / indacaterol nmbr ug / placebo )-indacaterol nmbr ug versus indacaterol nmbr ug-indacaterol nmbr ug versus indacaterol nmbr ug ""-indacaterol nmbr ug versus placebo"
844,characteristic_name,"ethnicity , n ( % ) ""-baseline copd exacerbation history , * n ( % )-ethnicity , n ( % )-smoking history , n ( % )-severity airflow limitation ( gold nmbr ) , n ( % )"
845,characteristic_level,"ex - smoker-native american ""-nmbr exacerbation-nmbr exacerbations-other-current smoker-caucasian-moderate-native american-$ nmbr exacerbations-severe"
846,arms,"ind + gly ( n = nmbr )-ind + pbo ( n = nmbr ) ""-ind + pbo ( n = nmbr )"
848,characteristic_level,"nmbr-pdqol scale-> nmbr-adl-nmbr - nmbr-white race-total-age onset , y-mental-modified se - adl scale-male sex-motor-symbol digit score-diagnosed , y-age diagnosis , y-age , y-modified rankin score-duration pd , y-hoehn yahr stage-duration pd , ""-< nmbr"
849,characteristic_name,"continuous variables , mean ( sd ) ""-continuous variables , mean ( sd )-no . ( % ) participants"
850,measures,"treatment group ""-pvalue-treatment group"
851,arms,"coenzyme qnmbr ""-coenzyme qnmbr"
852,measures,"nmbr mg ( n = nmbr ) ""-nmbr mg ( n = nmbr )"
855,characteristic_name,"mini - mental state examination-ethnic origin-education *-digit symbol substitution-sex ""-sex"
856,arms,"overall ( n = unmbr ) ""-omega - nmbr fatty acid ( n = nmbr )-placebo ( n = nmbro )-overall ( n = unmbr )-standard care ( n = nmbr )-insulin glargine ( n = nmbrll )"
857,outcomes,"b digit symbol substitution , insulin glargine vs standard care-a mini - mental state examination , insulin glargine vs standard care-b digit symbol substitution , insulin glargine vs standard care """
860,outcomes,"b digit symbol substitution , omega - nmbr fatty acids vs placebo ""-b digit symbol substitution , omega - nmbr fatty acids vs placebo-a mini - mental state examination , omega - nmbr fatty acids vs placebo"
863,characteristic_name,"history peripheral arterial disease ( % )-hbanmbrc ( % )-body mass index ( kg / mnmbr ) ""-hdl cholesterol ( mg / dl )-current smoker ( % )-systolic bp ( mm hg )-k ( mmol / l )-history stroke ( % )-triglyceride ( mg / dl )-left ventricular hypertrophy ( % )-on drug treatment ( % )-body weight ( kg )-total cholesterol ( mg / dl )-history myocardial infarction ( % )-alcohol intake ( + ) ( % )-pulse rate ( bpm )-age ( years )-egfr ( mumin / nmbr . nmbr mnmbr )-uric acid ( mg / dl )-diastolic bp ( mm hg )-fasting plasma glucose ( mg / dl )-men ( % )-na ( mmol / l )-body mass index ( kg / mnmbr )-positive family history type nmbr diabetes ( % )"
864,arms,"- diuretics group ( n = nmbr ) ""-diuretics group ( n = nmbr )-no - diuretics group ( n = nmbr )"
866,arms,"non diuretics ""-non diuretics"
868,characteristic_name,"prior heart failure-statin-second - generation stent-drug - eluting stent implanted-older nmbr years-circumflex ""-first - generation stentt-women-prior stroke-left main-dyslipidaemia-prior myocardial infarction-calcium - channel inhibitor-current smoker-p blockers-high - treatment platelet reactivity *-body weight index ( kg / mnmbr )-proton - pump inhibitors-left anterior descending-prior coronary artery bypass graft-ace inhibitors-coronary artery bypass graft-right coronary artery-diabetes-prior percutaneous coronary intervention-age years-circumflex-hypertension"
869,arms,"interruption ( n = nmbr ) ""-continuation ( n = nmbr )-interruption ( n = nmbr )"
870,characteristic_level,"aqc < nmbr-no acs-bmi > nmbr-diabetes ""-woman-diabetes-no smoking-number stent > nmbr-number stent = nmbr-full population-age > nmbr-bmi < nmbr-acs-no diabetes-men-smoking"
872,measures,"% ""-%-n"
873,characteristic_level,"aqc < nmbr-no acs-bmi > nmbr-woman-diabetes-no smoking-number stent > nmbr-number stent = nmbr-full population-age > nmbr-bmi < nmbr-acs-no diabetes-aqc < nmbr ""-men-smoking"
875,characteristic_name,"place randomization-place randomization "" ; na-time randomization symptom onset-infarct location"
876,characteristic_level,"( n , % )-ambulance , n ( % )-inferior ( n , % )-anterior ( n , % )-> nmbr h , n ( % )-> nmbr < nmbr h , n ( % )-community hospital , n ( % )-nmbr < nmbr h , n ( % )-community hospital , n ( % ) "" ; na"
877,arms,"pharmaco - invasive ( n = nmbr )-pharmaco - invasive ( n = nmbr ) ""-primary pci ( n = nmbr )"
878,characteristic_level,"female ( % )-ii - iv ( % )-male ( % )-inferior ( % )-ambulance ( % )-< nmbr { % )-after amendment ( % )-> = nmbr ( % )-yes ( % )-nmbr < nmbr ( % )-l ( % )-< nmbr ( % )-< nmbr ( % ) ""-anterior { % )-before amendment ( % )-nmbr - < nmbr ( % )-no ( % )-> = nmbr * ( % )-community hospital ( % )"
879,characteristic_name,"previous ml ( interaction : p = nmbr . nmbr )-killip class ( interaction : p = nmbr . nmbr )-sex ( interaction : p = nmbr . nmbr )-age [years] ( interaction : p = nmbr . nmbr )-p lace randomization ( interaction : p = nmbr . nmbr )-systolic blood pressure [mmhg] ( interaction : p = nmbr . nmbr )-infarct location ( interactsn $ : p = nmbr . nmbr ) ""-time randomization ( interaction : p = nmbr . nmbr )-timi risk score ( interaction : p = nmbr . nmbr )-time randomisation [hours] ( interaction : p = nmbr . nmbr )-infarct location ( interactsn $ : p = nmbr . nmbr )"
880,arms,"prehospital ticagrelor ( n = nmbr )-in - hospital ticagrelor ( n = nmbr ) ""-in - hospital ticagrelor ( n = nmbr )"
882,arms,"( nmbr % cl )-pre - h-or ( nmbr % cl ) ""-in - h"
883,arms,"placebo ( n = nmbr )-ivabradine ( n = nmbr )-placebo ( n = nmbr ) """
884,characteristic_name,"previous coronary revascularization-heart rate-age-history diabetes-previous myocardial infarction-heart rate ""-angina class baseline-beta - blocker use randomization-sex"
885,characteristic_level,"no-class > nmbr-male-yes-> nmbr beats / min-class nmbr symptoms-< nmbr yr-> nmbr yr-< nmbr beats / min-female-< nmbr beats / min """
886,other,"p value-p value """
888,characteristic_name,"female sex , n ( % )-age , years-duration copd , years-white race , n ( % )-body mass index , kg / mnmbr-smoking pack - years-baseline % predicted fevnmbr ""-emphysema ( % )-baseline pre - bronchodilator fevnmbr , l-reversible ( % )-baseline % predicted fevnmbr-both ( % )-fevnmbr % reversibility-non - reversible ( % )-chronic bronchitis ( % )"
890,characteristic_level,"beta - blockers-left atrial dimension , cm-paroxysmal af-class iii aad use nmbr months enrollment-class l / heart failure-persistent af ""-acei arb-persistent af-age , yrs-coronary disease-sinus rhythm baseline-female-time since first af diagnosis , yrs-left ventricular hypertrophy echo-oral anticoagulant-valvular disease-bmi , kg / mnmbr-waist circumference , cm-diabetes-nmbr - lead ecg heart rate , beats / min-hypertension"
891,characteristic_name,"left ventricular ejection fraction , % af history-concomitant medications-cardiac echocardiography parameters-left ventricular ejection fraction , % af history ""-demographic medical variables"
892,arms,"fish oil ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) """
893,characteristic_level,"apolipoprotein b ( g / l ) ""-lipoprotein ( ) ( nmol / l )-apolipoprotein anmbr ( g / l )-hdl cholesterol ( mmol / l )-> nmbr - nmbr mmol / l-apolipoprotein b ( g / l )-< nmbr - nmbr mmol / l-triglycerides ( mmol / l )"
894,characteristic_name,"coronary artery disease-other lipid parameters-ldl cholesterol baseline ( mmol / l ) * ldl cholesterol screening-age ( years )-female sex-hscrp ( nmol / l )-unbound pcsknmbr ( nmol / l )-other lipid parameters """
895,arms,"evolocumab nmbr mg monthly ( n = nmbr )-evolocumab nmbr mg monthly ( n = nmbr ) ""-placebo every nmbr weeks ( n = nmbr )-evolocumab nmbr mg every nmbrweeks ( n = nmbr )-placebo monthly ( n = nmbr )"
896,measures,"age , years-asian-hbanmbrc , %-hbanmbrc , mmol / mol-other-bmi , kg / mnmbr-women-duration diabetes , years-< nmbr % ( nmbr mmol / mol )-> = nmbr % ( nmbr mmol / mol )-ppg , mg / dl-white-fasting c - peptide , ng / ml-ppg , mg / dl ""-egfr , * ml / min / nmbr . nmbr mnmbr-> = nmbr % < nmbr % ( > = nmbrand < nmbr mmol / mol )-fpg , mg / dl-african american"
898,characteristic_level,"> nmbr % ( > nmbr mmol / mol )-< nmbr % ( < nmbr mmol / mol ) ""-> nmbr % < nmbr % ( > nmbr < nmbr mmol / mol )-< nmbr % ( < nmbr mmol / mol )"
899,measures,"mean ( nmbr % ci ) difference vs saxa + dapa + met-baseline mean ( sd ) , % [mmol / mol]-n *-adjusted mean change baseline ( nmbr % ci ) , % [mmol / mol] ""-adjusted mean change baseline ( nmbr % ci ) , % [mmol / mol]"
900,arms,"saxa + dapa + met n = nmbr-dapa + met n = nmbr-saxa + met n = nmbr-saxa + met n = nmbr """
901,characteristic_level,"< nmbr ""-< nmbr-> nmbr"
902,measures,"mean ( nmbr % ci ) difference vs saxa + dapa + met-baseline mean ( sd ) , % [mmol / mol]-n *-adjusted mean change baseline ( nmbr % ci ) , % [mmol / mol] ""-adjusted mean change baseline ( nmbr % ci ) , % [mmol / mol]"
903,arms,"saxa + dapa + met n = nmbr-dapa + met n = nmbr-saxa + met n = nmbr-saxa + met n = nmbr """
904,characteristic_level,"> nmbr % ( > nmbr mmol / mol )-< nmbr % ( nmbr mmol / mol )-> nmbr % < nmbr % ( > nmbr nmbr mmol / mol )-< nmbr % ( nmbr mmol / mol ) """
905,measures,"mean ( nmbr % ci ) difference vs saxa + dapa + met-baseline mean ( sd ) , % [mmol / mol]-proportion ( nmbr % ci ) adjusted baseline hbanmbrc , % ""-proportion ( nmbr % ci ) adjusted baseline hbanmbrc , %-x / n *"
906,arms,"saxa + dapa + met n = nmbr-dapa + met n = nmbr-saxa + met n = nmbr-saxa + met n = nmbr """
907,arms,"abatacept monotherapy ( n = nmbr )-total ( n = nmbr )-mtx ( n = nmbr )-total ( n = nmbr ) ""-abatacept plus mtx ( n = nmbr )"
908,characteristic_name,"haq - di , number ( % )-symptom duration ""-symptom duration-synovitis-pain ( nmbr mm vas )-osteitis-dasnmbr ( crp )-erosion"
909,arms,"abatacept monotherapy ( n = nmbr )-abatacept monotherapy ( n = nmbr ) ""-abatacept plus mtx ( n = nmbr )-mtx ( n = nmbr )"
910,characteristic_name,"onsetofaf , . ( % )-region enrollment , . ( % )-previous warfarin use , . ( % )-previous warfarin use , . ( % ) ""-classification af , . ( % )-score , . ( % )-chadsnmbr scoreb-risk factors stroke , . ( % )-blood pressure , mean ( sd ) [range] , mm hg-race / ethnicity , . ( % )"
911,characteristic_level,"nmbr-congestive heart failure-body mass index , mean ( sd ) [range]a-other-united states-europe-black / african american-persistent-< nmbry-history hypertension-previous ischemic stroke ortia-white-permanent-hawaiian pacific islander-paroxysmal-age nmbr y-mean ( sd ) [range]-diastolic-hispanic / latino-systolic-age , mean ( sd ) [range] , y-lv ejection fraction , mean ( sd ) [range] , %-heart rate , mean ( sd ) [range] , beats / min-asian-unknown-no estimate-diabetes-male sex , . ( % )-nmbry-nmbry """
912,arms,"device group ( n = nmbr )-warfarin group ( n = nmbr )-warfarin group ( n = nmbr ) """
913,characteristic_name,"chadsnmbr score-lv ejection fraction-laa ostium-laa length-af pattern-prior years taking warfarin ""-history tia stroke-prior years taking warfarin-age-sex"
914,characteristic_level,"male-nmbr-paroxysmal-yes-no-< nmbr y-> median ( nmbr mm )-all patients-> nmbr-persistent-< nmbr ""-female-permanent-< median-< nmbr-> nmbr y-> median ( nmbr % )"
916,measures,". events-no . events ""-no . patients"
917,characteristic_name,"treatment characteristics-subject characteristics-indication pci-region-treatment characteristics """
918,characteristic_level,"congestive heart failure-number treated vessels ""-other-north america-zotarolimus - eluting-number treated lesions-* * positive stress test-europe-> nmbr-total stent length-everolimus - eluting-paclitaxel - eluting-> nmbr des type-native coronary-stemi-stroke / tia-stable angina-race - non - white-number treated vessels-diabetes mellitus-left main-current cigarette smoker within past year-lad-arterial graft-modified acc / aha lesion class bnmbr cj-bmi ( kg / mnmbr )-venous graft-rca-prior pci-number stents-age ( years )-hispanic latino-peripheral arterial disease-female-sirolimus - eluting-weight ( kg )-prasugrel-= nmbr-prior mi-lesion characteristics-nstemi-clopidogrel-* * * unstable angina-australia / new zealand-prior cabg-< nmbr-circumflex-hypertension"
919,arms,"placebo n = nmbr subjects-placebo n = nmbr subjects ""-continued thienopyridine n = nmbr subjects"
920,characteristic_name,"thienopyridine type ""-aspirin dose randomization-des type-region-age-bmi-thienopyridine type-race-sex"
921,characteristic_level,"current tobacco use-non - white-north america-no current tobacco use-no prior ml-everolimus-< median-male-> = median-> = nmbr years-prior ml-clopiodogrel ""-overall-white-any clinical lesion rf st-no diabetes-clopiodogrel-no prior cabg-zotarolimust-european union-> nmbr mg-< nmbr years-prior pci-paclitaxel-no clinical lesion rfs st-female-sirolimus-prasugrel-diabetes-australia / new zealand-prior cabg-no prior pci-< nmbr mg"
923,characteristic_name,"clinical characteristics-baseline medical therapy-demographics-clinical characteristics """
924,characteristic_level,"drug - eluting stent-peripheral artery disease ""-prior myocardial infarction-coronary artery bypass grafting-weight < nmbr kg-crcl baseline < nmbr ml / min-prior stemi-aspirin-current smoker-diabetes mellitus-peripheral artery disease-thienopyridine-female-age , yrs-aspirin thienopyridine therapy-hyperlipidemia-white race-hypertension"
926,outcomes,"stroke ""-ischemic stroke without hemorrhagic conversior-all stroke-ischemic stroke hemnrrhnaic cnnversinn-all ischemic stroke"
927,arms,"+ thienopyridine-- thienopyridine-+ thienopyridine """
928,characteristic_level,"past smoking-alcohol use ( > nmbr drink / wk )-non - colorectal cancer-age > nmbr years-peri - postmenopausal-diabetes mellitus-high sensitivity c - reactive protein ( mg / l )-blood pressure lowering medication use-total cholesterol ( mg / dl )-history dyspepsia-hormone replacement therapy use ""-family history cancera-never smoking-high density lipoprotein ( mg / dl )-major gastro - intestinal bleeding-hormone replacement therapy use-systolic blood pressure ( mmhg )-age ( years )-caucasian ethnicity-colorectal cancer-family history premature chd-randomized aspirin use-current smoking-body mass index ( kg / mnmbr )-lipid lowering medication use-major cardiovascular events"
929,characteristic_name,"< nmbr % predicted arr ( n = nmbr , nmbr )-total study population ( n = nmbr , nmbr )-> nmbr % predicted arr ( n = nmbr )-> nmbr % predicted arr ( n = nmbr ) ""-> nmbr % < nmbr % predicted arr ( n = nmbr , nmbr )"
930,outcomes,"major gastro - intestinal bleeding-major cardiovascular event-colorectal cancer ""-total , adjusted weight nmbr . nmbr gastrointestinal bleeding-colorectal cancer-total-non - colorectal cancer"
932,measures,"annt bnnh ( nmbr % ci ) ""-arr ( nmbr % ci )-annt bnnh ( nmbr % ci )"
933,characteristic_name,"female sex , n ( % )-age , yr mean ( sd )-smoking status , n ( % ) former-current-total pack - years mean ( sd )-age , yr mean ( sd ) ""-baseline fevnmbr % predicted-post - bronchodilator reversibility fevnmbr ( % ) mean ( sd )"
934,arms,"vi nmbr mg ( n = nmbr )-ff / vi nmbr mg / nmbr mg ( n = nmbr ) ""-ff / vi nmbr mg / nmbr mg ( n = nmbr )"
935,characteristic_name,"smoking status-bmi-bmi ""-gold stage-previous pneumonia-sex"
936,characteristic_level,"< nmbr kg / mnmbr-male-no-iv : fevnmbr < nmbr % predicted-yes-i & ii : fevnmbr > nmbr % predicted-current smoker-> nmbr-> nmbr kg / mnmbr ""-former smoker-female-iii : fevnmbr > nmbr % - < nmbr % predicted-< nmbr-> nmbr kg / mnmbr"
937,other,"hr ( nmbr % ci ) ""-hr ( nmbr % ci )"
938,characteristic_name,"angiographic data-risk factors-laboratory variables baseline ""-time intervals , h-laboratory variables baseline"
939,characteristic_level,"lymphocytes , nmbr / + il-ctn - l , ng / ml-previous pci cabg-ci - aki risk score-hdl cholesterol , mg / dl-monocytes , nmbr / nl-active smoking-male-neutrophils , nmbr / nl-hospital stay , days-hemoglobin , mg / dl-diabetes mellitus-glycemia , mg / dl-triglycerides , mg / dl-age , yrs-randomization angiography-multivessel disease-previous ml-total cholesterol > nmbr mg / dl-baseline lvef , %-leukocytes , nmbr / nl-ldl cholesterol , mg / dl-pci revascularization-serum creatinine , mg / dl-egfr , ml / min / mnmbr-high - risk clinical features-ecrcl , ml / min-bmi , kg / mnmbr-ck - mb , ng / ml-neutrophils , nmbr / nl ""-symptom onset randomization-hs - crp , mg / l-age > nmbr yrs-hypertension"
940,characteristic_name,"baseline hs - crp tertiles ( mg / i] ""-baseline hs - crp tertiles ( mg / i]"
941,characteristic_level,"nmbrnd > nmbr . nmbr / < nmbr . nmbr-nmbrrd > nmbr . nmbr-overall-nmbr st < nmbr . nmbr-nmbrrd > nmbr . nmbr """
942,outcomes,"cv death-mi-ischemic stroke-hospitalization hf-hospitalization hf ""-cv death , mi , ischemic stroke-cv death , mi , ischemic stroke , hospitalization hf , coronary revascularization , ua"
944,outcomes,"cv death-initiation insulin-cv death , ml , ischemic stroke , hosp . hf , cor . revasc . , ua-cv death , ml , ischemic stroke-primary renal endpoint death-ischemic stroke-hosp . hf-ml-any new anti - hyperglycemic rx-hosp . hf ""-primary renal endpoint"
945,characteristic_level,"egfr < nmbr ""-egfr > nmbr-egfr < nmbr-hosji fcrhypoglycemia-major hypoglycemia-egfr nmbr - nmbr-ebria"
947,arms,"p-s-p """
948,characteristic_level,"egfr . nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )-egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr , nmbr )-egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr )-egfr , nmbr ml / min / nmbr . nmbr mnmbr ( n = nmbr ) """
949,arms,"placebo-saxagliptin-placebo """
950,measures,"worsened-total ""-p value *-no change-total-improved"
951,characteristic_name,"male-post - bronchodilator screening fevnmbr ml-smoking status-post - bronchodilator screening fevnmbr ml ""-participants n-gold stage #-baseline pulmonary medication-pre - bronchodilator screening fevnmbr ml-co - morbidities-age years"
952,arms,"tiotropium nmbr . nmbr mg-olodaterol nmbr mg ""-tiotropium + olodaterol nmbr / nmbr mg-olodaterol nmbr mg-tiotropium + olodaterol nmbr . nmbr / nmbr mg-tiotropium nmbrmg"
953,arms,"tiotropium + olodaterol nmbr . nmbr / nmbr pg-tiotropium + olodaterol nmbr / nmbr pg-tiotropium + olodaterol nmbr . nmbr / nmbr pg """
954,arms,"versus tiotropium + olodaterol nmbr . nmbr / nmbr pg-versus tiotropium nmbr pg-common study baseline-versus tiotropium nmbr . nmbr pg-versus olodaterol nmbr pg-versus tiotropium nmbr . nmbr pg """
955,outcomes,"trough fevi l-fevi aucnmbr - nmbrl ""-fevi aucnmbr - nmbrl"
956,characteristic_name,"ics usage-ics usage """
957,characteristic_level,"no-yes ""-yes"
958,characteristic_name,"race , n ( % ) ""-race , n ( % )-concomitant medications , n ( % )"
959,characteristic_level,"thiazide diuretics-white ""-age , mean ( sd ) , years-hbanmbrc , mean ( sd ) , % [mmol / mol]-prior history cardiovascular disease , n ( % )-bmi , mean ( sd ) , kg / mnmbr-antihypertensives-white-dbp , mean ( sd ) , mmhg-type nmbr diabetes duration , mean ( sd ) , years-fpg , mean ( sd ) , mg / dl [mmol / l]-weight , mean ( sd ) , kg-female , n ( % )-angiotensin receptor blocker / ace-sbp , mean ( sd ) , mmhg"
960,arms,"placebo ( n = nmbr )-dapagliflozin nmbr mg / day ( n = nmbr ) ""-dapagliflozin nmbr mg / day ( n = nmbr )"
961,characteristic_level,"hbanmbrc patients baseline hbanmbrc > nmbr % ( > nmbr mmol / mol ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se )-hbanmbrc patients baseline hbanmbrc > nmbr % < nmbr % ( > nmbr < nmbr mmol / mol ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo subtracted change ( se )-hbanmbrc patients baseline hbanmbrc < nmbr % ( < nmbr mmol / l ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se )-hbanmbrc patients baseline hbanmbrc < nmbr % ( < nmbr mmol / l ) , % [mmol / mol] , la , n baseline ( sd ) adjusted mean change ( nmbr % ci ) placebo - subtracted change ( se ) """
962,arms,"placebo ( n = nmbr )-dapagliflozin nmbr mg ( n = nmbr ) ""-dapagliflozin nmbr mg ( n = nmbr )"
963,characteristic_name,"hdl - c , mg / dl-use concomitant lipid - modifying therapy-age , y-race ""-type concomitant statin-fc - ldl - c , mg / dl-fc - ldl - c , friedewald - calculated-gender-race"
964,characteristic_level,"mean ( sd )-tg mg / dl , median ( sd )-male , n ( % )-rosuvastatin , n ( % )-other , n ( % ) ""-atorvastatin , n ( % )-< nmbr , n ( % )-black , n ( % )-other , n ( % )-> nmbr , n ( % )-terol ; hdl - c , high - density lipoprotein cholesterol ;-diabetes , n ( % )-simvastatin , n ( % )-female , n ( % )-white , n ( % )-statin + fibrate or-statin , n ( % )-statin + ezetimibe , n ( % )"
965,arms,"placebo ( n = nmbr )-anacetrapib nmbr mg ( n = nmbr )-placebo ( n = nmbr ) """
966,characteristic_name,"body mass index > nmbr , n ( % )-hyperlipidemia , n ( % )-median age ( nmbr % , nmbr % ) , y-acei / arb-noninsulin therapy-aspirin-body mass index > nmbr , n ( % ) ""-insulin therapy-women , n ( % )-history heart failure , n ( % )-thienopyridine-hypertension , n ( % )-peripheral arterial disease , n ( % )-previous pci / cabg , n ( % )-current tobacco abuse , n ( % )-lipid - lowering agent-lifestyle modifications-baseline gfr < nmbr ml / min per nmbr . nmbr mnmbr , n ( % )"
968,outcomes,"cvd , mi , stroke-recurrent ischemia - urgent revascularization-hospitalization unstable angina-cv death-coronary revascularization-cvd mi-death-cvd , mi , stroke , recurrent ischemia - urgent revascularization , hospitalization unstable angina-death ""-mi-cvd , mi , stroke , recurrent ischemia - urgent revascularization-stroke"
969,characteristic_level,"diabetes mellitus-no diabetes mellitus-no diabetes mellitus """
971,characteristic_level,"patients treated statins ( n = nmbr )-patients treated statins ( n = nmbr ) ""-patients treated statins ( n = nmbr )"
972,outcomes,"recurrent vte ( statin use vs non - use ) ""-recurrent vte ( statin use vs non - use )"
973,characteristic_level,"age > nmbr years-male-bmi < nmbr kg / mnmbr-asa use baseline-rivaroxaban-cardiac disease-enoxaparin / vka-age < nmbr years-crcl > nmbr ml / min-female-crcl < nmbr ml / min-bmi > nmbr kg / mnmbr-no cardiac disease-asa use baseline ""-no asa use baseline"
975,outcomes,"major bleeding ( statin use vs non - use )-major bleeding ( statin use vs non - use ) """
976,characteristic_level,"age > nmbr years-male-bmi < nmbr kg / mnmbr-asa use baseline-rivaroxaban-cardiac disease-enoxaparin / vka-age < nmbr years-crcl > nmbr ml / min-female-crcl < nmbr ml / min-bmi > nmbr kg / mnmbr-no cardiac disease-asa use baseline ""-no asa use baseline"
978,characteristic_name,"type concomitant statin daily dose-baseline lipid lipoprotein values ""-baseline lipid lipoprotein values-use concomitant lipid - lowering treatment-race"
979,characteristic_level,"other-non - white-hdl - c ( mmol / l )-age < nmbr years-statin only-rosuvastatin nmbr mg-apo b ( g / l )-lp ( ) ( pmol / l )-white-atorvastatin nmbr mg-non - hdl - c ( mmol / l )-triglyceride ( mmol / l )-apo anmbr ( g / l ) ""-simvastatin nmbr mg-fluvastatin nmbr mg-statin ezetimibe-age ( years )-male sex-ldl - c * ( mmol / l )-pravastatin nmbr mg-apo anmbr ( g / l )-myocardial infarction-body - mass index ( kg / mj ) previous diagnosis-diabetes-coronary heart disease-hypertension"
980,arms,"anacetrapib nmbrmg ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
981,characteristic_name,"bmi ( kg / mnmbr ) ""-pharmacotherapy-bmi ( kg / mnmbr )"
982,arms,"saxagliptin ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr )-saxagliptin ( n = nmbr , nmbr ) """
983,outcomes,"unstable angina-coronary revascularization-primary *-cv mortality-heart failure-hypoglycemia-end point-nonfatal ischemic stroke-all - cause mortality-mi-heart failure ""-non - cv mortality-initiation dialysis , renal transplantation , creatinine . nmbr . nmbr mg / dl ( nmbr mmol / l )-secondary *"
985,arms,"placebo ( n = nmbr )-ticagrelor , nmbr mg ( n = nmbr ) ""-ticagrelor , nmbr mg ( n = nmbr )"
986,characteristic_name,"aspirin dose-second prior mi-age randomization-history pci-qualifying myocardial infarction-sex-time qualifying myocardial infarction-region-non - endstage renal dysfunction *-region ""-weight-multivessel disease-race-history diabetes"
987,characteristic_level,"multivessel disease-north america-south america ""-all patients-europe-< median ( nmbr kg )-south america-> nmbr years-male-stemi-age < nmbr-non - caucasian-age > nmbr-no diabetes-multivessel disease-no renal dysfunction-> nmbr mg-< nmbr years-prior pci-caucasian-> median ( nmbr kg )-female-second mi-renal dysfunction-asia-unknown-diabetes-nstemi-no prior pci-< nmbr mg-no second mi"
988,characteristic_name,"type des index procedure-thienopyridine randomization-treated vessel-minimum stent diameter-indication pci-indication pci ""-patients"
989,characteristic_level,"congestive heart failure-no . stents-unstable angina-other-bifurcation lesion-stroke tia-right-everolimus-any risk factor stent thrombosis-> nmbr type-> nmbr mm-lesions-stemi-stable angina ""-stable angina-extreme tortuosity-more nmbr lesions per vessel-diabetes mellitus-total stent length - mm-left main-no . treated vessels-bmi-more nmbr vessels stented-unprotected left main stented-modified acc aha lesion class bnmbr c-thrombus - containing lesion-renal insufficiency failure-lesion length > nmbr mm-prior myocardial infarction-< nmbr mm-vein graft stented-venous graft-arterial graft-in - stent restenosis-prior pci-non - white race-paclitaxel-heavy calcification-zotarolimus-age ( years )-lvef < nmbr %-in - stent restenosis des-peripheral arterial disease-female-cigarette smoker-sirolimus-weight ( kg )-left anterior descending-prasugrel-myocardial infarction-native coronary - artery lesions-des-nstemi-prior brachytherapy-clopidogrel-prior cabg-no . treated lesions-circumflex-hypertension"
990,characteristic_level,"myocardial infarction presentation ( n = nmbr )-no myocardial infarction presentation ( n = nmbr )-no myocardial infarction presentation ( n = nmbr ) """
991,arms,"thienopyridine n = nmbr-placebo n = nmbr ""-placebo n = nmbr"
992,characteristic_name,"qualifying type atherosclerosis , n ( % )-demographic characteristics-antiplatelet therapy-selected clinical characteristics , n ( % ) ""-selected clinical characteristics , n ( % )"
993,characteristic_level,"age > nmbr years , n ( % )-white race , n ( % )-aspirin-estimated glomerular filtration rate < nmbr ml / min per nmbr . nmbr mnmbr-peripheral artery disease-thienopyridine-ace inhibitors arb-hyperlipidemia-any established peripheral arterial disease ""-any established peripheral arterial disease-diabetes mellitus-prior coronary revascularization-current smoker-prior pci-age ( ) , median ( nmbrth nmbrth percentiles )-peripheral revascularization-any established coronary artery disease-myocardial infarction-lipid - lowering medications-female , n ( % )-prior cabg-hypertension"
994,arms,"vorapaxar ( n = nmbr nmbr )-placebo ( n = nmbr nmbr )-placebo ( n = nmbr nmbr ) """
995,characteristic_level,"male-no-europe i-> = nmbr kg-yes-latin america-asia-north america-europe ii-< nmbr kg-australia / nz-female-< nmbr-> = nmbr-europe ii """
996,characteristic_name,"egfr ( ml / min / nmbr . nmbrmnmbr )-diabetes-region ""-region-planned thienopyridine baseline-age-weight-prior stent-sex"
998,characteristic_name,"type treatment , n ( % )-race , n ( % ) ""-duration hypertension , n ( % )-qualifying cv event , n ( % )-concomitant medications , * n ( % )-oads , n ( % )-race , n ( % )-time recent qualifying"
999,characteristic_level,"nmbr-age , mean ( sd ) , years-loop diuretics-antihypertensive-other-black / african american-stroke tia-fpg , mean ( sd ) , mmol / l-acetylsalicylic acid-peripheral artery disease-subjects , nmbr years age , n ( % )-subjects $ nmbr years age , n ( % )-white-$ nmbr years-oad plus insulin-, nmbr years-seated dbp , mean ( sd ) , mmhg-insulin only-type nmbr diabetes duration , years-diuretics-white ""-hbanmbrc , mean ( sd ) , % [mmol / mol]-seated sbp , mean ( sd ) , mmhg-oad-daily insulin dose , mean ( sd ) , iu-bmi , mean ( sd ) , kg / mnmbr-aceis / arbs-cv event , years-$ nmbrand , nmbr years-not reported-female sex , n ( % )-asian-bw , mean ( sd ) , kg-. nmbr-lipid - lowering medications-coronary heart disease"
1000,arms,"placebo group ( n = nmbr )-dapagliflozin nmbr mg group ( n = nmbr )-dapagliflozin nmbr mg group ( n = nmbr ) """
1002,arms,"aiirocumab ( n = nmbr ) ""-aiirocumab ( n = nmbr )"
1003,characteristic_name,"statin treatment-diabetes randomization-ethnicity-history ml ischemic stroke-age-bmi-bmi ""-moderate ckd randomization-gender-race-other llt randomization"
1004,characteristic_name,"duration diabetes ( years ) t-cigarette smoking-antihypertensive-urinary albumin : creatinine ratio ( mg / g )-duration diabetes ( years ) ""-lipid lowering-qualifying hbanmbrc ( % )-antiplatelet-race / ethnicity-antihyperglycemic"
1005,arms,"n = nmbr , nmbr-sitagliptin n = nmbr-sitagliptin n = nmbr ""-placebo n = nmbr"
1006,characteristic_name,"aspirin-region-history hypertension-hbanmbrc subgroups-thiazolidinedione ( includes pioglitazone )-calcium channel blockers-prior congestive heart failure-insulin-renal function subgroups-age subgroups-diuretics-ace inhibitors angiotensin receptor blockers-insulin ""-medications taken time randomization statins-sulfonylurea-cigarette smoking status-sex-diastolic blood pressure subgroups-systolic blood pressure subgroups-diabetes duration subgroups-beta blockers-metformin-race"
1007,measures,"hazard ratio-interaction p - value-n / n-hazard ratio ""-nmbr % cl"
1008,outcomes,"rec . ischemia leading hasp-rec . ischemia due worsening angina-cv death-primary ep ( cvd / mi / ri )-recurrent ischemia-ml-rec . ischemia requiring revasc-rec . ischemia due ecg changes-rec . ischemia requiring revasc "" ; na"
1009,characteristic_level,"pa-no pci-no pci ""-no pa-no po-pci"
1010,characteristic_name,"mmrc grade-gold nmbr groups-cat score category-copd exacerbation history , n ( % )-race , n ( % )-medication , n ( % ) ""-copd severity , n ( % ) a-medication , n ( % )"
1011,characteristic_level,"nmbr-age , years-duration copd , years-postbronchodilator fevnmbr / fvc , %-other-nmbr - nmbr ( severe )-postbronchodilator fevnmbr , % predicted-> nmbr-nmbr - nmbr ( severe )-missing-sex , male , n ( % )-gold b-patients prior copd - related-ics users baseline , n ( % )-sgrq total score-moderate-nmbr - nmbr ( mild )-bdi focal score-postbronchodilator fevnmbr reversibility , %-nmbr - nmbr ( moderate )-postbronchodilator fevnmbr , l-cat score-mild-caucasian-ics users baseline , n ( % ) ""-asian-gold d-current smokers , n ( % )-severe"
1012,arms,"sfc nmbr / nmbr | ig bid n = nmbr ""-qvanmbr nmbr / nmbr | ig od n = nmbr-sfc nmbr / nmbr | ig bid n = nmbr"
1013,characteristic_name,"copd severity : severe / severe-overall-age ( years ) : < nmbr-age ( years ) : > nmbr-copd severity : mild / moderate-baseline ics use : no-smoking history : ex - smoker-copd exacerbation : yes-copd exacerbation : no-baseline ics use : yes-age ( years ) : nmbr - < nmbr-smoking history : current smoker-smoking history : current smoker """
1015,characteristic_level,"asian-black / african american ""-black / african american-white-other *"
1016,characteristic_name,"hbanmbrc , mean = sd , %-male , n ( % )-female , n ( % ) ""-sbp , mean = sd , mmhg-race , n ( % )-body weight , mean = sd , kg-female , n ( % )-egfr , mean = sd , ml / min / nmbr . nmbr mnmbr-age , mean = sd , years"
1017,arms,"placebo ( n = nmbr )-total ( n = nmbr )-cana nmbr mg ( n = nmbr )-cana nmbrmg ( n = nmbr )-total ( n = nmbr ) """
1018,outcomes,"ldl - c / hdl - cx-triglycerides * *-hdl - cy-ldl - c / hdl - cx ""-non - hdl - c *-ldl - cz"
1019,measures,"ls mean % change baseline _ se-baseline . mean _ sd . mg / mg-baseline . mean _ sd . mg / mg ""-baseline . mean _ sd . mg / dl-baseline . mean _ sd , mg / dl"
1020,characteristic_level,"asian-black / african american-white-other *-asian """
1021,arms,"cana nmbr mg ""-cana nmbr mg-pbo"
1022,arms,"liraglutide ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1023,characteristic_level,"bmi > = nmbr-bmi ( nmbr . nmbr ; nmbr . nmbr )-bmi ( nmbr . nmbr ; nmbr . nmbr ) ""-pooled analysis"
1024,measures,"pooled analysis ""-estimated means difference-pooled analysis"
1026,characteristic_level,"bmi > nmbr-bmi ( nmbr . nmbr ; nmbr . nmbr )-bmi ( nmbr . nmbr ; nmbr . nmbr ) ""-pooled analysis"
1027,measures,"pooled analysis ""-pooled analysis-estimated response rate odds ratio"
1028,arms,"placebo mean ( n )-liraglutide nmbr . nmbr mg mean ( n )-estimated odds ratio ""-estimated odds ratio"
1029,characteristic_level,"bmi > nmbr-bmi ( nmbr . nmbr ; nmbr . nmbr )-bmi ( nmbr . nmbr ; nmbr . nmbr ) """
1030,measures,"nmbr . nmbr-nmbr . nmbr ""-nmbr . nmbr % ( nmbr )"
1031,arms,"nmbr . nmbr-nmbr . nmbr ""-nmbr . nmbr % ( nmbr )"
1032,characteristic_name,"patients specific disease characteristics-ethnic origin-number previous anti - tnf treatments psoriatic arthritis-patients specific disease characteristics ""-baseline disease quality - - life scores"
1033,characteristic_level,"nmbr-enthesitis ""-other-dasnmbr - crp-enthesitis-tender joint count ( nmbr joints )-haq - di-women-white-sfnmbr - pcs-nmbr nmbr-dactylitis-methotrexate use randomisation-systemic glucocorticoid use randomisation-physician ' global assessment ( vas )-patient ' global assessment ( vas )-dactylitis count-age ( years )-pasi < nmbr *-black-pain ( vas )-asian-weight ( kg )-unknown-pasi *-swollen joint count ( nmbr joints )-enthesitis count-pasi score > nmbr *-psoriasis body surface area > nmbr %"
1034,arms,"secukinumab nmbr mg ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) """
1035,characteristic_level,"anti - tnf - naive patients-anti - tnf - naive patients ""-anti - tnf - ir patients"
1036,outcomes,"acrnmbr response ""-pasinmbr response }-acrnmbr response"
1037,arms,"placebo-secukinumab nmbr mg-secukinumab nmbr mg """
1038,measures,"odds ratio versus placebo ( nmbr % ci )-value *-p value versus placebo-value * """
1039,characteristic_name,"bone erosion ( judged physician ) , n ( % )-sdai-crp ( mg / dl )-sjc ( / nmbr joints )-anti - ccp antibody positive , n ( % )-< nmbr months , n ( % )-previous dmards use , n ( % )-erosion score ""-mmp - nmbr ( ng / ml ) *-dasnmbr ( esr )-average weekly mtx dose ( mg / week )-nmbr - nmbr months , n ( % )-phgada ( mm )-nmbr - < nmbr months , n ( % )-joint space narrowing score-bmi ( kg / mnmbr )-steroid use baseline , n ( % )-mtss-age ( years )-tjc ( / nmbr joints )-haq - di score-ra duration ( months ) *-weight ( kg )-negative ( < nmbr . nmbr ) , n ( % )-titre ( u / ml ) t-esr ( mm / h )-rf positive , n ( % )-high titre ( > nmbr times uln ) , n ( % )-female , n ( % )-ptgada ( mm )-erosion score"
1040,arms,"czp + mtx n = nmbr-pbo + mtx n = nmbr-pbo + mtx n = nmbr """
1041,characteristic_level,"nmbr - < nmbr-> nmbr - nmbr-> nmbr . nmbr - < nmbr . nmbr-> nmbr-nmbr . nmbr - nmbr . nmbr-< nmbr . nmbr-< nmbr . nmbr ""-> nmbr . nmbr-nmbr - nmbr-< nmbr"
1042,arms,"pbo + mtx ""-czp + mtx-pbo + mtx"
1043,characteristic_name,"method used diagnose incident pulmonary embolism , . ( % )-main concomitant treatments , . ( % )-creatinine clearance category , ml / min , . ( % ) b-characteristics pulmonary embolism inclusion ""-medical conditions , . ( % )-characteristics pulmonary embolism inclusion-accp bleeding risk inclusion , . ( % ) f-treatmentofpulmonary embolismpriorto randomization-thrombophilia , . ( % ) e"
1044,characteristic_level,"fluindione , . ( % )-> nmbr , . ( % )-associatedproximaldeep - veinthrombosisatdiagnosis , . ( % )-duration initial anticoagulation , mean ( sd ) , mo-use compression stockings , . ( % )-high - probability ventilation / perfusion lung scanning-acecoumarol , . ( % )-> nmbr-moderate ( nmbr risk factor )-women , . ( % )-previousdistaldeep - veinthrombosisorsuperficial - vein thrombosis-systolic pulmonary arterial pressure , mean ( sd ) , mm hg-major-warfarin , . ( % )-residual perfusion defect > nmbr % lung scan , . ( % )-low ( risk factor )-> nmbr - < nmbr-chronic heart failure-> nmbry , . ( % )-previous cancerc-residual deep - vein thrombosis , . ( % )-age , mean ( sd ) , y-residual perfusion defect > nmbr % lung scan , . ( % ) ""-percentage time therapeutic inr range , mean ( sd )-minor-chronic respiratory failure-spiralcomputedtomographyangiography-high ( > nmbr risk factor )-body mass index , mean ( sd )-statins-d - dimer level , mean ( sd ) , ng / mld-< nmbr-antiplatelet agent"
1045,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-warfarin ( n = nmbr )"
1046,characteristic_name,"perfusion defectsatinclusion-previous cancer-right ventriculardysfunction atinclusion-thrombophilia-time therapeutic range inclusion-accp score ""-accp score-compression stockings-age-bmi-pe associated dvt diagnosis-d - dimer levelsatinclusion-sex"
1047,characteristic_level,"male-< nmbr kg / nmbr-no-yes-> nmbr microg / l-overall-< nmbr years-> nmbr-< nmbr ""-> nmbr %-female-< nmbr %-< nmbr microg / l-> nmbr years-< nmbr-> nmbr kg / mnmbr-nmbr - nmbr years"
1049,measures,". patients ""-no . patients-no . events"
1050,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-liraglutide nmbr . nmbr mg / day ( n = nmbr )"
1051,characteristic_level,"baseline hbanmbrc > nmbr . nmbr % ""-baseline hbanmbrc < nmbr . nmbr %-baseline hbanmbrc > nmbr . nmbr %"
1052,arms,"placebo ( n = nmbr )-liraglutide nmbr . nmbr mg ( n = nmbr ) ""-liraglutide nmbr . nmbr mg ( n = nmbr )"
1053,measures,"r-n %-n ( % )-e-e """
1054,outcomes,"mean change radiographic end points-acr response , %-mean change radiographic end points """
1055,other,"shs , mean nmbr sd-acrnmbr-erosion score , mean nmbr sd-jsn score , mean nmbr sd ""-jsn score , mean nmbr sd-lda , %-dasnmbr - esr remission , %-change baseline dasnmbr - esr , meannmbr sd"
1056,arms,"czp nmbr mg ( n nmbr nmbr )-pbo ( nnmbr )-czp nmbr mg ( n nmbr nmbr ) ""-czp nmbr mg ( n nmbr )-czp nmbr mg ( nnmbr )-pbo ( nnmbr nmbr )"
1057,outcomes,"cv death-cv death , mi , ischemic stroke-death-death ""-timi major bleeding-mi-ischemic stroke-stent thrombosis-timi major minor bleeding"
1058,characteristic_level,"aspirin nmbr clopidogrel-aspirin ""-aspirin"
1060,measures,"rate * ( n ) ""-rate * ( n )-hr ( nmbr % ci )"
1061,characteristic_level,"bdmard - ir-bdmard - naive ""-bdmard - naive"
1062,arms,"tofacitinib nmbr mg twice daily n = nmbr ""-tofacitinib nmbr mg twice daily n = nmbr-placebo n = nmbr"
1063,outcomes,"dasnmbr - nmbr ( esr ) < nmbr . nmbr *-sdai < nmbr t-cdai < nmbrt-cdai < nmbr . nmbr * ""-dasnmbr - nmbr ( esr ) < nmbr . nmbrt-haq - di improvement > nmbr . nmbr-cdai < nmbr . nmbr *-sdai < nmbr . nmbr *"
1064,characteristic_level,"bdmard - ir-bdmard - naive ""-bdmard - naive"
1065,arms,"tofacitinib nmbr mg twice daily n = nmbr ""-tofacitinib nmbr mg twice daily n = nmbr-placebo n = nmbr"
1066,arms,"control ( n = nmbr )-cyclosporine ( n = nmbr )-cyclosporine ( n = nmbr ) """
1067,characteristic_name,"rentrop score-symptom onset-diabetes-initial timi flow-killip baseline-dyslipidemia-age-ejection fraction-lad-killip baseline ""-thrombus aspiration-final timi flow-hypertension"
1068,characteristic_level,"nmbr-> nmbr-> nmbrh-nmbr - nmbrh-< nmbr %-medial - distal - diag-male-yes-< nmbr yr-overall-proximal - mainleft-no-> nmbr %-nmbr ""-female-< nmbrh-= nmbr-nmbr yr-< nmbr"
1070,measures,". events / total-no . events / total """
1071,characteristic_level,"male , n ( % )-coronary heart disease , n ( % ) b-coronary heart disease risk equivalents , n ( % ) c-genotyping-high - dose statin use , n ( % ) e-current smoker , n ( % )-clinical criterianmbr-type nmbr diabetes , n ( % ) d-ezetimibe use-race , white , n ( % )-hypertension , n ( % )-diagnosis heterozygous familial hypercholester-body mass index , kg / mnmbr , mean + sd ""-age , years , mean + sd-body mass index , kg / mnmbr , mean + sd-statin use , n ( % )"
1072,other,"fh nmbr-fh ii-fh nmbr """
1073,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-alirocumab ( n = nmbr )"
1074,characteristic_name,"dose atorvastatin-dose rosuvastatin-statin treatment-moderate ckd-prior history ml ischemic stroke-ethnicity-region-diabetes mellitus-age-llt statin randomization-bmi-age ""-gender-race"
1075,arms,"placebo-alirocumab-placebo """
1076,characteristic_name,"age , y-risk factors , %-concomitant drugs , %-vascular history , % ""-vascular history , %"
1077,characteristic_level,"latin america-previous cabg ( % total )-aspirin-> nmbr mo-previous pci ( % total )-north america-< nmbr mo-crcl < nmbr ml / min-hyperlipidemia-lipid - lowering agents-time qualifying mi , %-weight < nmbr kg-des ( % previous stenting )-p - blockers-diabetes mellitus-europe ""-nmbr - nmbr mo-white race , %-mean ( sd )-europe i-europe ii-current smoker-female sex , %-region , %-asia-ace inhibitor arb-previous stenting ( % previous pci )-any coronary revascularization-australia / new zealand-> nmbr y-hypertension"
1080,outcomes,"cv death-cv death / mi / stroke-ischemic stroke-ml ""-ml-stroke-cv death / mi / stroke / ucr-ucr"
1081,characteristic_level,"thienopyridine ""-thienopyridine-no thienopyridine"
1082,measures,"n ( nmbryr km event rate , % )-n ( nmbryr km event rate , % ) """
1083,characteristic_name,"baseline measurements-demographic characteristics-albumin - - creatinine ratio ,-baseline antihyperglycemic medications , n ( % )-baseline cv medications , n ( % ) ""-baseline cv medications , n ( % )-race"
1084,characteristic_level,"age , median ( iqr ) , years-aspirin-median ( sd ) , mg / mmol-current smoker , n ( % )-bmi , median ( sd ) , kg / mnmbr-hbanmbrc , median ( sd ) , %-hispanic / latino ethnicity , n ( % )-diabetes duration , median ( iqr ) , years-insulin-prior coronary revascularization , n ( % )-prior myocardial infarction , n ( % )-diuretics-aspirin ""-weight , median ( sd ) , kg-fasting serum glucose , median ( sd ) , mg / dl-prior heart failure , n ( % )-b - blockers-caucasian , n ( % )-sulfonylurea-all others , n ( % )-dyslipidemia , n ( % )-female sex , n ( % )-egfr , median ( sd ) , ml / min-tzd-ace inhibitors-statins-hypertension , n ( % )-metformin"
1085,outcomes,"yes ( n = nmbr )-no ( n = nmbr , nmbr )-no ( n = nmbr , nmbr ) """
1087,arms,"placebo-saxagliptin-saxagliptin """
1088,measures,"event-hr-cl nmbr %-total ""-total"
1089,arms,"placebo ( n = nmbr )-empagliflozin nmbr mg ( n = nmbr )-pooled empagliflozin ( n = nmbr )-pooled empagliflozin ( n = nmbr ) """
1090,characteristic_name,"dpp - nmbr inhibitor-cardiovascular risk-region-acetylsalicylic acid-calcium channel blockers-angiotensin - converting enzyme inhibitors / angiotensin receptor blockers-glycated hemoglobin-insulin-statins / ezetimibe-age-thiazolidinediones-estimated glomerular filtration rate-diuretics-blood pressure control-antihypertensives-ethnicity-urine albumin - - creatinine ratio-sulfonylurea-age ""-sex-body mass index-beta blockers-metformin-race"
1091,characteristic_level,"< nmbr kg / mnmbr-latin america-> nmbr ml / min / nmbr . nmbrmnmbr-north america-all patients-europe-< nmbr . nmbr %-africa-> nmbr years-only cerebrovascular disease-> nmbr kg / mnmbr-male-yes-white-only peripheral artery disease-sbp > nmbr mmhg / dbp > nmbr mmhg-sbp < nmbr mmhg dbp < nmbr mmhg-< nmbr mg / g-only coronary artery disease-black / african - american-< nmbr ml / min / nmbr . nmbrmnmbr-< nmbr years ""-no-> nmbr mg / g-< nmbr years-not hispanic / latino-nmbr < nmbr ml / min / nmbr . nmbrmnmbr-hispanic / latino-female-nmbr nmbr mg / g-nmbr nmbr high cardiovascular risk categories-asian-asia-> nmbr . nmbr %"
1093,arms,"placebo-placebo """
1094,characteristic_name,"cardiovascular risk-region ""-region-acetylsalicylic acid-calcium channel blockers-angiotensin - converting enzyme inhibitors / angiotensin receptor blockers-glycated hemoglobin-insulin-statins / ezetimibe-age-diuretics-estimated glomerular filtration rate-blood pressure control-antihypertensives-ethnicity-urine albumin - - creatinine ratio-sulfonylurea-sex-body mass index-beta blockers-metformin"
1095,characteristic_level,"< nmbr kg / mnmbr-latin america-> nmbr ml / min / nmbr . nmbrmnmbr-all patients-europe-< nmbr . nmbr %-africa-> nmbr years-only cerebrovascular disease-> nmbr kg / mnmbr-male-yes-white-only peripheral artery disease-sbp > nmbr mmhg / dbp > nmbr mmhg-sbp < nmbr mmhg dbp < nmbr mmhg-< nmbr mg / g-north america plus australia new zealand-only coronary artery disease-black / african - american-< nmbr ml / min / nmbr . nmbrmnmbr-no-> nmbr mg / g-< nmbr years-not hispanic / latino-nmbr < nmbr ml / min / nmbr . nmbrmnmbr-hispanic / latino-female-nmbr nmbr high cardiovascular risk categories-asian-europe ""-asia-> nmbr nmbr mg / g-> nmbr . nmbr %"
1097,arms,"placebo-empagliflozin-placebo """
1098,characteristic_name,"age , years-demographic-medical history , n ( % )-weight , kg-medical history , n ( % ) """
1099,characteristic_level,"female sex , n ( % )-median-prior myocardial infarction-heart failure-prior ptca pci-current smoker-diabetes mellitus-heart failure ""-peripheral artery disease-interquartile range-cabg-prior stroke tia-hyperlipidaemia-hypertension-n"
1100,other,"radial ""-radial"
1101,outcomes,"ischemia driven revascularization "" ; na-ischemia driven revascularization-death-ml-stent thrombosis-primary endpoint death / mi / idr / st"
1102,characteristic_level,"femoral ""-radial-femoral-overall"
1104,arms,"placebo ( n = nmbr )-secukinumab , nmbr mg ( n = nmbr ) ""-secukinumab , nmbr mg ( n = nmbr )"
1105,characteristic_name,"anti - tnf - experienced patients-anti - tnf - experienced patients ""-anti - tnf - naive patientsnmbr"
1106,arms,"placebo-secukinumab-secukinumab """
1107,characteristic_name,"lev status , n ( % )-region , n ( % )-number prior aeds , n ( % )-number concomitant aeds , n ( % )-concomitant aedsa-number prior aeds , n ( % ) """
1108,characteristic_level,"nmbr-latin america-weight , kg , mean ( sd )-north america-age first seizure , years , mean ( sd )-lacosamide-baseline pos frequency per nmbr days , median ( min , max )-> nmbr-duration epilepsy , years , mean ( sd )-carbamazepine-never used lev-nmbr - nmbr-prior lev use-europe ( non - eu )-valproate-oxcarbazepine-lamotrigine-europe ( eu )-itt population-gender , female , n ( % )-bmi , kg / mnmbr , mean ( sd )-age , years , mean ( sd )-asia / pacific / other-race , white , n ( % )-nmbr - nmbr ""-topiramate"
1110,characteristic_name,"demographics-clinical characteristics-region ""-region-qualifying event"
1111,characteristic_name,"active smoking-history myocardial infarction-anti - platelet therapy-time end - - study ivus , median ( iqr ) , days-statin-ace inhibitor-men , n ( % )-age , mean ( sd ) , yrs-arb-history pci-beta - blocker-body - mass index , mean ( sd )-arb ""-hypertension"
1112,characteristic_level,"diabetes mellitus-diabetes mellitus ""-no diabetes mellitus"
1113,outcomes,"hyperkalemia ( > nmbr . nmbr meq / l )-elevated creatinine ( > nmbr pmol / l )-death-first mace-hospitalization acs-arterial revascularization-elevated bun ( > nmbr . nmbr meq / l ) ""-non - fatal stroke-hospitalization heart failure-elevated bun ( > nmbr . nmbr meq / l )-non - fatal myocardial infarction"
1114,characteristic_level,"diabetes mellitus-diabetes mellitus ""-no diabetes mellitus"
1115,arms,"dm - ( aliskiren vs . placebo ) ""-dm - ( aliskiren vs . placebo )-aliskiren ( dm - vs . dm + )-placebo ( dm - vs . dm + )-dm + ( aliskiren vs . placebo )"
1117,characteristic_name,"duration diabetes-urine albumin / creatinine ratio ( mg / g )-urine albumin / creatinine ratio ( mg / g ) """
1118,characteristic_level,"aspirin-egfr > nmbr ml / min-statin-ace inhibitor-male-< nmbr y-age ( )-white-insulin-thiazolidinedione-> = nmbr y-adp antagonist-established cardiovascular disease-duration diabetes ( )-nmbr - < nmbr-ace inhibitor ""-sulfonylurea-nmbr - < nmbr y-body mass index ( kg / mnmbr )-metformin-< nmbr-b - blocker-> = nmbr"
1119,characteristic_level,"hbanmbrc < nmbr % ( n - nmbr )-p value-hbanmbrc < nmbr % ( n - nmbr ) ""-hbalc > = nmbr % ( n - nmbr )-hbanmbrc nmbr % - < nmbr % ( n - nmbr )"
1120,characteristic_level,"overall-hbanmbrc > = nmbr %-hbanmbrc nmbr - < = nmbr % ""-hbanmbrc < nmbr %-hbanmbrc nmbr - < = nmbr %"
1122,characteristic_level,"overall-hbanmbrc > = nmbr %-hbanmbrc nmbr - < = nmbr % ""-hbanmbrc < nmbr %-hbanmbrc nmbr - < = nmbr %"
1124,characteristic_name,"region-nyha functional class-region """
1125,characteristic_level,"nmbr-latin america-atrial fibrillation-digoxin-cardiac resynchronization therapy-other-north america-percutaneous coronary intervention-asia - pacific ""-oral anticoagulant agent-beta - blocker-stroke-mineralocorticoid receptor antagonist-diuretic agent-implantable cardioverter - defibrillator-lipid - lowering agent-iii-coronary artery bypass surgery-black-iv-western europe other-asian-asia - pacific-myocardial infarction-diabetes-antiplatelet agent-central europe-hospitalization heart failure-ii-hypertension"
1126,measures,"risk score category ( points )-risk score category ( points ) ""-p value trend"
1127,characteristic_level,"nmbr - nmbr ( n = nmbr , nmbr ) ""-nmbr - nmbr ( n = nmbr , nmbr )"
1128,measures,"hr ( nmbr % cl )-ratet ( nmbr % cl )-hr ( nmbr % cl ) """
1129,outcomes,"hf hospitalization n-all - cause death n-cv death hf hospitalization n-all - cause death n ""-cv death n"
1130,characteristic_name,"risk category ( points )-risk category ( points ) """
1131,characteristic_level,"nmbr ( n = nmbr )-nmbr - nmbr ( n = nmbr )-nmbr ( n = nmbr ) ""-nmbr ( n = nmbr , nmbr )-nmbr - nmbr ( n = nmbr , nmbr )"
1132,arms,"lcznmbr ( n = nmbr )-enalapril ( n = nmbr )-lcznmbr ( n = nmbr ) ""-enalapril lcznmbr ( n = nmbr ) ( n = nmbr )"
1133,arms,"adalimumab ( n = nmbr ) ""-placebo ( n = nmbr )-adalimumab ( n = nmbr )"
1134,characteristic_name,"race , n ( % ) ""-race , n ( % )-sex , n ( % )"
1135,arms,"placebo ( n = nmbr )-cana nmbr mg ( n = nmbr )-total ( n = nmbr ) ""-total ( n = nmbr )"
1136,characteristic_level,"male-> nmbr years age-egfr > nmbr ml / min / nmbr . nmbr mz-duration tnmbrdm < nmbr years-duration tnmbrdm < nmbr years ""-female-fracture history-egfr < nmbr ml / min / nmbr . nmbr mz-duration tnmbrdm > nmbr years-no fracture history-< nmbr years age"
1137,arms,"cana ""-pbo-all cana"
1138,characteristic_name,"indication index pci-patients ""-thienopyridine randomization-type stent index procedure-patients"
1139,characteristic_level,"congestive heart failure-bare metal-other-prior cancer-stroke tia-drug eluting-body mass indexc-non - white raceb-stemi-stable angina-diabetes mellitus-female sex-prior myocardial infarction-age ( years )-peripheral arterial disease-renal insufficiency / failure-cigarette smoker-weight ( kg )-prasugrel-nstemi-clopidogrel-unstable anginad-hispanic latino ethnic groupb ""-hypertension-hispanic latino ethnic groupb"
1140,arms,"placebo ( n nmbr nmbr ) ""-continued thienopyridine ( n nmbr nmbr )-placebo ( n nmbr nmbr )"
1141,characteristic_name,"aspirin dose randomization ""-thienopyridine randomization-aspirin dose randomization-indication pci-body mass index-region-stent type-age-race-sex"
1142,characteristic_level,"> median-> nmbr mg ""-current tobacco use-non - white-north america-no mi-> nmbr-no current tobacco use-drug eluting stent-< nmbr mg-< median-male-white-no diabetes-no history cancer-no prior cabg-bare metal stent-european union-> nmbr mg-prior pci-mi-female-history cancer-prasugrel-diabetes-prior mi-clopidogrel-australia / new zealand-< nmbr-prior cabg-no prior pci-no prior mi"
1144,characteristic_name,"male-modified - bled-previous major bleeding-chanmbrdsnmbr - vasc-chanmbrdsnmbr - vasc $ nmbr ""-chadsnmbr-diabetes mellitus-previous myocardial infarction-age , yrs-age > nmbr yrs-previous stroke-hypertension-chanmbrdsnmbr - vasc $ nmbr"
1146,arms,"long - term warfarin ( n - nmbr )-long - term warfarin ( n - nmbr ) ""-laa closure ( n - nmbr )"
1147,characteristic_level,"chanmbrdsnmbr - vasc > nmbr-male-no history tia / stroke-chanmbrdsnmbr - vasc # nmbr-modified - bled $ nmbr-history tia / stroke-age # nmbr yrs-female-modified - bled < nmbr-age > nmbr yrs-age > nmbr yrs """
1149,characteristic_name,"b "" ; na-b"
1155,outcomes,"cardiovascular death-second co - primary outcome-cardiovascular death ""-first co - primary outcome"
1156,characteristic_level,"triglycerides nmbrnd third-alc > = nmbr . nmbr %-placebo allocation-alc < nmbr . nmbr %-male-new dm-age > = nmbr-no prior cv event-omega - nmbr fa intake nmbrnd third-overall-bmi > nmbr-age > : nmbr-age < nmbr-standard care allocation-prior dm-triglycerides nmbr , third-no statin use-heart rate < nmbr bpm-heart rate > nmbr bpm-omega - nmbr fa intake nmbrst third ""-insulin glargine allocation-neither ace - arb use-betablocker use-prior om-female-ace - arb use-omega - nmbr fa intake nmbr , third-no betablocker use-metformin use-bmi < = nmbr-omega - nmbr fa intake nmbrst third-omega nmbr allocation-prior cv event-new om-ifg / igt-statin use-triglycerides nmbrst third-no metformin use"
1159,characteristic_name,"screening-screening ""-baseline-demographic characteristics"
1160,characteristic_name,"- japan n = nmbr , nmbr-not - japan n = nmbr , nmbr ""-japan n = nmbr-overall n = nmbr , nmbr"
1161,characteristic_level,"- japan-not - japan "" ; na-japan-overall"
1162,arms,"placebo-ff / vi nmbr / nmbr pg od-ff / vi nmbr / nmbr pg od ""-ff nmbr pgod"
1163,characteristic_name,"hscrp ( nmol / l )-insulin ( pmol / l ) vital signs-dyslipidaemia hypertension , n ( % )-hbanmbrc ( % )-male-ffa ( mmol / l )-duration tnmbrdm ( years )-total-body weight ( kg )-diastolic bp ( mmhg )-hdl-n =-vldl-dyslipidaemia , n ( % )-insulin ( pmol / l )-n = nmbr-ldl-prediabetes , n ( % )-wc ( cm )-female-age , ( years )-age , ( years ) ""-hbaic ( % )-fpg ( mmol / l )-body mass index ( kg / mnmbr )-triglycerides ( mmol / l )-pulse ( beats / min ) cholesterol ( mmol / l )-hypertension , n ( % )-systolic bp ( mmhg )"
1164,characteristic_level,"white ( nmbr . nmbr % )-other ( nmbr . nmbr % ) ""-other ( nmbr . nmbr % ) t-asian ( nmbr . nmbr % )-black / african - american ( nmbr . nmbr % )"
1165,arms,"placebo n = nmbr ""-liraglutide nmbr . nmbr mg n = nmbr-placebo n = nmbr"
1166,characteristic_level,"asian-other-white-black / african - american-asian """
1169,characteristic_name,"history microvascular disease ( % )-p - blocker ( % )-ace / arb medication ( % )-age completion highest level of-heart rate ( bpm )-hbanmbrc ( % )-lipid - lowering medication ( % )-any blood pressure medications ( % )-aspirin thienopyridines ( % )-systolic blood pressure ( mm hg )-history stroke ( % )-creatinine clearance ( ml / min ) ""-number individuals-hdl cholesterol ( mmol / l )-duration diabetes ( years )-age ( years )-ldl cholesterol ( mmol / l )-history macrovascular disease ( % )-creatinine clearance ( ml / min )-exercise times per week , ( minimum-current weekly alcohol use ( % )-body mass index ( kg / mnmbr )-triglycerides ( mmol / l )-diastolic blood pressure ( mm hg )-total cholesterol ( mmol / l )"
1170,characteristic_level,"women-men-men """
1171,characteristic_level,"daily-former-daily ""-never"
1172,outcomes,"secondary ' outcomes-primary outcomes "" ; na-primary outcomes"
1174,outcomes,"secondary outcomes-primary outcomes "" ; na-primary outcomes"
1175,outcomes,"cause mortality-all cardiovascular ""-nephropathy-major cerebrovascular-all cardiovascular-major coronary-major cardiovascular-all cancer"
1177,characteristic_name,"medical history ( % )-type mi ( % ) ""-type mi ( % )"
1178,characteristic_level,"previous mi-age , years-symptom onset hospital arrival , hours-stemi-anemia ( % )-crusade bleeding score-creatinine clearance < nmbr ml / min ( % )-nstemi ""-current smoker-diabetes-previous pci-> nmbr-nstemi-body mass , kg-body mass index ( kg / mnmbr )-killip class > ii ( % )-previous stroke-hypertension"
1179,arms,"control ( n = nmbr )-bivalirudin ( n = nmbr )-control ( n = nmbr ) """
1180,characteristic_name,"drug - eluting stent , n ( % )-previous heart failure-white race , n ( % )-aspirin-united states-periprocedural medications , n ( % ) clopidogrel , nmbr mg *-bivalirudin-abnormal-bare metal stent , n ( % )-hyperlipidemia-nsteacs-previous mi-stemi-baseline hemoglobin , median ( iqr , g / dl )-age ( ) , median ( iqr )-stable angina-lmwh-duration pci ( min ) , median n ( iqr )-diabetes mellitus-dx presentation , n ( % )-previous stroke tia-radial-weight ( kg ) , median ( iqr )-femoral-ufh-normal-current smoker-peripheral arterial disease-other countries-poba , n ( % )-fondaparinux-previous cabg-clopidogrel , nmbr mg *-previous pci-age > nmbr , n ( % )-nsteacs ""-baseline hematocrit , median ( iqr )-brachial-hypertension"
1182,arms,"clopidogrel ( n = nmbr )-clopidogrel ( n = nmbr ) ""-cangrelor ( n = nmbr )"
1183,arms,"placebo-pioglitazone-placebo """
1184,measures,"( n = nmbr )-( n = nmbr ) """
1185,arms,"placebo ( n = nmbr )-baricitinib , nmbr mg daily ( n = nmbr ) ""-baricitinib , nmbr mg daily ( n = nmbr )"
1186,characteristic_name,"# prior non - tnfi bdmards * ""-# prior bdmards-# prior non - tnfi bdmards *-# prior tnfi among non - tnfi naive-overall population"
1187,characteristic_level,"nmbr-< nmbr-> nmbr-nmbr """
1188,arms,"baricitinib nmbr mg-baricitinib nmbr mg """
1189,characteristic_name,"asian-other ""-baseline nmbr - h ppg ,-current smoker ,-hdl - c , mg / dl-other-bmi , kg / mnmbr-tnmbrdm duration , y-age , y-white-sbp , mmhg-women , n ( % )-baseline hbanmbrc , %-baseline fpg ,-black"
1190,characteristic_level,"ukpds nmbr - year risk score > nmbr %-ukpds nmbr - year risk score < nmbr %-ukpds nmbr - year risk score > nmbr % """
1191,arms,"saxagliptin nmbr . nmbr mg ( n z nmbr )-saxagliptin nmbrmg ( n z nmbr )-saxagliptin nmbrmg ( n z nmbr ) ""-placebo ( n z nmbr )"
1192,characteristic_name,"baseline laboratory values , median ( iqr ) d-medical history-demographics-qualifying myocardial infarction ""-time study drug administration coronary revascularization , median ( iqr ) , h-qualifying myocardial infarction-pciperformed qualifying event-region-catheterization performed qualifying event-useofmedical therapyathospitaldischarge-race"
1193,characteristic_level,"nmbr-prior heart failure-other-aspirin-body mass index , median ( iqr ) b-north america-statin-pnmbrynmbr inhibitor-south america-hyperlipidemia-p - blocker-st - elevation myocardial infarction-st - elevation myocardial infarction ""-prior coronary artery bypass graft surgery-white-diabetes mellitus-high - sensitivityc - reactive protein , mg / l-eastern europe-non - st - elevation myocardial infarction-prior peripheralarterialdisease-prior myocardial infarction-ace inhibitor angiotensin receptor blocker-current smoker-prior pci-baseline egfr < nmbr ml / min / nmbr . nmbr mnmbrc-female-black-fibrinolytic qualifying event-asian-asia - pacific-age , median ( iqr ) , y-western europe-prior ischemic stroke-n - terminal pro - brain natriuretic peptide , pg / ml-hypertension"
1194,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-losmapimod ( n = nmbr )"
1195,characteristic_name,"qualifying diagnosis-prior heart failure-time randomization pci ( st - elevation mi ) , min-actual treatment strategy-prior mi ""-no . predictors cardiovascular risk-prior pci cabg surgery-age , y-chronic kidney disease-prior mi-diabetes mellitus-planned treatment strategy-time randomization pci ( non - st - elevation mi ) , h-sex"
1196,characteristic_level,"medical management only-male-no-nmbr-yes-yes ""-cabg surgery-invasive-overall-non - st - elevation mi-> nmbr-nmbr < nmbr-female-st - elevation mi-conservative-< nmbr-pci"
1198,arms,"placebo-losmapimod ""-losmapimod"
1199,characteristic_name,"medical history-demographics-demographics ""-indication index procedure-treatment"
1200,characteristic_level,"congestive heart failure-oral medications-atrial fibrillation-other-weight , kg-peripheral artery disease-previous mi-diet controlled no-stemi-stroke / tia-stable angina-insulin-diabetes mellitus-age , yrs-race nonwhitet-unstable anginat-female ""-prior pci-hispanic latino-female-history major bleeding-history cancer-cigarette smoker-bmi , kg / mnmbr-nstemi-prior cabg-hypertension-acute coronary syndrome"
1202,characteristic_name,"multivessel coronary artery disease-history atrial fibrillation-statin-qualifying mi < nmbr yrs prior-nonwhite race-history hypertension-history chf-male-stemi-qualifying mi type-prior angina-history stroke transient ischemic attack-non - end - stage renal dysfunction-egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd )-insulin-history peripheral artery disease-beta - blocker-age , yrs-ace - angiotensin receptor blocker-oral hypoglycemic-body mass index , kg / mnmbr ""-body mass index , kg / mnmbr-current smoker-systolic blood pressure , mm hg-history diabetes requiring drugs-history hypercholesterolemia-history second prior mi-prior coronary artery bypass grafting-unknown-age $ nmbr yrs-type nmbr diabetes-nstemi-history percutaneous coronary intervention"
1204,characteristic_name,"region-qualifying mi type-qualifying mi type """
1205,characteristic_level,"ace - arb use baseline-multivessel coronary artery disease-north america-south america-history claudication-history hypertension-asia / australia / new zealand-qualifying mi $ nmbr yrs prior-history chf-stemi-prior angina-egfr < nmbr ml / min / nmbr . nmbr mnmbr ( mdrd )-age , yrs-beta - blocker use baseline-history copd-eastern europe-history diabetes-body mass index , kg / mnmbr-current smoker-caucasian-western europe ( including south africa )-aspirin use baseline-history stroke tia-time qualifying mi , yrs-peripheral revascularization-female-history hypercholesterolemia-history second prior mi-unknown-statin use baseline-age $ nmbr yrs-history pci stenting-qualifying mi $ nmbr yrs prior ""-abi # nmbr . nmbr-nstemi-prior cabg-time last dose pnmbrynmbr inhibitor , days"
1207,characteristic_name,"ldl cholesterol-body - mass index-lvef ""-age-duration assigned regimen surgery post - randomisation characteristic *-lvef-previous ml"
1208,characteristic_level,"< nmbr kg / mnmbr-no-> nmbr % ""-yes-< nmbr yr-> nmbr , < nmbr mg / dl-> nmbr yr-nmbr - nmbr days-< nmbr days-> nmbr mg / dl-all patients-> nmbr %-< nmbr mg / dl-< nmbr %-nmbr - nmbr yr-> nmbr kg / mnmbr"
1210,characteristic_name,"duration assigned regimen surgery post - randomisation characteristic * *-troponin nmbr baseline *-postoperative nsaid glucocorticoid use post - randomisation characteristic * *-surgical technique post - randomisation characteristic * *-previous statin use-age-postoperative glucocorticoid use post - randomisation characteristic * *-procedure * *-sex ""-sex"
1211,characteristic_level,"male ""-male-no-yes-< nmbr yr-> nmbr yr-< nmbr days-all patients-< nmbr . nmbr ng / ml-> nmbr . nmbr ng / ml-off pump-female-on pump-avr-> nmbr days-cabg"
1213,characteristic_name,"ldl cholesterol-body - mass index-lvef ""-age-duration assigned regimen surgery post - randomisation characteristic *-lvef-previous ml"
1214,characteristic_level,"< nmbr kg / mnmbr-no-> nmbr % ""-yes-< nmbr yr-> nmbr , < nmbr mg / dl-> nmbr yr-nmbr - nmbr days-< nmbr days-> nmbr mg / dl-all patients-> nmbr %-< nmbr mg / dl-< nmbr %-nmbr - nmbr yr-> nmbr kg / mnmbr"
1216,characteristic_name,"region , n ( % ) ""-bmi ( kg / mnmbr )-region , n ( % )"
1217,characteristic_level,"mtss , median ( min , max )-presence erosions , n ( % )-< nmbr months , mean ( sd )-sdai , mean ( sd )-haq - di , mean ( sd )-dasnmbr ( esr ) , mean ( sd )-esr ( mm / h ) , median ( min , max )-< nmbr months , median ( min , max )-acpa positive ( > nmbr iu / ml ) , n ( % )-latin north america-sjc ( nmbr joints ) , mean ( sd )-erosion score , median ( min , max )-tjc ( nmbr joints ) , mean ( sd )-high disease activity : > nmbr . nmbr , n ( % )-moderate disease activity : > nmbr . nmbr < nmbr . nmbr , n ( % )-mean age , years ( sd )-months since first ra symptom , mean ( sd ) f-mean ( sd )-> nmbr months , mean ( sd )-> nmbr months , median ( min , max )-europe australia-presence erosions , n ( % ) ""-systemic corticosteroids , n ( % ) a-crp ( mg / l ) , median ( min , max )-n-cdai , mean ( sd )-rf positive ( > nmbr iu / ml ) , n ( % )-jsn , median ( min , max )-female , n ( % )-months since ra first diagnosed , mean ( sd )"
1219,arms,"indacaterol - glycopyrronium group ( n = nmbr )-salmeterol - fluticasone group ( n = nmbr )-all patients ( n = nmbr )-salmeterol - fluticasone group ( n = nmbr ) """
1220,characteristic_name,"copd exacerbations previous year-smoking status screening-inhaled glucocorticoid use screening ""-severity airflow limitation-severity copd-inhaled glucocorticoid use screening-lama use screening-laba - inhaled glucocorticoid use screening-laba use screening-race-sex"
1221,characteristic_level,"asian-male-very severe-nmbr exacerbation-> nmbr exacerbations-other-overall-group d-current smoker-white-moderate-former smoker-group b-female-no use-severe-use ""-use"
1223,characteristic_name,"mmrc dyspnea scale , n ( % )-severity copd , airflow limitation , n ( % )-severity copd , combined assessment , n ( % ) ""-copd exacerbation history , n ( % )-cardiovascular risk factors-race , n ( % )-smoking history , n ( % )-severity copd , combined assessment , n ( % )"
1224,characteristic_level,"nmbr-male , n ( % )-post - bronchodilator fevnmbr , % predicted-> nmbr-missing-group c-pre - bronchodilator fevnmbr ( l )-hyperlipidemia-severe ( gold nmbr )-group d-moderate ( gold nmbr )-diabetes mellitus-copd assessment test ( cat ) score-ex - smoker-duration copd ( years )-current smoker-caucasian-post - bronchodilator fevnmbr reversibility , % a-others-age ( years )-group b-black-ics use baseline , n ( % )-atrial fibrillation / flutter-number pack - years-grade nmbr-post - bronchodilator fevnmbr ( l )-ccv history / condition-very severe ( gold nmbr )-female , n ( % )-missing ""-hypertension"
1225,arms,"ind nmbr mg q . . n = nmbr-ind nmbr mg q . . n = nmbr ""-gly nmbr . nmbr mg b . . . n = nmbr"
1226,characteristic_name,"history atrial fibrillation / flutter-race-age ( years ) ""-ics use baseline-history cardiac arrhythmia-age ( years )-ccv history / condition baseline-long - acting bronchodilator use screening-severity airflow obstruction"
1227,characteristic_level,"male-no-yes-severe severe copd-nmbr < nmbr ""-mild moderate copd-> nmbr-nmbr < nmbr-caucasian-female-black-< nmbr"
1228,arms,"ind nmbr gg q . . n / n ( % )-gly nmbr . nmbr gg b . . n / n ( % )-ind nmbr gg q . . n / n ( % ) """
1229,characteristic_name,"geographic region-geographic region ""-renal function"
1230,characteristic_level,"heart failure nyha ii - iii-age , years-north america-documented asymptomatic cardiac ischemiac-cvd risk factors ( age > nmbr )-europe-microalbuminuria proteinuria-left ventricular systolic diastolic dysfunction-diastolic blood pressure , mm hg-ankle - brachial index < nmbr . nmbr-mild impairment ( egfr nmbr - nmbr )-severe impairment ( egfr < nmbr )-body weight , kg-moderate impairment ( egfr nmbr - nmbr )-prior stroke transient ischemic attack-> nmbr % stenosis coronary , carotid , lower extremity arteries-prior myocardial infarction-normal ( egfr > nmbr )-prior revascularization-systolic blood pressure , mm hg-male sex-chronic kidney diseased-documented symptomatic chdb-glycated hemoglobin , %-hypertension left ventricular hypertrophy-bmi , kg / mnmbr-established cvd ( age > nmbr )-heart failurea-diabetes duration , years-chronic kidney diseased ""-rest world-asia"
1231,arms,"placebo ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) ""-liraglutide ( n = nmbr , nmbr )"
1232,characteristic_level,"egfr > nmbr ml / min / nmbr . nmbr mnmbr-egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr ""-egfr nmbr - nmbr ml / min / nmbr . nmbr mnmbr-egfr < nmbr ml / min / nmbr . nmbr mnmbr"
1234,characteristic_name,"medical history-age , y-duration pci , min-periprocedural medications-weight-periprocedural medications """
1236,outcomes,"primary end point : death / mi / idr / st-idr-acuity - defined bleeding-key secondary end point : st-timi - defined bleeding-death / st-efficacy safety : net adverse clinical events *-q - wave mi-death cardiovascular causes-major-primary safety end point : severe / life - threatening-moderate-death cause-gusto - defined bleeding-mild-mi-any blood transfusion-minor-severe moderate-minor ""-efficacy-safety : non - cabg - related bleeding-death / mi / idr / st / gusto - defined moderate severe bleeding-death / q - wave mi / idr"
1239,characteristic_name,"mean ( sd ) post - bronchodilator-baseline pulmonary medication , n ( % )-mean ( sd ) pre - bronchodilator ""-smoking status , n ( % )-mean ( sd ) pre - bronchodilator"
1240,characteristic_level,"ex - smoker-fevnmbr % predicted-sama-lama-saba-male , n ( % )-patients , n-any-current smoker-mean ( sd ) age , years-fevnmbr , l-ics-fevnmbr / fvc ratio , % ( sd )-laba-fevnmbr , l """
1241,characteristic_level,"ics : yes-gold d-overall-gold a-gold c-naive : no-naive : yes ""-ics : no-gold nmbr-naive : yes-gold b"
1242,characteristic_name,"common concomitant aeds , n ( % )-lev status , n ( % )-seizure types reported baseline , b n ( % )-no . prior aeds , c n ( % )-lev status , n ( % ) ""-racial group , n ( % )"
1243,characteristic_level,"weight , kg , mean ( sd )-> nmbr-carbamazepine-nmbr - nmbr-partial evolving secondarily generalized ( ic )-lev - naive ""-mean age , ( sd )-valproate-complex partial ( ib )-prior lev treatment-oxcarbazepine-lamotrigine-whitea-black-asian-simple partial ( ia )-baseline focal seizure frequency / nmbr days , median ( qnmbr - qnmbr )-lev - naive-female , n ( % )-topiramate"
1244,arms,"brv dosage , mg / d-brv dosage , mg / """
1245,arms,"nmbr ( n nmbr nmbr )-nmbr ( n nmbr nmbr ) """
1246,characteristic_name,"medical history , n ( % ) "" ; na-medical history , n ( % )"
1247,characteristic_level,"atrial fibrillation-kccq score-heart rate ( b . p . . )-nyha class , n ( % ) i-number patients-lvef-age ( years ) ""-syst . bp ( mmhg )-nt - probnp pg / mla ( iqr )-egfr ( ml / min / nmbr . nmbr mnmbr )-bmi ( kg / mnmbr )-ischaemic aetiology-age ( years )-caucasian , n ( % )-iii-iv-female sex , n ( % )-hf hospitalization-diabetes-ckd ( egfr < nmbrb )-ii-hypertension"
1248,outcomes,"cardiovascular death-hf hospitalization-hf hospitalization ""-significant worsening kccq clinical score ( > nmbr ) nmbr monthsnmbr-all - cause mortality-hf hospitalization cardiovascular death"
1250,characteristic_name,"mra-nmbr-history af-other-icd-history af ""-ischemic cardiomyopathy-nt - probnp , pg / ml-diabetes-crt-bnp , pg / ml-history stroke-arb-ace-age , yrs-lvef-diuretics-sbp , mm hg"
1252,characteristic_level,"< nmbr months-> nmbr months-nmbr - nmbr months-no prior hf hospitalization-p value interaction-< nmbr months "" ; na"
1253,arms,"enalapril-sacubitril / valsartan ""-sacubitril / valsartan"
1254,outcomes,"drug discontinuation due death-average daily dose ( % target ) * ""-elevated serum potassium , > nmbr . nmbr mmol / l-average daily dose ( % target ) *-any dose reduction"
1255,characteristic_name,"lipid - lowering agents-time randomization-history ischemic stroke-sex-age-history hypercholesterolemia-history hypertension-sex ""-history diabetes"
1256,characteristic_level,"cortical only-vascular territory # nmbr-anterior circulation-male-yes-< nmbr yr-overall-< nmbr hr-> nmbr enroll-non - cortical-male ""-no-hospital factor # nmbr-mca-> nmbr beds-> nmbr yr-others-female-time treatment-posterior circulation-> nmbr hr-lesion location-< nmbr enroll-< nmbr beds"
1258,arms,"placebo plus aspirin ""-clopidogrel plus aspirin-placebo plus aspirin"
1259,characteristic_name,"glycatedhemoglobin category , %-race / ethnicity , %-cigarettesmoking , %-baseline heart failure severity amongthose priorheartfailure , %-cardiovascular medications , %-antihyperglycemictherapies , %-priorvascular disease , %-bloodpressure , mean ( sd ) , hg-region , %-cigarettesmoking , % """
1260,characteristic_level,"latin america-other-aspirin-north america-nmbr < nmbr . nmbr %-nyha class ii-statin-glycated hemoglobin , mean ( sd ) , %-< nmbr %-p - blocker-nyha class iii-nonaspirin antiplatelet agent-white-insulin-calcium channel blocker-thiazolidinedione-nmbr . nmbr %-not hispanic latino-nyha class i-egfr , mean ( sd ) , ml / min / nmbr . nmbr mnmbr-eastern europe-current-peripheral artery-ace inhibitor angiotensin receptor blocker-current ""-nyha class iv-age , mean ( sd ) , y-diuretic-former-nyha class reported-diastolic-hispanic latino-weight , mean ( sd ) , kg-sulfonylurea-systolic-priorheartfailure , %-female sex , %-black-cerebrovascular-asian-coronary artery disease-western europe-asia pacific other-myocardial infarction-body massindex , mean ( sd ) a-metformin-diabetesduration , mean ( sd ) , y-never"
1261,characteristic_level,"without ( n = nmbr nmbr ) ""-without ( n = nmbr nmbr )-with ( n = nmbr )"
1264,characteristic_name,"number ( ) features present-ada ifg-antihypertensive medication or-laboratory data , mean ( sd )-number ( ) features present ""-who / idf ifg"
1265,characteristic_level,"nmbr-fasting glucose ( mg / dl )-hbanmbrc nmbr . nmbr < nmbr . nmbr % ( nmbr - nmbr mmol / mol )-triglycerides $ nmbr mg / dl ( nmbr . nmbr mmol / l )-nmbr ""-sbp / dbp $ nmbr / $ nmbr mmhg-hbanmbrc $ nmbr . nmbr % ( nmbr mmol / mol )-abdominal obesity *-hdl < nmbr / nmbr mg / dl ( nmbr . nmbr / nmbr . nmbr mmol / l ) men / women-insulin ( mu / ml )-( $ nmbr mg / dl [nmbr . nmbr mmol / l] )-hbanmbrc ( % )-homa - ir-nmbr"
1266,arms,"placebo ( n = nmbr , nmbr )-pioglitazone ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) """
1267,characteristic_name,"aerobic activity-hdl-triglycerides-homa ""-glycated hemoglobin-body mass index-age-coronary artery disease history-abdominal obesity-hypertension history-hispanic ethnicity-homa-medication adherence-who / idf impaired fasting glucose-metabolic syndrome-race-ada impaired fasting glucose-sex"
1269,characteristic_name,"duration tnmbrdm ( % )-homa - ir ( % ) b-homa - ir ( % ) b ""-previous oad ( % )-race ( % )-bmi category ( % )"
1270,characteristic_level,"< nmbr kg / mnmbr-nmbr-> nmbr . nmbr mu / l $ mmol / l-> nmbr-nmbr enmbr years-male ( % )-> nmbr years-homa - ir , mean ( sd ) ( mu / l $ mmol / l ) b-< nmbr year-hbanmbrc ( % )-> nmbr kg / mnmbr-> nmbr . nmbr < nmbr . nmbr mu / l $ mmol / l-fasting c - peptide ( nmol / l ) c-white-< nmbr . nmbr mu / l $ mmol / l-bmi ( kg / mnmbr )-nmbr < nmbr kg / mnmbr-presence mets ( % ) a-age ( years )-none-black-asian-< nmbr . nmbr mu / l $ mmol / l """
1271,arms,"linagliptin ( n z nmbr )-placebo ( n z nmbr )-placebo ( n z nmbr ) """
1272,characteristic_name,"demographics-disease characteristics * ""-disease characteristics *"
1273,characteristic_level,"hscrp , mg / dl-rf positive , %-sjc-dasnmbr - nmbr ( esr )-caucasian , n ( % )-mean disease duration , years-acpa positive , %-vdhmtss-female , n ( % )-rf positive , % ""-tjc-erosion score-haq - di-mean age , years"
1274,arms,"tofacitinib nmbr mg two times day-mtx-tofacitinib nmbr mg two times day """
1275,measures,"early ( n = nmbr )-established ( n = nmbr )-established ( n = nmbr ) """
1276,characteristic_name,"hbanmbrc ( % ) ""-on sulfonylurea-hbanmbrc ( % )-hbanmbrc distribution"
1277,arms,"sitagliptin ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1278,outcomes,"fpg ( mg / dl )-nmbr - h pmg ( mg / dl ) ""-hbanmbrc ( % )-nmbr - h pmg ( mg / dl )"
1279,characteristic_level,"entire cohort-subset patients metformin ""-subset patients metformin-subset patients metformin"
1280,measures,"ls mean change baselinenmbr ""-difference ls means ( nmbr % ci ) nmbr-ls mean change baselinenmbr"
1281,arms,"sitagliptin ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1282,characteristic_name,"ara functional class ""-ara functional class-duration ra ( years )-age ( years )-gender-race"
1283,characteristic_level,"mean ( sd )-asian-class ii-biologics user-other-dmard corticosteroid-white-min - max age-low - dose corticosteroid user ""-class i-class iii-female-methotrexate user-dmard user-black-low - dose corticosteroid user-multi - racial"
1284,arms,"etoricoxib nmbr mg n = nmbr n ( % )-total n = nmbr n ( % ) ""-total n = nmbr n ( % )-placebo n = nmbr n ( % )"
1285,outcomes,"mi-gusto moderate severe bleeding-macce-gusto moderate severe bleeding """
1286,characteristic_level,"omt ""-off omt-on omt"
1287,characteristic_name,"comorbidities-comorbidities ""-medical therapies-cardiovascular history"
1288,characteristic_level,"multivessel cad , n ( % )-bmi , median ( iqr )-current smoking , n ( % ) ""-history pci , n ( % )-hypercholesterolemia , n ( % )-ace inhibitor , n ( % )-history chf , n ( % )-history atrial fibrillation , n ( % )-aspirin , n ( % )-white , n ( % )-current smoking , n ( % )-diabetes mellitus , n ( % )-history cabg , n ( % )-history stroke , n ( % )-egfr < nmbr , n ( % )-history hypertension , n ( % )-dbp ( mm hg ) , median ( iqr )-statin , n ( % )-history second prior mi , n ( % )-history tia , n ( % )-age , median ( iqr )-sbp ( mm hg ) , median ( iqr )-qualifying nstemi , n ( % )-weight kg , median ( iqr )-female , n ( % )-arb , n ( % )"
1289,characteristic_level,"p value-stroke n = nmbr ""-no stroke n = nmbr nmbr-stroke n = nmbr"
1290,characteristic_level,"history chf-prior stroke / tia-history af-no renal dysfunction-no history chf-diabetes-no prior stroke / tia-no history af-no history af ""-no diabetes-renal dysfunction"
1292,characteristic_name,"concomitant medication randomisation-medical history risk factors ""-medical history risk factors-coronary angiography intervention-age ( years )-previous cardiovascular events-killip class-stented vessels-sex"
1293,characteristic_level,"calcium - channel blocker-unstable angina-heart failure-aspirin-statin-number stents implanted-left anterior descending coronary artery-> nmbr-creatinine clearance < nmbr ml / min-one - vessel disease-body - mass index ( kg / ' )-peripheral vascular disease-male-secondary pci-stemi-percutaneous coronary intervention-left circumflex coronary artery-coronary artery bypass grafting-radial access-left main-mra ( spironolactone eplerenone )-dyslipidaemia-two - vessel disease-( blocker-previous cancer-coronary bypass graft-bodyweight ( kg )-inflammatory disease-median ( iqr )-current smoker-i-drug - eluting stent implanted ( least one )-dyslipidaemia ""-female-iii-left main artery-chronic respiratory failure-iv-myocardial infarction-multivessel ( two vessel , three vessel , left main )-ace inhibitor arb-diabetes-stent implanted-right coronary artery-nstemi-proton - pump inhibitor-ii-three - vessel disease-primary pci-haemoglobin ( g / dl )-left ventricular ejection fraction-creatinine clearance admission ( ml / min )-hypertension"
1294,arms,"monitoring group ( n = nmbr )-control group ( n = nmbr )-monitoring group ( n = nmbr ) """
1295,characteristic_level,"prior heart failure-creat clearance > nmbr ml / min-women ""-number stent = l nmbr nmbr-prior cancer-full population-no prior ml-length stent > median-prior ml-weight < nmbr kg-women-age < nmbr-creat clearance < nmbr ml / min-number stent > nmbr-age > nmbr-no prior heart failure-bms-length stent < median-no diabetes-weight > nmbr kg-no hypertension-no prior cancer-multi vessel ( left main )-st --st +-no current smoking-diabetes-des-current smoking-one vessel-men-hypertension"
1297,measures,"n ""-n"
1298,characteristic_name,"smoking history-age group ( years )-ethnic group ""-ethnic group-race-sex"
1299,characteristic_level,"missing data-acq - nmbr score *-local eosinophil count ( cells per pl ) t-black african american-male-central eosinophil count ( cells per pl ) t-reversibility ( % ) t-number resulting hospital admission-number resulting emergency department visit-atopic ( based phadiatop test )-white-> nmbr < nmbr-patients > nmbr exacerbations resulting hospital admission-not hispanic latino-history omalizumab treatment-nasal polyps-missing data ""-current-time since asthma diagnosis ( years )-total asthma symptom score :-former-age ( years )-other *-hispanic latino-female-body - mass index ( kg / mnmbr ) t-smoking pack year ( years ) fl-fevnmbr / fvc prebronchodilatort-asian-diagnosis allergic rhinitis-patients > nmbr exacerbations resulting emergency department visit-number exacerbations past nmbr months-prebronchodilator fevnmbr ( % predicted normal ) t-> nmbr nmbr-prebronchodilator fevnmbr ( l ) t-aqlq ( ) + nmbr scorets-never"
1300,characteristic_level,"high - dosage ics plus laba baseline blood eosinophils < nmbr cells per pl ( n = nmbr )-high - dosage ics plus laba baseline blood eosinophils anmbr cells per pl ( n = nmbr ) ""-all patients ( n = nmbr )-high - dosage ics plus laba baseline blood eosinophils anmbr cells per pl ( n = nmbr )"
1301,arms,"placebo ( n = nmbr )-benralizumab nmbr mg qnmbrw ( n = nmbr )-benralizumab nmbr mg qnmbrw ( n = nmbr ) """
1302,characteristic_name,"age group ( years )-ethnic group ""-ethnic group-race-sex"
1303,characteristic_level,"missing data-number resulting ed visit-body - mass index ( kg / ' )-prebronchodilator fevnmbr / fvc-patients > nmbr exacerbations resulting ed visit-black african american-male-number resulting hospital admission-atopic ( based phadiatop test )-smoker-white-> nmbr < nmbr-acq - nmbr scoret-prebronchodilator fevnmbr ( l )-nicotine pack - years-patients > nmbr exacerbations resulting hospital admission-not hispanic latino-total asthma symptom score-history omalizumab treatment-nasal polyps-reversibility ( % )-eosinophil count ( cells per pl )-time since asthma diagnosis ( years )-age ( years )-other *-hispanic latino-female-aqlq ( ) + nmbr scored-asian-diagnosis allergic rhinitis-predicted normal ( % )-number exacerbations past nmbr months-prebronchodilator fevnmbr ( l ) ""-> nmbr nmbr-central eosinophil count ( cells per pl )"
1304,characteristic_level,"high - dosage ics plus laba baseline blood eosinophils < nmbr cells per pl ( n = nmbr )-all patients ( n = nmbr )-high - dosage ics plus laba baseline blood eosinophils > nmbr cells per pl ( n = nmbr ) ""-high - dosage ics plus laba baseline blood eosinophils > nmbr cells per pl ( n = nmbr )"
1305,arms,"placebo ( n = nmbr )-benralizumab nmbr mg qnmbrw ( n = nmbr )-benralizumab nmbr mg qnmbrw ( n = nmbr ) """
1306,characteristic_name,"ncep risk category study entry , n ( % ) ""-ncep risk category study entry , n ( % )"
1307,characteristic_level,"other-triglycerides , median ( ql , qnmbr ) , mmol / l-waist circumference , mean ( sd ) , cm-high risk-sbp , mean ( sd ) , mm hg-apolipoprotein b , mean ( sd ) , g / l-black african american-current cigarette use , n ( % )-moderately high risk-white-other lipid - modifying drug use study entry , n ( % )-low risk-lipoprotein ( ) , median ( ql , qnmbr ) , nmol / l-female sex , n ( % ) race , n ( % )-homa . % b , median ( ql , qnmbr ) , %-statin use study entry , n ( % )-bmi , mean ( sd ) , kg / mnmbr-dbp , mean ( sd ) , mm hg glycaemic parameters-coronary artery disease , n ( % )-weight , mean ( sd ) , kg-hbalc , median ( ql , qnmbr ) , %-high - density lipoprotein cholesterol , mean ( sd ) , mmol / l-cerebrovascular peripheral arterial disease , n ( % )-demographics age , years , mean ( sd )-homa . ir , median ( ql , qnmbr ) , % / nmbr-c - peptide , median ( ql , qnmbr ) , nmol / l-insulin , median ( ql , qnmbr ) , pmol / l-low risk ""-low - density lipoprotein cholesterol , mean ( sd ) , mmol / l-hypertension , n ( % )-fpg , median ( ql , qnmbr ) , mmol / l-moderate risk"
1308,characteristic_level,"dysglycaemia mets ""-mets-type nmbr diabetes-no dysglycaemia mets-ifg"
1309,arms,"evomab ( n = nmbr )-pbo ( n = nmbr )-evomab ( n = nmbr ) """
1310,outcomes,"triglycerides tx difference vs pbo , ls mean % change baseline ( se )-apolipoprotein b tx difference vs pbo , ls mean % change baseline ( se )-high - density lipoprotein cholesterol tx difference vs pbo , ls mean % change baseline ( se )-insulin tx difference vs pbo , median change baseline ( se ) nmbr-c - peptide tx difference vs pbo , median change baseline ( se ) nmbr-hbalc tx difference vs pbo , median change baseline ( se ) nmbr ""-hbalc tx difference vs pbo , median change baseline ( se ) nmbr-lipoprotein ( ) tx difference vs pbo , ls mean % change baseline ( se )-low - density lipoprotein cholesterol tx difference vs pbo , ls mean % change baseline ( se )-fpg tx difference vs pbo , median change baseline ( se ) nmbr-parameter-homa_ % b tx difference vs pbo , median change baseline ( se ) nmbr-homajr tx difference vs pbo , median change baseline ( se ) nmbr lipid parameters"
1311,characteristic_level,"dysglycaemia mets ""-mets-type nmbr diabetes-no dysglycaemia mets-ifg"
1312,arms,"pbo ( n = nmbr ) vs ""-pbo ( n = nmbr ) vs"
1313,characteristic_name,"hdl-hdl ""-core laboratory percent stenosis-age , y-systolic blood pressure , mm hg-bmi-total cholesterol-albumin creatinine ratio-egfr-race"
1314,characteristic_level,"cohort nmbr ( uacr > nmbr . nmbr mg / g )-cohort nmbr ( uacr < nmbr . nmbr mg / g )-uacr available-cohort nmbr ( uacr > nmbr . nmbr mg / g ) """
1315,arms,"medical therapy ( n = nmbr ) ""-stent ( n = nmbr )-medical therapy ( n = nmbr )"
1316,characteristic_name,"acr deciles-acr deciles """
1317,characteristic_level,"nmbr , nmbr - < nmbr . nmbr ""-nmbr , nmbr - < nmbr . nmbr-> = nmbr . nmbr-overall-nmbr . nmbr - < nmbr . nmbr-nmbr . nmbr - < nmbr-< nmbr . nmbr-nmbr - < nmbr . nmbr"
1319,characteristic_name,"previous mi-male-congestive heart failure-prior stroke tia ""-previous cabg-smokers-previous pci-weight , kg-diabetes mellitus-u . . site-peripheral artery disease-age , yrs-prior stroke tia-white race"
1321,outcomes,"st-d / mi / idr / st-qmi-idr-death-ml-death "" ; na"
1322,characteristic_level,"acs-acs ""-sa"
1323,characteristic_name,"diabetes duration , n ( % )-renal function ( egfr , ml / min / nmbr . nmbr mnmbr , according mdrd ) , n ( % )-hbanmbrc , % , n ( % ) b ""-age , n ( % )-hbanmbrc , % , n ( % ) b-ethnicity , n ( % )-race , n ( % )-number antidiabetes drugs screening , n ( % )"
1324,characteristic_level,"nmbr-male , n ( % )-concomitant medication , n ( % )-aspirin-< nmbr . nmbr %-peripheral artery disease-normal ( > nmbr )-macrovascular disease , n ( % )-mild impairment ( nmbr < nmbr )-< nmbr year-> nmbr years-nephropathy-fasting plasma glucose , mg / dl , mean ( sd ) b-moderate impairment ( nmbr < nmbr )-native american / alaskan-white-nmbr < nmbr years-retinopathy-microvascular disease , n ( % )-cerebrovascular disease-< nmbr years-severe impairment ( < nmbr )-hispanic / latino-non - hispanic / latino-black-asian-bmi , kg / mnmbr , mean ( sd )-coronary artery disease-lipid - lowering drugs-neuropathy-hbanmbrc , % , mean ( sd ) b-antihypertensive drugs-> nmbr . nmbr %-> nmbr . nmbr % ""-hypertension-age , years ( sd )"
1325,arms,"linagliptin-linagliptin / metformin-linagliptin """
1326,characteristic_name,"bmi ( kg / mnmbr )-ethnicity-age ( years )-race ""-creatinine clearance ( ml / min )-race"
1327,measures,"difference ( nmbr % cl ) ""-difference ( nmbr % cl )-number patients"
1328,arms,"placebo ( n = nmbr )-baricitinib nmbr mg qd ( n = nmbr )-baricitinib nmbr mg qd ( n = nmbr ) """
1329,characteristic_name,"cardiovascular risk factors , n ( % )-sex , n ( % )-cardiovascular risk factors , n ( % ) ""-medical history , n ( % )"
1330,characteristic_level,"smoker ( current / former )-male-mean % predicted dlco * ( sd )-mean nmbrmwd * , ( sd )-copd-mean ucsd - sobq score * ( sd )-diabetes-cardiovascular disease-hypercholesterolaemia-obesity t-mean % predicted fvc ( sd )-smoker ( current / former ) ""-mean age , years ( sd )-chronic renal failure-hypertension"
1332,outcomes,"absolute fvc decrease > nmbr %-nmbrmwd decrease > nmbr m-death absolute fvc decrease > nmbr %-relative decrease > nmbr %-ipf - related-all - cause mortality-respiratory - related^-disease - progression composite outcome !-all - cause-death nmbrmwd decrease > nmbr m-all - cause ""-absolute decrease > nmbr %"
1333,measures,"bivariate frailty model ( statin users vs non - users )-crude analysis , n ( % ) ""-crude analysis , n ( % )"
1335,characteristic_name,"gold nmbr groups , n ( % )-copd exacerbation history , n ( % )-catscorecategory , n ( % )-mmrc grade , n ( % ) ""-mmrc grade , n ( % )-copd severity , n ( % ) *"
1336,characteristic_level,"nmbr-age , years-duration copd , years-nmbr - nmbr ( severe )-nmbr - nmbr ( severe )-sex , male , n ( % )-post - bronchodilator fevnmbr / fvc , %-gold b-post - bronchodilator fevnmbr reversibility , %-yes-moderate-nmbr - nmbr ( mild )-nmbr - nmbr ( moderate )-no-mild-icsusers atbaseline , n ( % )-nmbr ""-post - bronchodilator fevnmbr , l-post - bronchodilator fev , , % predicted-gold d-current smokers , n ( % )-severe"
1337,arms,"sfcnmbr / nmbr pg b . . . n = nmbr-ind / glynmbr / nmbr pg . . n = nmbr-sfcnmbr / nmbr pg b . . . n = nmbr """
1338,characteristic_name,"glucose - lowering therapies-cigarette smoking ""-cardiovascular medications-cigarette smoking"
1339,characteristic_level,"heart failure-egfr ( ml / min / nmbr . nmbrmnmbr )-statin-aspirin-hbanmbrc ( mmol / mol )-ldl - cholesterol ( mg / dl )-thienopyridine-hbanmbrc ( % )-white race-women-insulin-calcium channel blocker-thiazolidinedione-total cholesterol ( mg / dl )-bmi ( kg / mnmbr )-cerebrovascular disease-current-uacr ( mg / g )-beta blocker-systolic blood pressure ( mmhg )-current ""-diuretic-former-age ( years )-diastolic blood pressure ( mmhg )-previous vascular disease-peripheral arterial disease-sulfonylurea-acei / arb-coronary artery disease-myocardial infarction-metformin-diabetes duration ( years )-never"
1340,characteristic_name,"stage nmbr-stage nmbrb-stage nmbrb ""-stage nmbra"
1341,characteristic_level,"egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % ) ""-egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr , nmbr ( nmbr . nmbr % )-egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr n = nmbr ( nmbr . nmbr % )-egfr > = nmbrml / min / nmbr . nmbrmnmbr n = nmbr , nmbr ( nmbr . nmbr % )"
1342,outcomes,"nmbr - point mace ""-hospitalization unstable angina-cv death-all - cause death-myocardial infarction-nmbr - point mace-hospitalization heart failure-stroke"
1343,characteristic_name,"stage nmbr-stage nmbrb-stage nmbr ""-stage nmbra-treatment egfr stage"
1344,characteristic_level,"egfr > nmbr ml / min / nmbr . nmbrmnmbr ""-egfr nmbr - nmbr ml / min / nmbr . nmbrmnmbr-egfr > nmbr ml / min / nmbr . nmbrmnmbr"
1345,characteristic_name,"il - nmbr ( pg / ml )-swollen joint count ( n / nmbr )-dasnmbr-number previous dmards-haemoglobin ( g / l )-disease duration ( years )-current smoker-c - reactive protein ( mg / dl )-serum creatinine ( mmol / l )-female sex-age-troponin ( pg / ml )-white ethnicity-baseline diabetes-white ethnicity ""-tender joint count ( n / nmbr )-nt - probnp ( pg / ml )"
1346,characteristic_name,"demographics-clinical characteristics-baseline medical therapy-peripheral artery disease details-clinical characteristics """
1347,characteristic_level,"claudication ( fontaine class > nmbr )-aspirin-egfr crcl < nmbr ml / min / nmbr . nmbr mnmbr-thienopyridine-prior carotid intervention-hyperlipidemia-white race-weight < nmbr kg-prior amputation-diabetes mellitus-former smoker-age , yrs-peripheral artery revascularization without amputation-hypertension ""-no antiplatelet therapy-smoking status-history atrial fibrillation fl utter-current smoker-abi < nmbr . nmbr-statin therapy-history stroke tia-female-aspirin thienopyridine therapy-bmi , kg / mnmbr-any coronary artery disease-ace inhibitor arb-abi > nmbr . nmbr-never smoker-cilostazol-abi-hypertension"
1349,characteristic_name,"medical history-treatment randomization-clinical features hf-medical history ""-nyha class-race / ethnicity"
1350,characteristic_level,"nmbr-atrial fibrillation-cardiac resynchronization therapy-other-bnp , median ( iqr ) , pg / ml-p - blocker-sbp , mean ( sd ) , mm hg-ischemic cardiomyopathy-white-female sex-stroke-diuretics-left ventricular ef , mean ( sd ) , %-atrial fibrillation ""-creatinine , mean ( sd ) , mg / dl-potassium supplement-implantable cardioverter - defibrillator-age , mean ( sd ) , y-potassium , mean ( sd ) , meq / l-iii-nt - probnp , median ( iqr ) , pg / ml-black-iv-asian-myocardial infarction-diabetes-heart rate , mean ( sd ) , beats / min-hospitalization hf-bmi , mean ( sd )-ii-digitalis-hypertension"
1351,measures,"p value mra vs mra-no . ( % ) participants ""-no . ( % ) participants"
1352,arms,"mra baseline-mra baseline ""-mra baseline"
1353,arms,"sacubitril / valsartan ( n = nmbr )-enalapril ( n = nmbr )-enalapril ( n = nmbr ) """
1354,outcomes,"severe hyperkalemiac-hyperkalemiab ""-hyperkalemiab"
1355,characteristic_level,"mra baseline-mra baseline ""-mra baseline"
1357,characteristic_name,"baseline medications-lntensityd-lntensityd ""-race / ethnicity"
1358,characteristic_level,"other-native hawaiian pacific islander-ace inhibitor-low ""-bmi , mean ( sd ) b-arb-p - blocker-black african american-multiple-american indian alaska native-baseline ezetimibe usec-antiplatelet therapy-white-moderate-previous ml-high-age , mean ( sd ) , y-baseline statin usec-asian-diabetes-previous pci-low-men-smoking-hypertension"
1359,arms,". ( % )-no . ( % ) """
1360,characteristic_name,"male ( n = nmbr , nmbr )-age ( years ) - > = median ( n = nmbr , nmbr )-prior statin ( n = nmbr , nmbr )-proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - > = median ( n = nmbr , nmbr )-current smoker ( n = nmbr , nmbr )-non - high density lipoprotein ( mg / dl ) - baseline - > = median ( n = nmbr , nmbr )-history mi ( n = nmbr , nmbr )-baseline pav - < median ( n = nmbr , nmbr )-baseline tav - > = median ( n = nmbr , nmbr )-baseline pav - > = median ( n = nmbr , nmbr )-type nmbr diabetes ( n = nmbr , nmbr )-high dose statin ( n = nmbr , nmbr )-no history mi ( n = nmbr , nmbr )-female ( n = nmbr , nmbr ) ""-female ( n = nmbr , nmbr )-no family history chd ( n = nmbr , nmbr )-family history chd ( n = nmbr , nmbr )-non high dose statin ( n = nmbr , nmbr )-non - smoker ( n = nmbr , nmbr )-no type nmbr diabetes ( n = nmbr , nmbr )-non - high density lipoprotein ( mg / dl ) - baseline - < median ( n = nmbr , nmbr )-no prior statin ( n = nmbr , nmbr )-baseline tav - < median ( n = nmbr , nmbr )-race - non - white ( n = nmbr , nmbr )-proprotein convertase subtil / kexin typnmbr ( ng / ml ) - baseline - < median ( n = nmbr , nmbr )-race - white ( n = nmbr , nmbr )-age ( years ) - < median ( n = nmbr , nmbr )"
1361,measures,"pav , mean ( nmbr % ci )-pav , mean ( nmbr % ci ) """
1362,arms,"placebo-evolocumab ( nmbr mg ) ""-evolocumab ( nmbr mg )"
1363,measures,"- treatment-baseline-on - treatment """
1364,characteristic_name,"type concomitant statin daily dose - . ( % )-race - . ( % )-baseline lipid / lipoprotein values-at ldl - c ( bq ) goal * baseline - . ( % )-prior diagnosis - . ( % )-type concomitant statin daily dose - . ( % ) ""-chd risk - . ( % )-use concomitant lipid - lowering therapy - . ( % )"
1365,arms,"placebo ( n = nmbr )-anacetrapib nmbr mg ( n - nmbr ) ""-anacetrapib nmbr mg ( n - nmbr )"
1366,characteristic_name,"medication use baseline , n ( % ) ""-medication use baseline , n ( % )"
1367,characteristic_level,"syndesmophyte present , n ( % )-basfi , mean ( sd )-current smoker , n ( % )-sulfasalazine-patient ' global assessment disease activity , mean ( sd )-hscrp , median ( min , max ) , mg / l-time since diagnosis , mean ( sd ) years-basmi ( linear ) , mean ( sd )-hla - bnmbr positive , n ( % )-anti - tnf - naive , n ( % )-male gender , n ( % )-methotrexate ""-weight , mean ( sd ) kg-msasss , mean ( sd )-methotrexate-glucocorticoids-age , mean ( sd ) years-elevated hscrp > nmbr mg / l , n ( % )-total back pain , mean ( sd )-total basdai , mean ( sd )"
1368,arms,"secukinumab intravenous nmbr mg ( n = nmbr ) ""-secukinumab intravenous nmbr mg ( n = nmbr )"
1369,characteristic_level,"male ""-male-normal hscrp-elevated hscrp-non - smokers ( baseline )-female-patients syndesmophytes baseline-patients without syndesmophytes baseline-smokers ( baseline )-overall population"
1370,measures,"change week nmbr-baseline-patients ( n )-baseline """
1371,arms,"placebo secukinumab nmbr mg ""-placebo secukinumab pooled-placebo secukinumab nmbr mg"
1372,characteristic_name,"smoking status , n ( % )-baseline pulmonary medication , n ( % )-gold , n ( % )-baseline pulmonary medication , n ( % ) """
1373,characteristic_level,"male , n ( % )-nmbr ( nmbre < nmbr % )-laba-cardiac rhythm disorders-co - morbidities , n ( % )-vascular disordersb-sama-mean ( sd ) age , years-diabetes mellitus-baseline cardiovascular medication , c n ( % )-ex - smoker-saba-nmbr ( < nmbr % )-current smoker-cardiac history-ics ""-nmbr ( > nmbr % )-xanthines-lama-mean ( sd ) extent exposure , days-ischaemic heart disease-ics-b - blocker"
1374,arms,"tiotropium nmbr mg ( n = nmbr )-tiotropium nmbr mg ( n = nmbr ) ""-olodaterol nmbr mg ( n = nmbr )-tiotropium / olodaterol nmbr / nmbr mg ( n = nmbr )"
1375,outcomes,"tachyarrhythmias , n ( % )-ischaemic heart disease , n ( % )-cardiac failure , n ( % )-cerebrovascular disorders , n ( % )-myocardial infarction-any aes , n ( % )-haemorrhagic-cerebrovascular disorders , n ( % ) ""-hypertension , n ( % )-other ischaemic heart disease ( non - infarction )-supraventricular tachyarrhythmias ( incl . atrial-ischaemic-total patients , n-ventricular tachyarrhythmias"
1376,characteristic_level,"cardiac rhythm disorder baseline yes ""-cardiac rhythm disorder baseline yes"
1377,arms,"tiotropium nmbr g ""-tiotropium nmbr g-tiotropium / olodaterol nmbr / nmbr mg-olodaterol nmbr g"
1378,characteristic_name,"ics use baseline-racea-diabetes mellitus-cardiac history-age-copd disease severity-cardiac rhythm disorders-age ""-sex"
1379,arms,"tiotropium nmbr . nmbr mg-tiotropium / olodaterol nmbr . nmbr / nmbr mg ""-tiotropium nmbr mg-olodaterol nmbr mg-total-tiotropium / olodaterol nmbr . nmbr / nmbr mg-tiotropium / olodaterol nmbr / nmbr mg"
1380,measures,"n ( % )-n ( % ) ""-n"
1381,characteristic_name,"nationality-nationality ""-race-ethnicity"
1382,characteristic_level,"korea , republic of-asian-romania-body weighta , kg-age , years-sex , male-malaysia-india-bmi , kg / mnmbr-duration tnmbrdm , years-china-white-philippines-not hispanic latino-malaysia """
1383,characteristic_level,"chinese subgroup ""-chinese subgroup-full analysis set"
1384,arms,"sitagliptin nmbr mg n = nmbr ""-sitagliptin nmbr mg n = nmbr-placebo n = nmbr"
1385,outcomes,"fpg , mmol / l ""-hbanmbrc , %-fpg , mmol / l"
1386,characteristic_level,"chinese subgroup ""-chinese subgroup-full analysis set"
1387,arms,"sitagliptin nmbr mg n = nmbr ""-sitagliptin nmbrmg n = nmbr-sitagliptin nmbr mg n = nmbr-placebo n = nmbr"
1388,characteristic_name,"disease hare . . ( % ) i-organ system involvement , . ( % )-medications . . ( % )-enrollment region , . ( % )-selena - sledai ( range u - nmbrunmbr ) t-( nmbr - nmbr - cm vas )-enrollment region , . ( % ) ""-immunosuppressants-race / ethnicity"
1389,characteristic_level,"mycophenolate mofetil-facit - fatigue . mean nmbrsd ( range nmbr - nmbr )-renal-mean nmbr sd-western europe / australia / israel-corticosteroids . immunosuppressants . antimalarials-at least nmbr flare-americas , excluding us-vascular-score # nmbr , . ( % )-antimalarials only-immunologic-corticosteroids immunosuppressants only-constitutional-not hispanic latino-hematologic-female , . ( % )-us ""-eastern europe-mucocutaneous-central nervous system-musculoskeletal-physician ' global assessment . mean nmbr sd-immunosuppressants only-hispanic latino-azathioprine-at least nmbr severe flare-immunosuppressants antimalarials only-us-age , mean nmbr sd years-weight , mean nmbr sd kg-score $ nmbr , . ( % )-disease duration , median ( range ) years-methotrexate-corticosteroids only-cardiovascular respiratory-asia-median ( range )-corticosteroids antimalarials"
1390,arms,"belimumab nmbr mg sc ( n nmbr ) ""-belimumab nmbr mg sc ( n nmbr )-placebo ( n nmbr )"
1391,characteristic_name,"race-ss baseline-steroid use baseline ""-race ss baseline-baseline body weight quartile-steroid use baseline"
1392,characteristic_name,"bone erosion ( judged physician ) , n ( % )-sdai-crp ( mg / dl )-sjc ( / nmbr joints )-anti - ccp antibody positive , n ( % )-mmp - nmbr ( ng / ml )-dasnmbr ( esr )-joint space narrowing score-bmi ( kg / mnmbr )-average weekly mtx dose ( mg / week ) t-mtss-age ( years )-tjc ( / nmbr joints )-sjc ( / nmbr joints ) ""-haq - di score-ra duration ( months ) *-weight ( kg )-rf positive , n ( % )-female , n ( % )-erosion score-esr ( mm / hour )"
1393,arms,"czp + mtx^mtx-czp + mtx^mtx ""-pbo + mtx^mtx"
1394,measures,"total patients n = nmbr-patients entering pt period n = nmbr ""-patients entering pt period n = nmbr"
1395,measures,"pt baseline ( week nmbr )-db baseline ( week nmbr ) ""-db baseline ( week nmbr )"
1396,characteristic_name,"ra duration ( months ) *-il - nmbr ( pg / ml )-mmp - nmbr ( ng / ml )-il - nmbr ( pg / ml ) "" ; na-dasnmbr-tnf - alpha ( pg / ml )-baseline erosion-baseline steroids-rf ( iu / ml )-crp ( mg / dl )-mtss-mtx exposure ( mg / week )-haq - di"
1397,characteristic_level,"no-yes-nmbr - < nmbr-nmbr < - nmbr-> nmbr . nmbr - < nmbr . nmbr-> nmbr-> nmbr - < nmbr-< nmbr . nmbr-> nmbr . nmbr - < nmbr . nmbr ""-> nmbr . nmbr-nmbr - nmbr-< nmbr"
1398,arms,"czp + mtx mtx ""-pbo + mtx mtx-czp + mtx mtx"
1399,other,"mtss cfb-mtss cfb """
1400,measures,"mean ""-sd-mean-n"
1401,characteristic_name,"ethnic origin-age range ( years )-ethnic origin ""-methotrexate dose baseline-sex"
1402,characteristic_level,"simplified disease activity index score ( nmbr - nmbr )-clinical disease activity index score ( nmbr - nmbr )-other-bmi ( kg / mnmbr ) ""-> nmbr-> nmbr < nmbr - nmbr mg / week-dasnmbr ( c - reactive protein )-> nmbr - nmbr mg / week-stiffness ( min )-male-anti - ccp antibody positive-duration rheumatoid arthritis ( years )-white-> nmbr < nmbr-haq - di score ( nmbr - nmbr )-conventional synthetic dmard use baseline-bmi ( kg / mnmbr )-c - reactive protein ( mg / l )-age ( years )-none-female-black-swollen joint count ( nmbr - nmbr )-asian-tender joint count ( nmbr - nmbr )-unknown-duration morning-< nmbr-rheumatoid factor - positive"
1404,characteristic_name,"prior biologic therapy ( including anti - tnfs ) ""-prior biologic therapy ( including anti - tnfs )-prior anti - tnf therapy-overall"
1405,measures,"acrnmbr response week nmbr , n ( % )-acrnmbr response week nmbr , n ( % ) """
1406,characteristic_level,"received nmbr prior anti - tnf therapy , n-received nmbr prior biologic therapy , n-evaluable acrnmbr week nmbr , n-received nmbr prior biologic therapies , n-received > nmbr prior anti - tnf therapies , n-received nmbr prior biologic therapies , n """
1407,arms,"sirukumab nmbr mg qnmbrw ""-placeboa-sirukumab nmbr mg qnmbrw"
1408,characteristic_name,"laboratory findings-coexisting conditions ""-medications-demographics-coexisting conditions-at randomization-type event"
1409,characteristic_level,"unstable angina-time acs randomization-aspirin-statin-ml without st - segment elevation !-hypertension *-thienopyridine-current smoking *-heart failure *-previous cabg ( index acs ) *-age , yrs-egfr < nmbr ml / min / nmbr . nmbr mnmbr *-previous pci ( index acs )-beta - blocker !-total cholesterol , mg / dl-diabetes * ""-caucasian-lipid - lowering agent-female-non - hdl - c , mg / dl-age > nmbr yrs *-acei / arb-bmi , kg / mnmbr-pre - randomization pci-peripheral artery disease *-previous ml ( index acs )-previous stroke *-ldl - c , mg / dl-hs - crp , mg / l-diabetes *-ml st - segment elevation-egfr , ml / min / nmbr . nmbr mnmbr"
1410,characteristic_level,"overall ( n = nmbr , nmbr )-high ( > nmbr ) ( n = nmbr , nmbr ; nmbr % )-low ( nmbr - nmbr ) ( n = nmbr , nmbr ; nmbr % )-high ( > nmbr ) ( n = nmbr , nmbr ; nmbr % ) ""-intermediate ( nmbr ) ( n = nmbr , nmbr ; nmbr % )"
1411,characteristic_name,"hs - crp-tg-apo - b-hdl - c-total cholesterol ""-ldl - c-total cholesterol-non - hdl - c"
1412,characteristic_level,"overall-intermediate risk ( ri = nmbr ) ""-intermediate risk ( ri = nmbr )-low risk ( ri = nmbr - nmbr )-high risk ( ri = nmbr )"
1413,measures,"nmbryr-baseline-nmbryr """
1414,arms,"ez / simva-simva-pooled-simva """
1415,measures,"n = nmbr ""-n = nmbr"
1416,characteristic_name,"race * ""-hdl cholesterol-race *-cholesterol ( mmol / l )-blood pressure ( mm hg )-bmi category-waist circumference ( cm )-sex"
1417,characteristic_level,"nmbr-other-hypertensiont-native hawaiian pacific islander-men ( n = nmbr vs nmbr )-male-nmbr - h plasma glucose ogtt ( mmol / l )-american indian alaska native-overall-> nmbr , obesity class nmbr-women-free fatty acids ( mmol / l )-dyslipidaemia hypertensiont-white-black african - american-total-nmbr - nmbr - nmbr , overweight-women ( n = nmbr vs nmbr )-non - hdl cholesterol-other ""-bmi ( kg / mnmbr )-diastolic-age ( years )-systolic-fasting glucose ( mmol / l )-asian-weight ( kg )-nmbr - nmbr - nmbr , obesity class nmbr-ldl cholesterol-dyslipidaemiat-glycated haemoglobin ( % )-hispanic latino ethnic group *-vldl cholesterol-triglycerides ( mmol / l )-fasting insulin ( pmol / l )-men"
1418,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-liraglutide nmbr - nmbr mg ( n = nmbr )"
1419,characteristic_name,"demographic features-concomitant medications , n ( % )-concomitant medications , n ( % ) ""-laboratory data-clinical history , n ( % )-physical examination"
1420,arms,"placebo-pioglitazone-placebo """
1421,measures,"( n = nmbr )-( n = nmbr ) """
1422,characteristic_name,"atrial fibrillation-triglycerides-arb / ace-statin-aspirin-glycated hemoglobin-body mass index-body mass index ""-homa > median-age-coronary artery disease history-hypertension history-gender-race-ada impaired fasting glucose"
1423,characteristic_level,"fema le-< nmbr . nmbr %-> nmbr-> nmbr years-absent ( < nmbr mg / dl )-black african american-male-yes-nmbr . nmbr % - nmbr . nmbr %-< nmbr ""-< nmbr mg / dl-all participants-white / other-no-nmbr . nmbr - nmbr . nmbr % t-< nmbr years-present ( > nmbr mg / dl )-> nmbr mg / dl-< nmbr"
1425,characteristic_name,"medical history-medications-clinical characteristics-ecg-medications ""-physical examination"
1426,characteristic_level,"previous cabg , n ( % )-atrial fibrillation / flutter , n ( % )-other cause , n ( % )-nyha iii , n ( % )-qrs duration > nmbr ms , n ( % )-diuretics , n ( % )-heart rate ( beats / min )-ace inhibitors / arbs , n ( % )-nitrates , n ( % )-other antiplatelet agents , n ( % ) ""-nyha ii , n ( % )-hypertensive , n ( % )-non - detectable / unknown , n ( % )-ischaemic , n ( % )-aspirin , n ( % )-pathologic q waves , n ( % )-aortic stenosis , n ( % )-nyha iv , n ( % )-lv hypertrophy , n ( % )-diabetes , n ( % )-total cholesterol ( mg / dl )-dilatative , n ( % )-previous hf hospitalization , n ( % )-heart failure cause-peripheral vascular disease , n ( % )-snmbr gallop , n ( % )-oral anticoagulant , n ( % )-bmi ( kg / mnmbr )-age ( yrs )-symptoms-amiodarone , n ( % )-systolic blood pressure ( mmhg )-other antiplatelet agents , n ( % )-previous cancer , n ( % )-beta - blockers ( ) , n ( % )-previous myocardial infarction , n ( % )-women , n ( % )-diastolic blood pressure ( mmhg )-previous pci , n ( % )-former / current smoker , n ( % )-rales , n ( % )-history atrial arrhythmia , n ( % )-pm , n ( % )-digoxin , n ( % )-calcium channel blockers , n ( % )-icd , n ( % )-previous stroke , n ( % )-hypertension , n ( % )-spironolactone , n ( % )-mitral regurgitation , n ( % )"
1428,outcomes,"non cv mortality-cv mortality-non cv mortality "" ; na-all - cause mortality-all - cause hospitalization"
1430,measures,"p-hr ( nmbr % cl )-p """
1431,characteristic_name,"blood eosinophils count-blood eosinophils count """
1432,characteristic_level,"> nmbr cells / pl ""-nmbr < nmbr cells-> nmbr %-< nmbr %-> nmbr cells / pl-< nmbr cells / pl"
1433,measures,"rate ratio ( nmbr % ci )-no . patients ind / gly sfc-no . patients ind / gly sfc ""-annualized rate ind / gly sfc"
1434,measures,"age , mean ( sd ) , years-age , mean ( sd ) , years ""-> nmbr-female , n ( % )-baseline focal seizure frequency / nmbr days , median ( qnmbr , qnmbr )-nmbr - nmbr"
1435,arms,"topiramate-lamotrigine ""-carbamazepine-lamotrigine-levetiracetam"
1436,characteristic_name,"naive ( n = nmbr ) ""-naive ( n = nmbr )-exposed ( n = nmbr )"
1437,arms,"aspirin nmbr mg ( n = nmbr )-rivaroxaban ""-rivaroxaban"
1438,characteristic_name,"duration pre - randomization anticoagulant therapy-known thrombophilia-extent index event-fragile-active cancer ""-creatinine clearance-body mass index-history recurrent venous thromboembolism-body weight-active cancer-age-risk factor profile index event-presentation index event-sex"
1439,arms,"rivaroxaban nmbr mg-aspirin nmbr mg-aspirin nmbr mg """
1440,characteristic_name,"smoking status-copd medication study entry-race ""-race-sex"
1441,characteristic_level,"ischaemic cardiomyopathy-blood eosinophil concentration , nmbr cells per l-other-fevnmbr / fvc ratio *-black / african american-coronary artery osteochondrosis-body - mass index ( kg / - ) ""-< nmbr %-laba / lama-blood eosinophil proportion ( % )-body - mass index ( kg / - )-inspiratory capacity ( l )-male-angina pectoris-myocardial ischaemia-white-diabetes mellitus-ics / laba-patients least one concomitant disease *-ex - smoker-% predicted normal value *-fevnmbr , l *-reversibility ( % )-cat total score-spacer use study-current smoker-age ( years )-female-cholecystitis chronic-arteriosclerosis-coronary artery disease-lama-fvc ( l ) *-ischaemic heart disease-> nmbr % < nmbr %-blood leucocyte concentration ( nmbr cells per l )-chronic bronchitis !-myocardial infarction-ics / lama-time since first copd diagnosis ( years )-obesity-cardiac failure-exacerbation rate previous year ( range )-hypertension"
1442,arms,"fixed triple ( n = nmbr )-tiotropium ( n = nmbr )-open triple ( n = nmbr )-tiotropium ( n = nmbr ) """
1443,outcomes,"tnmbrdm duration ( years )-fpg ( mmol / l )-hbanmbrc ( % ) "" ; na-hbanmbrc ( % )-daily iglar dose week nmbr ( u )-nmbr - h ppg ( mmol / l )"
1444,arms,"iglar ( insulin glargine lnmbr u ) ""-iglarlixi ( fixed - ratio combination )-iglar ( insulin glargine lnmbr u )"
1445,characteristic_level,"< lnmbr years-> lnmbr years-> lnmbr years ""-< nmbr years"
1446,arms,"ularitide ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1447,characteristic_name,"time first eval-baseline systolic bp-coronary artery disease-troponin t-diabetes-gender ""-gfr assessed mdrd-region-ejection fraction-age screening-history chronic hf-gender-nt - pro bnp-race"
1448,characteristic_name,"disease activity ""-european quality life - nmbr dimensions - nmbr level ( eq - nmbrd )-activity ( nmbr - nmbr vas )-patient characteristics-disease activity-number prior csdmards , n ( % )-short form nmbr ( sf - nmbr )-patient - reported outcome measures-number concomitant csdmards , n ( % )-( haq - di , nmbr - nmbr )"
1449,characteristic_level,"mtx-age , years-nmbr-health assessment questionnaire - disability index-patient ' assessment pain ( nmbr - nmbr vas )-physical component score ( pcs )-non - mtx-sdai-> nmbr-mental component score ( mcs )-cdai-swollen joint count , nmbr-mtx + non - mtx-concomitant corticosteroid use , n ( % )-nmbr non - mtx-functional assessment chronic illness-esr , mm / hour-mean ( sd ) mtx dose , mg / week-vas ( nmbr - nmbr )-dasnmbr - hscrp-tender joint count , nmbr-duration ra ( time symptom onset ) , years-female patients , n ( % )-tender joint count , nmbr ""-patient ' global assessment disease-hscrp , mg / l-concomitant mtx use , n ( % )-health state index score , uk algorithm"
1450,arms,"placebo ( n = nmbr )-baricitinib nmbr mg ( n = nmbr ) ""-baricitinib nmbr mg ( n = nmbr )"
1451,characteristic_name,"concomitant cardiovascular therapy ( taken > nmbr days )-high risk ( receiving treatment ) : ""-high risk ( receiving treatment ) :-cardiovascular inclusion criteriat-race"
1452,arms,"combination therapy , n = nmbr-vilanterol , n = nmbr-placebo , n = nmbr ""-fluticasone furoate , n = nmbr-total , n = nmbr nmbr-placebo , n = nmbr"
1453,characteristic_name,"age group-smoking status-african - american / african heritage ( n = nmbr )-ischemic heart disease indicator ( n = nmbrl )-african - american / african heritage ( n = nmbr ) ""-nmbr - nmbr cv risk disease ( n = nmbr )-ethnicity-region-cv entry criteria-vascular disease indicator ( n = nmbr )-gender-race"
1454,characteristic_level,"female ( n = nmbr )-current smoker ( n = nmbr )-hispanic latino ( n = nmbr )-male ( n = nmbr )-usa ( n = nmbr )-< nmbr years ( n = nmbr )-not hispanic latino ( n = nmbr )-asian ( n = nmbr )-asia ( n = nmbr )-white ( n = nmbr )-asian ( n = nmbr ) "" ; na-> nmbr years ( n = nmbr )-former smoker ( n = nmbr )-europe nmbr ( n = nmbr )-rest - - world ( n = nmbr )-> nmbr years < nmbr years ( n = nmbr )-yes ( n = nmbr )-nmbr - nmbr cv disease ( n = nmbr )-other ( n = nmbr )"
1455,measures,"hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr )-hazard ratio ( nmbr % cl ) nmbr . nmbr ( nmbr . nmbr , nmbr . nmbr ) """
1456,other,"octave sustain-octave induction nmbr ""-octave induction nmbr"
1457,arms,"placebo ( n = nmbr )-tofacitinib , nmbr mg ( n = nmbr )-tofacitinib , nmbr mg ( n = nmbr ) """
1458,characteristic_name,"disease characteristics ""-medication use-demographic characteristics-disease characteristics"
1459,arms,"abatacept ( n = nmbr * )-placebo ( n = nmbr * )-placebo ( n = nmbr * ) """
1460,characteristic_level,"total population-tnfi naive-tnfi naive ""-tnfi exposed"
1461,measures,"acrnmbr ""-acrnmbr"
1462,other,"week nmbr ""-week nmbr"
1464,characteristic_name,"copd severity-copd severity """
1465,characteristic_level,"male , n ( % )-baseline ics use , n ( % ) ""-moderate , n ( % ) a-previous treatment laba / lama , n ( % ) c-cigarette smoking , mean pack - years ( sd )-mean fevnmbr , l ( sd )-post - bronchodilator percent predicted fevnmbr , % ( sd )-current smoker , n ( % )-severe , n ( % ) b-baseline ics use , n ( % )-white , n ( % )-mean number exacerbations previous nmbr months ( sd )-mean sgrq total score ( sd )-mean age , years-mean bdi focal score ( sd )"
1466,arms,"ab nmbr pg ( n = nmbr )-placebo ( n = nmbr ""-ff nmbr pg ( n = nmbr )-placebo ( n = nmbr-ab / ff nmbr / nmbr pg ( n = nmbr )"
1467,characteristic_name,"insulin use-beta - blocker use-region-duration diabetes-history amputation-egfr-history heart failure-study-antithrombotic use-history peripheral vascular disease-raas inhibitor use-glycated hemoglobin-age-bmi-diuretic use-blood pressure control-history cardiovascular disease-sex-blood pressure control ""-statin use-race"
1468,characteristic_level,"nmbr < nmbr ml / min / nmbr . nmbr mnmbr-systolic blood pressure > nmbr mm hg diastolic blood pressure > nmbr mm hg-other-north america-canvas-all patients-europe-> nmbr-< nmbr %-male-central america south america-yes-< nmbr yr-white-systolic blood pressure < nmbr mm hg diastolic blood pressure < nmbr mm hg-no-> nmbr yr-> nmbr %-female-black-systolic blood pressure < nmbr mm hg diastolic blood pressure < nmbr mm hg ""-asian-> nmbr ml / min / nmbr . nmbr mnmbr-canvas - r-rest world-< nmbr"
1470,measures,". participants per nmbr patient - yr-no . participants per nmbr patient - yr """
1471,characteristic_name,"time since diagnosis diabetesa , n ( % )-egfr ( ckd - epi , cystatinc ) , ml / min / nmbr . nmbr mnmbr , n ( % )-time since diagnosis diabetesa , n ( % ) ""-race , n ( % )-uacra , mg / g , n ( % )"
1472,characteristic_level,"age , years-male , n ( % )-other-calcium antagonists-> nmbr-^ - blockers-weight , kg-> nmbr years-< nmbr year-antihypertensive therapy , n ( % )-hawaiian / pacific islander-white-arbs-systolic blood pressurea , mm hg-black / african - american-< nmbr year ""-diuretics-egfr ( ckd - epi , cystatin c ) , ml / min / nmbr . nmbr mnmbr-egfr ( mdrd ) , ml / min / nmbr . nmbr mnmbr-oral antidiabetes monotherapya , n ( % )-diastolic blood pressurea , mmhg-nmbr < nmbr-hbanmbrca , % ( mmol / mol )-uacra , mg / g , gmean = gcv-oral antidiabetes combination therapy without insulina , n ( % )-insulina , n ( % )-asian-bmi , kg / mnmbr-ace inhibitors-> nmbr nmbr years-statins-metformin-< nmbr"
1473,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-linagliptin ( n = nmbr )"
1474,characteristic_level,"europe ""-baseline uacr > nmbr mg / g-baseline uacr < nmbr mg / g-north america-europe-baseline hbalc < nmbr . nmbr % ( nmbr mmol / mol ) nmbr-all participants-baseline hbalc > nmbr . nmbr % ( nmbr mmol / mol ) nmbr-asia"
1476,characteristic_name,"egfr --hdl cholesterol *-hbanmbrc-egfr - ""-total cholesterol *-triglycerides *-time since diagnosis type nmbr diabetes-race-ldl cholesterolt-sex"
1477,characteristic_level,"microalbuminuria baseline ( nmbr % patients treated )-macroalbuminuria baseline ( nmbr % patients treated )-normoalbuminuria baseline ( nmbr % patients treated )-normoalbuminuria baseline ( nmbr % patients treated ) """
1478,arms,"placebo ( n = nmbr )-empagliflozin ( n = nmbr ) ""-empagliflozin ( n = nmbr )"
1479,characteristic_level,"uric acid tertile nmbr ( nmbr . nmbr < nmbr . nmbr mg / dl )-uric acid tertile nmbr ( > nmbr . nmbr mg / dl )-uric acid tertile nmbr ( < nmbr . nmbr mg / dl )-uric acid tertile nmbr ( > nmbr . nmbr mg / dl ) ""-uric acid fertile nmbr ( > nmbr . nmbr mg / dl )"
1480,measures,"n analysed-change baseline *-difference vs placebo * *-difference vs placebo '-change baseline * """
1481,characteristic_level,"patients macroalbuminuria baseline ""-patients microalbuminuria baseline-patients normoalbuminuria baseline-patients macroalbuminuria baseline"
1482,arms,"placebo-empagliflozin-placebo """
1483,characteristic_name,"number exacerbation previous nmbr months , n ( % )-baseline treatments , n ( % ) a-dyspnoea - mmrc grade , n ( % )-baseline treatments , n ( % ) "" ; na"
1484,characteristic_level,"nmbr-othersc-> nmbr-othersc "" ; na-lama ( monotherapy )-laba + ics ( free fixed - dose combination )-laba ( monotherapy )"
1485,arms,"ind / glyb n = nmbr ""-laba + ics n = nmbr-ind / gly n = nmbr-ind / glyb n = nmbr-laba lamab n = nmbr"
1486,characteristic_name,"age , years-smoking status-reversibility-baseline therapy-fevnmbr baseline-exacerbations previous year-smoking status "" ; na-mmrc baseline-sex"
1487,characteristic_level,"male-nmbr-ex - smokers ""-current-= nmbr-sfc-other-ex - smokers-> nmbr %-female-< nmbr %-= nmbr %-form / bud-< nmbr"
1488,measures,"laba + ics versus indzgly lsm difference ( nmbr % cl )-number patients ""-number patients"
1489,arms,"laba + ics-indzgly-indzgly """
1490,characteristic_name,"fev , baseline-age , years-smoking status-reversibility-baseline therapy-exacerbations previous year-age , years "" ; na-mmrc baseline-sex"
1491,characteristic_level,"nmbr-male-snmbr-lama-current-ex - smokers nmbr-nmbr nmbr-> nmbr % nmbr-others-nmbr ""-female-< nmbr %-laba-< nmbr-snmbr %-nmbr % nmbr"
1492,outcomes,"gusto severe-st-gusto moderate-gusto moderate / severe-timi major / minor-idr-gusto severe ""-death , mi , idr , st , timi bleeding-death-death , mi , idr , st-acuity major-mi-st ( arc definite )-death , mi , idr , st , gusto moderate / severe bleeding-death , mi , idr , st gusto severe bleeding-timi major-timi minor-ipst"
1493,characteristic_level,"age < nmbr ( n = nmbr )-age < nmbr ( n = nmbr ) ""-age > nmbr ( n = nmbr )"
1495,arms,"aspirin alone ( n = nmbr )-rivaroxaban plus aspirin ( n = nmbr )-rivaroxaban alone ( n = nmbr ) ""-rivaroxaban alone ( n = nmbr )"
1496,characteristic_name,"estimated gfr-coronary artery disease-body weight-baseline tobacco use-age-baseline dyslipidemia-peripheral arterial disease-sex ""-baseline diabetes-history hypertension-geographic region-race-sex"
1498,other,". events / total . ( % )-no . events / total . ( % ) """
1499,characteristic_name,"infarct location ""-killip class-timi risk score-infarct location"
1500,characteristic_level,"crp , mg / l-previous angina pectoris-systolic blood pressure-hypercholesterolemia-ii - iv-moderate risk ( nmbr - nmbr )-weight , kg-ischemic stroke-peripheral artery disease-anterior-hemoglobin , g / l-men-previous coronary intervention-scr , gmol / l-not anterior-glucose , mmol / l-diabetes mellitus-hdl - c , mmol / l-heart rate , beats / min-platelet , nmbr / l-hemorrhagic stroke-body mass index , kg / mnmbr-i-family history coronary disease-anterior ""-ldl - c , mmol / l-low risk ( nmbr - nmbr )-diastolic blood pressure-high risk ( nmbr - nmbr )-red blood cell counting , nmbr / l-total cholesterol , mmol / l-age , y-mean platelet volume , fl-triglyceride , mmol / l-hypertension"
1502,characteristic_level,"no-yes-< nmbrkg-women-nmbr < nmbrkg-nmbr - nmbr hr-i-nmbr < nmbrmmhg-< nmbr hr-nmbrlnmbrmmhg-nmbr < nmbrmmhg ""-iiiv-nmbrto < nmbrmmhg-men"
1503,characteristic_name,"systolic blood pressure-time randomization-diabetes-systolic blood pressure ""-weight-killip class-hypertension-sex"
1505,measures,". panents . total . nmbr % ) ""-no . panents . total . nmbr % )"
1506,arms,"patients ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr )-anacetrapib ( n = nmbr , nmbr )-placebo ( n = nmbr , nmbr ) """
1507,characteristic_name,"medication-triglycerides ( mg / dl )-alcohol intake-cigarette smoking-prior disease-region-apolipoprotein b ( mg / dl )-apolipoprotein anmbr ( mg / dl )-waisthip ratio-glomerular filtration rate ( ml / min / nmbr . nmbrma ,-waisthip ratio ""-hdl cholesterol ( mg / dl )-non - hdl cholesterol ( mg / dl )-age randomization ( years )-ldl cholesterol ( mg / dl )-total cholesterol ( mg / dl )-urinary albumimcreatinine ratio-lipoprotein ( ) ( nmol / l )-systolic blood pressure ( mmhg )-diastolic blood pressure ( mmhg )-gender-atorvastatin dose-time since qualifying event-body mass index ( kg / mnmbr )"
1508,characteristic_level,"micro - albuminuria-all-macro - albuminuria-> nmbr < nmbr-heart failure-north america-europe-> nmbr-non - smoker-< nmbr months-male-> nmbr months-calcium channel blocker-former smoker-beta - blocker-high ""-medium-cerebrovascular disease-high-normal-current smoker-diuretic-china-female-> nmbr , < nmbr-current drinker-anti platelet therapy-peripheral - artery disease-ace inhibitor arb-diabetes-low-former / non - drinker-< nmbr-coronary heart disease"
1509,measures,"lipid difference ( mg / dl )-no . participants events ( % )-lipid difference ( mg / dl ) """
1511,characteristic_name,"renal function ( egfr , ml / min / nmbr . nmbr mnmbr ) ""-renal function ( egfr , ml / min / nmbr . nmbr mnmbr )"
1512,characteristic_level,"age , years-ace inhibitors arb-loop diuretics-macroalbuminuria-nmbr bmi , kg / m-calcium channel blockers-mild impairment ( egfr nmbr - nmbr )-severe impairment ( egfr < nmbr )-oad only-not treated ""-moderate impairment ( egfr nmbr - nmbr )-insulin treated-egfr ( ml / min / nmbr . nmbr mnmbr )-diuretics-microalbuminuria-insulin only-hba , % nmbrc-normal ( egfr > nmbr )-others-not treated-antihypertensive therapy-lipid - lowering drugs-insulin + oad-diastolic blood pressure , mmhg-beta blockers-statins-insulin - na ' ive-diabetes duration , years-systolic blood pressure , mmhg-male sex , n ( % )"
1513,arms,"liraglutide ( n = nmbr )-placebo ( n = nmbr ) ""-placebo ( n = nmbr )"
1514,outcomes,"post - bronchodilation fvc-pre - bronchodilation fvc ""-post - bronchodilation fevnmbr-pre - bronchodilation fvc-pre - bronchodilation fevnmbr"
1516,characteristic_level,"cat > nmbr-cat < nmbr-cat > nmbr """
1518,measures,"mean ( se )-mean ( se ) ""-n"
1519,arms,"placebo ( n = nmbr )-mepolizumab , nmbr mg ( n = nmbr )-placebo ( n = nmbr ) """
1520,characteristic_name,"< nmbr historical count > nmbr-> nmbr-< nmbr historical count > nmbr ""-> nmbr < nmbr-< nmbr regardless historical count-< nmbr historical count > nmbr"
1522,other,"randomization groups nmbr nmbr ""-randomization groups nmbr nmbr"
1523,characteristic_level,"pfo closure group ( n = nmbr )-antiplatelet - onl group ( n = nmbr )-antiplatelet - onl group ( n = nmbr ) ""-antiplatelet - group ( n = nmbr )-anticoagulant group ( n = nmbr )"
1524,characteristic_name,"comorbidities-number exacerbations nmbr months randomisation-asthma control test score baseline-comorbidities """
1525,characteristic_level,"nmbr-vascular-any-diabetes ""-> nmbr-diabetes-cardiac-nmbr - nmbr-< nmbr"
1526,arms,"usual care ( n = nmbr )-fluticasone furoate vilanterol ( n = nmbr )-fluticasone furoate vilanterol ( n = nmbr ) """
1527,characteristic_name,"medication taken alone combination-ethnicity ,-region , ""-cv risk factor-urine albumin - - creatinine ratio-anti - hypertensive therapy-anti - coagulants-region ,-lipid - lowering therapy-time since diagnosis type nmbr diabetes-race"
1528,characteristic_level,"patients without prevalent kidney disease baseline ""-patients without prevalent kidney disease baseline-patients prevalent kidney disease baseline"
1529,arms,"placebo ( n = nmbr )-empagliflozin ( n = nmbr ) ""-empagliflozin ( n = nmbr )"
1530,outcomes,"weight ( kg )-hdl - cholesterol ( mg / dl )-serum uric acid ( mg / dl )-systolic blood pressure ( mmhg )-hemoglobin ( g / dl )-ldl - cholesterol ( mg / dl )-hdl - cholesterol ( mg / dl ) ""-hbanmbrc ( % )"
1531,measures,"difference vs placebo-change baseline week nmbr ""-change baseline week nmbr-baseline-week nmbr"
1532,characteristic_level,"patients egfr > nmbr ml / min / nmbr . nmbrmnmbr baseline ""-patients egfr > nmbr ml / min / nmbr . nmbrmnmbr baseline-patients egfr < nmbr ml / min / nmbr . nmbrmnmbr baseline"
1533,arms,"placebo ( n = nmbr )-empagliflozin nmbr mg ( n = nmbr )-empagliflozin nmbr mg ( n = nmbr ) """
1534,characteristic_name,"mean ( . . ) non - hdl cholesterol-age group , n ( % )-mean ( . . ) hdl cholesterol-race , n ( % ) ""-mean ( . . ) calculated ldl cholesterol-mean ( . . ) fpg-concomitant antihyperglycaemic drugs , n ( % )-ethnicity , n ( % )-statin intensitynmbr * nmbr-concomitant lipid - lowering therapy , n ( % )-race , n ( % )-median ( qnmbr : qnmbr ) total daily insulin dosenmbr-median ( qnmbr : qnmbr ) tgs-total cholesterol-median ( qnmbr : qnmbr ) tg - rich lipoprotein cholesterol-mean ( . . ) measured ldl cholesterol"
1535,characteristic_level,"tnmbrdm-tnmbrdm """
1536,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-alirocumab ( n = nmbr )"
1537,outcomes,"% change baseline , mean ( . e . )-baseline-week nmbr-baseline """
1539,characteristic_level,"tnmbrd ""-tnmbrd"
1540,arms,"placebo ( n = nmbr )-difference vs placebo , % [nmbr % cl] , p-placebo ( n = nmbr ) ""-alirocumab ( n = nmbr )"
1541,arms,"pbo "" ; na-pbo-ali"
1542,characteristic_name,"history cardiovascular disease-antihyperglycemic medication usage-other medication usage-ethnicity-region-european subcategories-antihyperglycemic medication usage ""-cardiovascular medication usage-cigarette smoking status-race"
1543,characteristic_level,"digoxin / digitalis glycoside-exenatide-north america-europe-> nmbr-hispanic-ace inhibitor-antithrombotic anticoagulant medications-< nmbr %-dpp - nmbr inhibitor therapy-hbanmbrc ( % )-insulin plus nmbr oral agent-insulin plus > nmbr oral agent-glp - nmbr receptor agonist ( study drug )-direct thrombin inhibitors-proton pump inhibitors-cerebrovascular disease-niacini-pramlintide-< nmbr years-diuretic-fish oil-none-black-prior cv event randomization !-egfr via mdrd ( ml / min / nmbr . nmbrmnmbr )-western europe-angiotensin receptor blockers-fibrate-diabetes duration ( years )-linagliptin-nitrates-aspirin-dapagliflozint-sitagliptin-nmbr - nmbr-> nmbr - < nmbr years-vildagliptin-white-insulin-min , max-thiazolidinedione-other antihyperglycemic agents , listed-liraglutide-monotherapy-antihypertensive , antianginal , cardiovascular medications-former-hispanic latino-sulfonylurea-asian-coronary artery disease-lipid - lowering medications^-other antihypertensive-ranolazine-never-latin america-native hawaiian pacific islander-non - sulfonylurea secretagogues-indian ( american ) alaska native-other sglt - nmbr inhibitor-> nmbr years-allogliptin-hormone replacement therapy-aldosterone antagonists ( e . g . spironolactone )-statini-history congestive heart failure-age randomization ( years )-vitamin k antagonist ( e . g . warfarin / coumarol )-ezetimibe-chronic non - steroidal antiinflammatory drugs-low molecular weight heparin-current-alpha - glucosidase inhibitors-> nmbr oral agents-saxagliptin-> nmbr %-biguanides-alpha - glucosidase inhibitors ""-beta blockers-body mass index ( kg / mnmbr )-< nmbr-alpha nmbr blockers-clopidogrel / ticlopidine-other anti - platelet agents-exenatide lar-asia pacific-sglt - nmbr inhibitors^-calcium channel blockers-thiazide-renin inhibitor ( e . g . aliskerin )-chronic coxnmbr inhibitors-hydralazine-not hispanic latino-factor xa inhibitor-eastern europe-peripheral arterial disease-female-insulin alone-dual therapy-other glp - nmbr receptor agonist-oral agents use"
1544,arms,"exenatide n = nmbr-placebo n = nmbr ""-placebo n = nmbr"
1545,characteristic_name,"background aha therapy screening , n ( % ) ""-background aha therapy screening , n ( % )-region , n ( % )-race / ethnicity , n ( % )"
1546,characteristic_level,"age , years-male , n ( % )-north america-europe-c - peptide-south america-fpg , mmol / l-ras agents-egfr , ml / min / nmbr . nmbr mnmbr ""-two agents-black african american-calcium channel blockers-american indian alaska native-hbanmbrc , mmol / mol-body weight , kg-white-dbp , mm hg-diuretics-one blood pressure medications , n ( % )-three agents-other anti - hypertensives-hispanic latino-fpg , mg / dl-sbp , mm hg-asian-biguanides-hbanmbrc , %-bmi , kg / mnmbr-duration tnmbrdm , years-beta blockers-dpp - nmbr inhibitors-egfr , ml / min / nmbr . nmbr mnmbr-sulphonylureas-asia-multiple"
1548,characteristic_name,"hbanmbrc distribution baseline , n ( % ) ""-hbanmbrc distribution baseline , n ( % )"
1549,characteristic_level,"< nmbr . nmbr % ( nmbr mmol / mol )-nmbr . nmbr < nmbr . nmbr % ( nmbr < nmbr mmol / mol )-nmbr . nmbr < nmbr . nmbr % ( nmbr < nmbr mmol / mol ) ""-= nmbr . nmbr % ( = nmbr mmol / mol )"
1550,arms,"placebo-ertugliflozin nmbr mg-ertugliflozin nmbr mg """
1551,characteristic_name,"medical history-nyha functional class screening-medications randomization-physiological measures-cause heart failure-region-racenmbr ""-devices heart failure screening visit-time since diagnosis heart failure-racenmbr-lv ejection fraction ( % )-laboratory measures"
1552,characteristic_level,"ischaemic cardiomyopathy-latin america-atrial fibrillation-heart rate ( b . p . . )-north america-> nmbr - nmbr years-< nmbr %-> nmbr years-< nmbr year-percutaneous coronary intervention-mineralocorticoid receptor antagonists-stroke-antiplatelet drug-egfr ( ml / min / nmbr . nmbr mnmbr )-crt - d-non - ischaemic cardiomyopathy-other / missing ""-icd-systolic blood pressure ( mmhg )-caucasian-nt - probnp ( pg / ml ) ( qnmbr - qnmbr )-> nmbr %-diuretic-lipid - lowering agent-crt - p-iii-other / missing-black-coronary artery bypass surgery-iv-asian-oral anticoagulant-western europe-myocardial infarction-central europe-hospitalization heart failure-ii-digitalis-asia-beta - adrenergic blocker-hypertension"
1553,outcomes,"diabetes-diabetes ""-diabetes"
1554,arms,"aliskiren ( n = nmbr )-enalapril + aliskiren ( n = nmbr )-aliskiren ( n = nmbr ) ""-enalapril ( n = nmbr )"
1556,characteristic_level,"diabetes ""-diabetes-non - diabetes"
1557,characteristic_level,"hdl - c ( median , iqr ) , mg / dl-prior cabg ( index acs )-atrial fibrillation-unstable angina-heart failure-statin-aspirin-egfr ( median , iqr ) , ml / min / nmbr , nmbrmnmbr-time acs randomization ( median , iqr )-peripheral artery disease-thienopyridine-bmi ( median , iqr ) , kg / mnmbr-stemi-triglycerides ( median , iqr ) , mg / dl-white-diabetes mellitus-prior stroke-chanmbrdsnmbr - vasc score ( median , iqr )-egfr < nmbr ml / min / nmbr . nmbrmnmbr-ldl - c ( median , iqr ) , mg / dl-ldl - c ( median , iqr ) , mg / dl ""-lipid - lowering agent-female-prior ml ( index acs )-hs - crp ( median , iqr ) , mg / l-age ( median , iqr ) , y-total cholesterol ( median , iqr ) , mg / dl-acei / arb-age > nmbr , y-nstemi-p blocker-current smoking-score nmbr - nmbr-hypertension"
1558,characteristic_name,"labs index acs event-demographics-coexisting conditions-at index acs event-labs index acs event ""-before index acs event"
1560,characteristic_level,"prior llt-crcl < nmbr-ldl - csmedian-no prior stroke-males-ldl - csmedian ""-stemi-overall-age < nmbr-non - caucasian-prior stroke-no smoking-age > nmbr-no diabetes-females-no prior llt-crci > nmbr-caucasian-ldl - c > median-no htn-htn-diabetes-current smoking-crci > nmbr - < nmbr-nste - acs"
1562,outcomes,"urgent coronary revascularization-unstable angina-coronary revascularization-stroke etiology-hemorrhagic stroke-cv death-primary trial end point-cv death , ml , stroke ""-cv death , ml , stroke-all - cause mortality-ischemic stroke-ml-coronary heart disease death"
1565,characteristic_name,"modified rankin scale score-index event subtype-modified rankin scale score """
1566,characteristic_level,"nmbr-atrial fibrillation-stroke ( vs tia )-hemoglobin anmbrc , mean ( sd ) , % b-peripheral artery disease-motor weakness-aphasia-prior stroke-hypertension history-other defined-atrial fibrillation ""-cardioembolic-systolic blood pressure , mean ( sd ) , mm hga-lacunar-large vessel atherosclerosis-age , mean ( sd ) , y-current smoker-male sex-coronary artery disease-uncertain"
1567,measures,"patients , . / total . ( % )-patients , . / total . ( % ) """
1568,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-pioglitazone ( n = nmbr )"
1569,characteristic_name,"current smoker ""-aphasia-cad-current smoker-prior stroke-age-htn hx"
1570,characteristic_level,"no-yes ""-yes-nmbr +-nmbr - nmbr-< nmbr"
1572,measures,"risk *-events / n-risk * """
1573,characteristic_name,"ibdq domain scores , mean [sd] ""-sf - nmbrvnmbr domain scores , mean [sd]-years [range]-ibdq domain scores , mean [sd]"
1574,characteristic_level,"bowel function-role physical-physical function-age , mean years , [sd]-bodily pain-social functioning-social function-duration disease , median-previous anti - tnf therapy , n [ % ]-vitality-concomitant aminosalicylates , n [ % ] concomitant corticosteroids , n [ % ] mayo score , mean [sd]-role emotional-sf - nmbrvnmbr mcs , mean [sd]-ibdq total score , mean [sd]-emotional status-systemic symptoms-general health-sf - nmbrvnmbr pcs , mean [sd] ""-gender , n [ % ] male-mental health-sf - nmbrvnmbr pcs , mean [sd]"
1575,other,"octave sustain-octave induction nmbr ""-octave induction nmbr"
1576,arms,"tofacitinib nmbr mg bid [n = nmbr |-placebo [n = nmbr |-placebo [n = nmbr]-tofacitinib nmbr mg bid [n = nmbr | """
1577,characteristic_level,"no-male-yes-male "" ; na-female"
1578,characteristic_name,"gender-corticosteroid use baseline-prior anti - tnf therapy-gender """
1579,other,"octave induction nmbr nmbr ""-octave induction nmbr nmbr"
1580,arms,"placebo-tofacitinib nmbr mg bid-placebo """
1581,characteristic_name,"gender-corticosteroid use baseline-prior anti - tnf therapy-prior anti - tnf therapy """
1582,characteristic_level,"no-male-yes-female-no """
1583,other,"octave sustain ""-octave sustain"
1584,arms,"placebo-tofacitinib nmbr mg bid ""-tofacitinib nmbr mg bid"
1585,outcomes,"ibdq total score week nmbr , mean [se] ""-in ibdq total score week nmbr , mean [se]"
1586,characteristic_level,"congestive heart failure-atrial fibrillation-nmbr-other-number treated vessels ( per patient )-zotarolimus - eluting-everolimus - eluting-paclitaxel - eluting-nonwhite race-vein bypass graft stented-number stents ( per patient )-> nmbr des type-> nmbr lesions per vessel-previous mi-male-non - stemi-stemi-stable angina-diabetes mellitus-age , yrs-current cigarette smoker within past year-stroke / transient ischemic attack-unprotected left main stented-unstable angina *-thrombus - containing lesion-stent diameter < nmbr mm-body mass index , kg / mnmbr-hispanic latino-sirolimus - eluting-peripheral arterial disease-hispanic latino ""-history cancer-lesion length $ nmbr mm-renal insufficiency / failure-prasugrel-coronary artery bypass graft-stent diameter $ nmbr mm-left ventricular ejection fraction < nmbr %-stent type-prior brachytherapy-previous percutaneous coronary intervention-clopidogrel-bifurcation lesion side branch $ nmbr . nmbr mm stented-hypertension"
1587,characteristic_name,"anatomic complexity characteristics-anatomic complexity characteristics "" ; na"
1589,characteristic_name,"demographic features-concomitant medications-concomitant medications ""-index event-index event subtype-laboratory data-clinical history-physical examination"
1590,characteristic_level,"atrial fibrillation-statin-current cigarette smoking-diastolic blood pressure , mm hg-triglycerides , mmol / l-antiplatelet-black race-modified rankin scale screening , nmbr - nmbr-carotid artery intervention *-other defined-c - reactive protein-cardioembolic-lacunar-body mass index , kg / mnmbr-systolic blood pressure , mm hg-male sex-ischemic stroke ( vs . tia )-hispanic ethnicity-anticoagulant-prior stroke ( index event )-coronary artery disease-nihss randomization , nmbr - nmbr-hbanmbrc , %-large vessel-uncertain-unknown-age , y-ldl cholesterol , mmol / l-statin ""-homa - ir-hypertension"
1591,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-pioglitazone ( n = nmbr )"
1592,characteristic_name,"atrial fibrillation-ldl - cholesterol-glycated hemoglobin-body mass index-prior stroke-age-homa > median-carotid stenosis-hypertension history-race ""-gender-race"
1593,characteristic_level,"black african american-male-no-> nmbr . nmbr mmol / l-yes-< nmbr kg / mnmbr-nmbr . nmbr % - nmbr . nmbr %-< nmbr years-< nmbr . nmbr %-nmbr . nmbr - nmbr . nmbr % f-white / ""-female-> nmbr years-< nmbr . nmbr mmol / l-> nmbr kg / mnmbr-white /"
1595,measures,"risk ""-events / n-risk"
1596,characteristic_name,"egfr category , n ( % )-race , n ( % ) ""-race , n ( % )-sex , n ( % )"
1597,characteristic_level,"black african american-male-asian-> nmbr ml / min / nmbr . nmbr mnmbr-other-nmbr onmbr ml / min / nmbr . nmbr mnmbr-white-bmi , mean ( sd ) ""-female-bmi , mean ( sd )-nmbr nmbr ml / min / nmbr . nmbr mnmbr"
1598,arms,"canagliflozin dose-canagliflozin dose """
1599,arms,"total ( n = nmbr )-nmbr mg ( n = nmbr ) ""-nmbr mg ( n = nmbr )"
1600,characteristic_name,"previous treatment-previous treatment ""-smokinq status-reqion-sex"
1601,characteristic_level,"north american-peripheral artery disease-> nmbr years-< nmbr year-male-calcium channel blocker-former smoker-asia , pacific other-( e - blocker-nmbr - nmbr years-current smoker-western european includinq australia , israel , south africa-previous myocardial infarction-female-lipid - lowerinq druq-south american-eastern european-ace inhibitor arb-diabetes-calcium channel blocker ""-hypertension"
1602,arms,"aspirin alone ( n = nmbr )-rivaroxaban alone ( n = nmbr )-rivaroxaban alone ( n = nmbr ) ""-low - dose rivaroxaban plus aspirin ( n = nmbr )"
1603,characteristic_name,"ethnic origin-timi risk score !-non - smokers receiving lipid - lowering drugs , p blockers ,-region-age ( years )-history pci / ptca-peripheral artery disease-history cabg-baseline diabetes-myocardial infarction / cabg / pci < nmbr years-baseline total cholesterol-baseline diabetes ""-history myocardial infarction-sex"
1604,characteristic_level,"nmbr-other-asia pacific other-north america-no previous myocardial infarction-south america-n o-> nmbr years-nmbr - nmbr-male-y es-yes-overall-white-f emale-nmbr - nmbr years-no-< nmbr years-< nmbr mmol / l-w est europe-black-asian-n ""-east europe-< nmbr-> nmbr mmol / l"
1606,characteristic_name,"medications-smoking status-history pad-risk factors pad-abi-medications ""-blood pressure-sex"
1607,arms,"aspirin alone ( n = nmbr )-rivaroxaban alone ( n = nmbr )-rivaroxaban alone ( n = nmbr ) ""-low - dose rivaroxaban plus aspirin ( n = nmbr )"
1608,characteristic_name,"smoking status-cad-diabetes ""-diabetes-symptomatic pad-abi-egfr-pad lower extremities"
1609,characteristic_level,"no-< nmbr - nmbr-yes-overall pad-current-> nmbr - nmbr-> nmbr-former never-no ""-< nmbr"
1611,characteristic_name,"screening bmi ( kg / mnmbr )-screening hbanmbrc ( % )-basal insulin dose run - ( u / day )-female ( % )-duration tnmbrd ( years )-age ( years )-baseline hbanmbrc ( % )-iglar dose randomization ( u / day )-duration tnmbrd ( years ) """
1612,arms,"iglar-iglar ""-iglarlixi"
1613,characteristic_name,"hbanmbrc > nmbr % ( n nmbr nmbr )-nmbr % < hbanmbrc < = nmbr % ( n nmbr nmbr )-hbanmbrc < = nmbr % ( n nmbr nmbr )-all completers ( n nmbr nmbr )-hbanmbrc > nmbr % ( n nmbr nmbr ) """
1614,arms,"iglar-iglar ""-iglarlixi"
1615,characteristic_name,"completers-hbanmbrc < = nmbr %-hbanmbrc > nmbr % ""-hbanmbrc > nmbr %-nmbr % < hbanmbrc < = nmbr %"
1616,outcomes,"hbanmbrc , %-body weight , %-waist circumference , cm-iwqol - lite physical score ( arbitrary units ) ""-iwqol - lite physical score ( arbitrary units )-body weight , kg-fpg , mmol / l-iwqol - lite total score ( arbitrary units ) #-dbp , mm hg-sbp , mm hg"
1617,characteristic_name,"individuals without diabetes , n = nmbr , nmbr ""-individuals without diabetes , n = nmbr , nmbr"
1619,outcomes,"hbanmbrc , %-body weight , %-waist circumference , cm-iwqol - lite physical score ( arbitrary units ) ""-iwqol - lite physical score ( arbitrary units )-body weight , kg-fpg , mmol / l-iwqol - lite total score ( arbitrary units ) #-dbp , mm hg-sbp , mm hg"
1620,characteristic_name,"individuals diabetes , n = nmbr-individuals diabetes , n = nmbr """
1622,characteristic_name,"qualifying myocardial infarction ""-qualifying myocardial infarction-sex"
1623,characteristic_level,"lipid - lowering therapy-body - mass index ( kg / ' )-male-non - stemi-stemi-unknown missing-history congestive heart failure-triglycerides ( mmol / l ) ""-egfr ( ml / min per nmbr - nmbr ' )-randomised canakinumab nmbr mg-history cabg-anti - ischaemia agents *-hypertension-hdl cholesterol ( mmol / l )-age ( years )-ldl cholesterol ( mmol / l )-female-waist circumference ( cm )-interleukin - nmbr ( ng / l )-history pci-renin - angiotensin inhibitors-diabetes-current smoking-triglycerides ( mmol / l )-hscrp ( mg / l )-total cholesterol ( mmol / l )"
1624,arms,"placebo ( n = nmbr )-canakinumab , hscrp > nmbr - nmbr mg / l nmbr months ( n = nmbr )-canakinumab , hscrp < nmbr - nmbr mg / l nmbr months ( n = nmbr )-canakinumab , hscrp > nmbr - nmbr mg / l nmbr months ( n = nmbr ) """
1625,characteristic_name,"age < nmbr years-triglycerides > nmbr - nmbr mmol / l-non - smoker-ldl cholesterol < nmbr - nmbr mmol / l-age > nmbr years-hscrp > nmbr < nmbr mg / l-bmi < nmbr kg / mnmbr-overall-women-smoker-bmi > nmbr kg / mnmbr-no diabetes-hdl cholesterol < nmbr - nmbr mmol / l-triglycerides < nmbr - nmbr mmol / l-hdl cholesterol > nmbr - nmbr mmol / l-ldl cholesterol > nmbr - nmbr mmol / l-hscrp > nmbr mg / l-diabetes-men-no diabetes """
1626,measures,"incidence rate per nmbr person - years-incidence rate per nmbr person - years ""-hr ( nmbr % ci )"
1627,arms,"placebo-canakinumab-placebo """
1628,characteristic_name,"qualifying event-at randomization "" ; na-at randomization"
1629,characteristic_level,"unstable angina-ldl - c < nmbr mg / dl-aspirin-statin-history coronary revascularization-prior statin use-thienopyridine-history chf-history chf ""-stemi-dual antiplatelet-diabetes mellitus-egfr < nmbr ml / min / nmbr . nmbr mnmbr-current smoker-history stroke tia-peripheral arterial disease-bmi , kg / mnmbr-age , y-prior lipid - lowering agent use-nstemi-age > nmbr y-cabg-hypertension"
1630,characteristic_name,"women ( n = nmbr )-men ( n = nmbr nmbr )-men ( n = nmbr nmbr ) """
1631,characteristic_level,"women ""-women-men"
1632,characteristic_name,"cardiovascular death-hospitalization unstable angina-any death-coronary revascularization nmbr days randomization-cardiovascular death / myocardial infarction / stroke-myocardial infarction-cardiovascular death / myocardial infarction / stroke ""-primary endpoint-stroke-chd death"
1634,outcomes,"rhabdomyolysis , myopathy , myalgia ck elevation > nmbrx uln-rhabdomyolysis myopathy-rhabdomyolysis-cancer ""-alt , ast , > nmbrx uln-permanently stopped study drug adverse events-gallbladder - related aes-cancer"
1635,characteristic_level,"women ""-women-men"
1637,outcomes,"rhabdomyolysis , myopathy , myalgia ck elevation > nmbrx uln-rhabdomyolysis-alt , ast , > nmbrx uln-myopathy-rhabdomyolysis , myopathy , myalgia ck elevation > nmbrx uln ""-gallbladder - related aes-cancer"
1638,characteristic_level,"women ""-women-men"
1640,characteristic_name,"medical history-medications admission-medications randomization-laboratory values admission ( median iqr )-medications randomization ""-laboratory values randomization ( median iqr )-at index event"
1641,characteristic_level,"congestive heart failure-high - density lipoprotein cholesterol , mg / l-creatine clearance , ml / min-aspirin-statin-statin admission-prior statin use-hyperlipidemia-p - blocker-percutaneous coronary intervention-coronary artery bypass grafting-no prior statin use-low - density lipoprotein cholesterol , mg / dl-c - reactive protein , * mg / l-white-triglycerides , mg / l-aspirin ""-hypertension-median weight , kg ( iqr )-peripheral arterial disease-female-no statin admission-diagnostic angiography-mean age ( sd ) , y-myocardial infarction-current smoking-median body mass index , kg / mnmbr ( iqr )-st - segment elevation myocardial infarction-angiotensin - converting enzyme inhibitor angiotensin receptor blocker"
1643,outcomes,"alanine aminotransferase aspartate aminotransferase > nmbrx upper limit normal ( n = nmbr )-cholecystectomy ( n = nmbr )-cancer ( n = nmbr )-cancer ( n = nmbr ) ""-rhabdomyolysis ( n = nmbr )-gall bladder adverse event ( n = nmbr )-hemorrhagic stroke ( n = nmbr )"
1644,characteristic_name,"dm absent-dm present-dm present """
1646,characteristic_name,"male , n ( % )-time since psa diagnosis ( years ) , mean ( sd )-tender joint count ( nmbr joints ) , mean ( sd )-haq - di total score , mean ( sd )-weight ( kg ) , mean ( sd )-age ( years ) , mean ( sd )-van der heijde mtss , mean ( sd )-time since psa diagnosis ( years ) , mean ( sd ) ""-swollen joint count ( nmbr joints ) , mean ( sd )"
1647,characteristic_name,"mtx-none ( cdmard - naive past use baseline )-none ( cdmard - naive past use baseline ) ""-cdmard"
1648,arms,"ixeqnmbrw , n = nmbr ""-ixeqnmbrw , n = nmbr-pbo , n = nmbr"
1649,characteristic_name,"exposure "" ; na-pah classification-geographical region-exposure-congenital shunts"
1650,characteristic_level,"time since pah diagnosisc ( years )-latin america-associated hiv infection-associated drug / toxin-north america-western europe / australia-associated corrected-age ( years )-female sex-idiopathic-heritable-nmbr - min walk distance ( )-asia-female sex ""-eastern europe-associated ctd"
1651,characteristic_name,"fc iii symptoms baseline-overallb ""-overallb-who fc ii symptoms baseline"
1652,arms,"placebo ( n = nmbr )-placebo ( n = nmbr ) ""-selexipag ( n = nmbr )"
1653,characteristic_name,"sjc , nmbr - nmbr-age , years-crp , mg / l-pain vas , nmbr - nmbr mm-mtss ( nmbr - nmbr )-pga , nmbr - nmbr-sdai-clinical patient - reported characteristics baseline randomization-cdai-erosion score ( nmbr - nmbr )-acpa positive , n ( % )-disease duration , years-esr , nmbr - nmbr mm / hour-total haq , nmbr - nmbr-tjc , nmbr - nmbr-prior tobacco use , n ( % )-crp , mg / l ""-ptga , nmbr - nmbr-dasnmbr-jsn score ( nmbr - nmbr )-general health vas , nmbr - nmbr mm-rf positive , n ( % )-radiographic characteristics baseline randomization-female , n ( % )"
1654,arms,"etn nmbr mg + mtx n = nmbr ""-mtx n = nmbr-etn nmbr mg + mtx n = nmbr"
1655,characteristic_name,"egfr < nmbr ml / min / nmbr . nmbr mnmbr *-male-pad ""-qualifying mi : stemi-pad-chf-prior pci-caucasian-diabetes mellitus-age , yrs-prior cabg-hyperlipidemia-smoking-hypertension"
1657,characteristic_name,"pre - bronchodilator fevnmbr ""-race , n ( % )-pre - bronchodilator fevnmbr-sex"
1658,characteristic_level,"age , years-male , n ( % )-former smoker , n ( % )-median blood eosinophil count , cells per pla-american indian-absolute , litres-biomarker high ( periostin > nmbrng / ml blood eosinophils > nmbrcells per pl ) , na-saba puffs per day baseline-reversibility , %-black african american-biomarker low ( periostin < nmbr ng / ml blood eosinophils < nmbr cells per pl ) , na ""-white-median feno , ppba-aqlq ( ) score-body mass index , kg / mnmbr-asian-median serum periostin , ng / mla-% predicted-female , n ( % )-biomarker low ( periostin < nmbr ng / ml blood eosinophils < nmbr cells per pl ) , na-multiple"
1659,arms,"lebrikizumab ( n = nmbr )-placebo ( n = nmbr )-placebo ( n = nmbr ) ""-montelukast ( n = nmbr )"
1660,characteristic_name,"age , years-baseline weight , kg-seropositivity-corticosteroid use-region ( pooled )-disease duration , years ""-disease duration , years-overall population"
1661,arms,"placebo-baricitinib nmbr mg-placebo """
1662,characteristic_name,". non - tnfi-no . prior bdmards-no . tnfi among non - tnfi naive-overall population ""-prior tnfi treatment-no . prior tnfi-overall population"
1663,characteristic_level,"nmbr-nmbr mg-snmbr-inflix , no-inflix , yes-nmbr mg ""-ada , no-ada , yes-< nmbr-etn , yes-etn ,"
1664,arms,"placebo-baricitinib nmbr mg-placebo """
1665,characteristic_name,"smoking status-clinical copd phenotype^ ""-race *-clinical copd phenotype^-sex"
1666,arms,"bdp / ff / g ( n = nmbr )-ind / gly ( n = nmbr )-ind / gly ( n = nmbr ) """
1667,characteristic_name,"nyha class ""-nyha class-race"
1668,characteristic_level,"age , years-dbp , mmhg-other-ef , %-aspirin-other vasodilator-ace inhibitor-dm-lipid - lowering-physical exam oedema-spironolactone-hypertensive-angina pectoris-af-previous hf-european-anti arrhythmic-creatinine , mg / dl_-beta - blocker-stroke-cancer-icd-current smoker-diuretic-sbp , mmhg-other antiplatelet-iii-idiopathic-bmi , kg / mnmbr ""-female gender-black-ischaemic-iv-pci-candesartan-oral anticoagulant-bmi , kg / mnmbr-ml-pacemaker-calcium antagonist-ii-digitalis-cabg-hypertension"
1670,outcomes,"hf hospitalization-cv death-all - cause death-cv death + hf hospitalization-all - cause hospitalization-recurrent hf hospitalization-all - cause death """
1671,measures,"unadjusted hr-incidence rate-unadjusted irr-incidence rate "" ; na-unadjusted hr ."
1673,arms,"placebo-candesartan ""-candesartan"
1674,characteristic_name,"anthropometry : mean ( sd )-number patients with-risk factors-m / f-mean ( sd ) age years-medication within nmbr days enrolment-medication enrolment ""-medication enrolment"
1675,characteristic_level,"nitrates-infarction , date reported-aspirin-calcium antagonists-hypertension *-intravenous heparin-current smokers *-ticlopidin-infarct ion w ithin previous nmbr day s-w eight ( k g )-( nmbr - blockers-height ( cm )-aspirin ""-ptca-infarction > nmbr days previously-a ngina > nmbr day previously *-diabetes *-cabg-infarction nmbr - nmbr days"
1676,arms,"placebo ( n = nmbr )-abciximab ( n = nmbr )-abciximab ( n = nmbr ) """
1677,arms,"pravastatin ( n = nmbr > ""-placebo ( n = nmbr )-pravastatin ( n = nmbr >"
1678,characteristic_name,"ldl cholesterol-hdl cholesterol-triglycerides-qualifying event ""-diabetes-unstable angina age-qualifying event-total cholesterol-hypertension !-smoking-sex"
1679,characteristic_level,"male-no-hospitalization for-yes-< nmbr yr-nonsmoker-nmbr mg / dl-myocardial infarction-current smoker-former smoker-nmbr - nmbr mg / dl-hospitalization ""-female-nmbr yr-< nmbr mg / dl-nmbr nmbr mg / dl-nmbr - nmbr yr"
1680,arms,"placebo-pravastatin-placebo """
1681,measures,"event ( % )-n ""-reduction risk ( nmbr % ci ) %-n"
1682,characteristic_name,"concurrent illness-plasma lipoproteins , mmol / l-concurrent medications ""-concurrent medications-race-sex"
1683,characteristic_level,"baseline pfd , m-weight , kg-/ nmbr - blocker-minority-male-angina pectoris-hdlnmbr-white-insulin-baseline mwd , m-oral hypoglycemic-lpa , mg / dl-baseline abi , affected limb-prior myocardial infarction-cholesterol-triglycerides-plasma creatine , mg / dl-diuretic-hdl - c-female-diuretic ""-apoanmbr , mg / dl-n-apob , mg / dl-age , y-diabetes-ldl - c-hypertension"
1684,arms,"placebo-cilostazol-placebo """
